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SUMMARY 
 
Repair of damage to the DNA is essential for the maintenance of genomic stability, 
both during embryonic development and normal growth. The cell has therefore 
evolved a complex array of interconnected pathways to ensure the appropriate 
response to DNA damage is initiated, such as cell cycle checkpoint arrest, activation 
of DNA repair pathways or induction of apoptotic processes. These co-ordinated 
signal transduction pathways have been termed the DNA damage response (DDR). 
A previous study showed that ATR-dependent damage responses were frequently 
defective in cell lines from patients with Microcephalic Primordial Dwarfism (MPD) 
disorders. In this thesis I have further characterised ATR–dependent damage 
response signalling in several cell lines from patients with various MPD disorders. I 
have shown that novel mutations in PCNT, which encodes a structural centrosomal 
protein, result in an MPD disorder and have characterised the associated ATR-
dependent DNA damage responses. I also contributed to the identification of 
mutations in ORC1, encoding a component of the DNA replication Origin 
Recognition Complex, in further MPD patients and examined origin licensing and S-
phase progression in the patient derived cell lines. As a novel finding, I observed 
defects in the ATR-dependent G2/M checkpoint response in these cells. Additionally, 
I have characterised novel mutations in ATRIP, a gene encoding the obligate 
partner of ATR, in Seckel Syndrome patients, denoting a novel genetic defect in this 
condition. Finally, I have explored the role of PLK1 and AurA kinase in ATR-
dependent G2/M checkpoint control and provided compelling evidence of mis-
regulation of this pathway in various MPD-patient derived cell lines. Collectively 
these data provide important functional insights into the genetic defects that cause 
MPD disorders and further explore the link between defective ATR-dependent 
damage response signalling and microcephaly. 
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XRCC4  X-ray cross–complementing group 4 
 
53BP1  p53 binding protein 1 
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CHAPTER ONE 
 
1. INTRODUCTION 
 
Primordial dwarfism is a medical term used to describe individuals that display 
severe short stature at birth. This description has come to encompass many 
subtypes of human genetic disorder, including Seckel syndrome (SS) (OMIM 
210600, 606744, 608664 and 613676), Microcephalic Osteodysplastic Primordial 
Dwarfism, Type II (OMIM 210720) and Meier-Gorlin Syndrome (OMIM 224690). 
These disorders are inherited in an autosomal recessive manner and common 
clinical features include intrauterine growth retardation, proportionate dwarfism, 
severe microcephaly and varying degrees of intellectual disability (Majewski and 
Goecke, 1982, Gorlin, 1992, Hall et al., 2004). These disorders will be discussed in 
detail in due course. 
 
Microcephaly is defined as a reduced head circumference of greater than 3 standard 
deviations below the normal mean for age, sex and length of gestation. The 
reduced head circumference is an external manifestation of an overall reduction in 
brain volume, which may or may not be accompanied by other neurological defects 
(O'Driscoll et al., 2006). The exact cause of microcephaly is unclear and there are 
likely to be multiple causes, however changes to cell cycle duration, spindle position 
and the efficiency of DNA repair have all been shown to affect cortical expansion 
(Thornton and Woods, 2009). 
 
1.1 MAMMALIAN BRAIN DEVELOPMENT 
 
The bulk of work undertaken in order to understand the process of brain 
development has been performed using the mouse as a model. Therefore the 
following section will focus on this data. The mammalian brain develops from a 
single specialised embryonic cell layer called the neuroepithelium (NE). This layer is 
formed at the base of the ventricular zone, around the ventricles of the developing 
brain (O'Driscoll and Jeggo, 2008). Neural progenitor cells present in the 
neuroepithelium can divide either symmetrically to expand stem cell numbers and 
therefore brain volume, or asymmetrically in order to give rise to the specialized 
differentiated cells of the brain (Lu et al., 2000) (Huttner and Kosodo, 2005) 
(Figure 1.1).  
 
Symmetric 
proliferative 
• NE ! NE + NE 
• RGC ! RGC + 
RGC 
• BP ! BP + BP 
Symmetric 
differentiating 
•  NE ! RGC + 
RGC 
•  NE ! N + N 
•  RGC ! N + N 
•  BP ! N + N 
Asymmetric 
mono-
differentiating 
• NE ! NE + N 
• RGC ! RGC + 
BP 
• RGC ! RGC + 
N 
Asymmetric  bi-
differentiating*  
•  NE ! RGC +       
BP 
•  NE ! RGC +  
N  
Figure 1.1 Progenitor cell divisions 
 
NE: neuroepithelial cell, RGC: radial-glial cell, BP: basal progenitor,  
N: neuron. * Proposed but not reported 
 
Adapted from Huttner & Kosodo, 2005 and Götz & Huttner, 2005.      
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NE progenitor cells are attached to the apical surface of the neuroepithelium and 
are polarized along the apico-basal axis (Thornton and Woods, 2009). They are 
anchored to the apical surface via adherens junctions, the integrity of which are 
required to maintain cell polarity (Zhadanov et al., 1999). The apical-basal polarity 
is an important factor in the decision between symmetric and asymmetric division, 
along with cleavage plane orientation, cell cycle length and interkinetic nuclear 
migration (Götz and Huttner, 2005). 
 
The apical plasma membrane is a tiny portion of the whole cellular membrane but 
is a critical factor in determining symmetric versus asymmetric division (Kosodo et 
al., 2004). In symmetric division, the apical membrane is bisected by vertical 
cleavage during cytokinesis, with two identical daughter cells each inheriting a 
segment. These cells therefore retain their NE progenitor cell characteristics and 
remain attached to the apical surface (Thornton and Woods, 2009). These 
symmetric divisions are proliferative and serve to expand the cellular population 
laterally.  
 
In asymmetric division, two daughter cells with different fates are produced. The 
apical membrane is bypassed either by horizontal cleavage or a vertical cleavage 
(Figure 1.2). This results in one daughter cell inheriting all of the apical membrane 
and the adherens junction, thus remaining an NE progenitor. The other daughter 
cell, receiving no apical membrane, detaches from the ventricular surface, migrates 
in a sub-ventricular fashion and differentiates into a radial glial cell (RG), basal 
progenitor (BP) or neuron (N) (Götz and Huttner, 2005).  
 
The precise location of the poles of the mitotic spindle is likely to be an important 
factor in determining the orientation of the cleavage plane in these highly polarised 
cells. The cleavage furrow during cytokinesis proceeds from the basal to the apical 
surface of the cell and this has been shown to be dependent on the positioning of 
the asters and midzone of the mitotic spindle (Bringmann and Hyman, 2005). 
Therefore, any small deviation of the mitotic spindle from its position of 
perpendicular to the apical-basal axis, can alter the cleavage furrow from bisecting 
the apical membrane to bypassing it, resulting in a switch from symmetrical to 
asymmetrical division (Götz and Huttner, 2005). 
 
Cell cycle length has also been implicated in proliferative versus differentiating 
divisions. Differentiating divisions have been shown to have a longer cell cycle 
length than proliferative ones, indeed if G1 phase is artificially shortened, an 
Figure 1.2 Symmetric and asymmetric division of progenitor cells 
 
a) Symmetric division – the mitotic spindle is perpendicular to the apical-
basal axis of the cell. Vertical cleavage results in inheritance of apical 
plasma membrane and adherens junctions by both daughter cells. 
 
b) Asymmetric division – the mitotic spindle is not exactly perpendicular 
to the apical-basal axis. Vertical cleavage results in inheritance of apical 
plasma membrane and adherens junctions by one daughter cell only.  
 
Figure and legend adapted from Götz and Huttner, 2005 
 
 
Plasma membrane 
Apical plasma membrane Nucleus 
Centrosome 
Adherens junction 
Spindle 
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increase in proliferative versus differentiating divisions is observed (Huttner and 
Kosodo, 2005). Recent findings also demonstrate that the duration of S phase is an 
important factor in the ability of neural progenitor cells to self-renew. This study 
found that the S phase duration of a self-renewing, proliferative neural progenitor 
was on average 3.3 fold longer than that of a neural cell committed to differentiate 
(Arai et al., 2011). 
 
Interkinetic nuclear migration (IKNM) is observed in both NE cells and RG cells. The 
nucleus migrates to the basal side of the cell during G1 and S phase and then 
returns to the apical side during G2 phase. Mitosis is completed at the apical 
surface (Götz and Huttner, 2005). The exact function of IKNM is unclear although 
recent studies have implicated the process in the maintenance of the neural 
progenitor pool (Xie et al., 2007) (Farkas and Huttner, 2008).  
 
The positioning of the centrosomes within neural progenitor cells is critical for 
ensuring the fidelity of symmetric versus asymmetric division, via correct spindle 
orientation. It is thought that association of the centrosome with adherens 
junctions helps to maintain centrosome positioning during neurogenesis 
(Higginbotham and Gleeson, 2007). The centrosome will be discussed in detail in 
later sections.   
 
The switch from symmetric to asymmetric division is therefore highly regulated by 
various different processes and the number of symmetric versus asymmetric 
divisions is critical for determining the final number of neurons in the brain (Cox et 
al., 2006). For example, if a progenitor cell undergoes ten rounds of asymmetric 
division, it will produce ten neurons. If the progenitor cell divides symmetrically for 
all except the last round of division, approximately 512 neurons can be generated. 
The point at which the cell moves from symmetric to asymmetric division may 
therefore be critical in order to prevent microcephaly (Thornton and Woods, 2009). 
 
1.2 THE DNA DAMAGE RESPONSE 
 
Microcephaly is a clinical feature commonly observed in many DNA damage 
response disorders (O'Driscoll and Jeggo, 2008), suggesting that efficient DNA 
damage responses are essential for normal brain development.  
 
Repair of damage to the DNA is essential for the maintenance of genomic stability, 
both during embryonic development and during normal growth. The cell is 
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continuously assaulted by both endogenous DNA damaging agents, such as reactive 
oxygen species and exogenous agents including ionising radiation, UV radiation or 
mutagenic chemicals. It is imperative that the integrity of the genome is 
maintained in order to prevent the introduction of mutations that could potentially 
lead to disease such as cancer. In some cases the most favourable outcome may be 
cell death, rather than allowing further proliferation of damaged cells. The cell has 
therefore evolved a complex array of interconnected pathways to ensure the 
appropriate response to DNA damage is initiated. This may include the induction of 
cell cycle checkpoint arrest, activation of DNA repair pathways or induction of 
apoptotic processes. This co-ordinated response of signal transduction and DNA 
repair pathways has been termed the DNA damage response (DDR) (Figure 1.3).  
 
1.2.1 UV-induced DNA damage 
 
UV radiation, particularly UV-B and UV-C, is absorbed by DNA resulting in its 
chemical and physical modification in the form of introduction of dimers (Rastogi et 
al., 2010).  Many types of photoproducts have been observed in the DNA following 
exposure to UV radiation. The most common of these are Cyclobutane pyrimidine 
dimers (CPDs), in which adjacent pyrimidine bases are joined together by a 
cyclobutane ring structure, and pyrimidine 6-4 pyrimidone photoproducts (6-4PPs) 
where the carbon in position 6 of the 5’ pyrimidine is linked to the carbon in 
position 4 of the 3’ pyrimidine (Figure 1.4). Both of these dimers distort the helical 
structure of the DNA as the bases are drawn together and create blocks to 
replication until their removal. Oxidation products can also be formed by reaction of 
the DNA reactive oxygen species (ROS) of which 8-oxo-7,8-dihydroguanine (8-
oxoG) is the most common lesion formed (Figure 1.4) (Rastogi et al., 2010). If 
unrepaired, this can lead to the conversion of the guanine base to a thymine and is 
therefore a potential cause of mutagenesis (Cheng et al., 2005). 
 
Repair of lesions of this nature is important as they can represent blocks to faithful 
replication of the DNA and can lead to the introduction of double-strand breaks 
(DSBs) through the collapse of stalled replication forks. Replication forks can stall 
when the polymerase becomes uncoupled from the helicase due to a distortion in 
helical DNA structure. Photolyase enzymes in mammals bind to CPDs or 6-4PPs and 
use energy from visible light to monomerise the cyclobutane ring, splitting the 
dimer (Rastogi et al., 2010). This process is termed photoreactivation. Base 
excision repair (BER) and Nucleotide excision repair (NER) are important repair 
processes for UV-induced lesions and are discussed in detail below.  
Genetic 
Diseases 
Aging Cancer Development 
Figure 1.3 The DNA Damage Response (DDR).  
 
The response to DNA damage involves control of the cell cycle, induction of 
DNA repair processes, senesence or apoptosis. A broader role of the DDR is 
increasingly evident involving pathways such as spindle checkpoints, 
transcription and circadian rhythm proteins. 
 
Adapted from Harper & Elledge, 2007. 
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Figure 1.4 UV –induced photoproducts 
 
a) T-T Cyclobutane pyrimidine dimer (CPD) 
b) pyrimidine 6-4 pyrimidone photoproduct (6-4PP) 
c) 8-oxo-7,8-dihydroguanine (8-oxoG)  
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UV irradiation also activates checkpoint mechanisms within the cell to delay the cell 
cycle in order to allow damaged bases to be repaired. This checkpoint activation will 
be discussed in detail in section 1.5. 
 
1.2.2 Base excision repair 
 
Base excision repair (BER) is the principal pathway that repairs bases damaged by 
alkylating agents, deamination and reactive oxygen species (Berquist and Wilson, 
2012). Short-patch BER repairs lesions involving one nucleotide and long-patch BER 
repairs lesions involving two or more nucleotides (Figure 1.5). Both pathways are 
initiated by the removal of the damage by a DNA Glycosylase. DNA glycosylases 
cleave the N-glycosidic bond to remove the base, resulting in an abasic site (AP 
site) or a single-strand break. In short patch repair, AP endonuclease 1 (APE-1) 
then makes an incision at this site to create a gap in the DNA, which is detected by 
Poly(ADP-ribose) polymerase 1 (PARP1). PARP1 plays an important role in the 
recruitment of further repair factors to the damage site.  End processing of the 
damaged termini is then performed by enzymes such as polynucleotide kinase 3’-
phosphatase (PNKP) and aprataxin (APTX). This restores the 3’ hydroxyl and 
5’phosphate ends required for gap-filling and ligation steps to occur (Caldecott, 
2008). X-ray cross–complementing group 1 (XRCC1), is a scaffold protein that 
interacts with end-processing enzymes and promotes their accumulation at damage 
sites. DNA polymerase beta (Pol!) is then recruited to the damage site. Pol! 
possesses both dRP lyase activity and polymerase activity and is thus able to fill the 
gap and remove the 5’ phosphate to enable DNA ligase III (LIGIII) to seal the 
remaining nick.  
 
In long-patch BER, the damaged flap 5’ to the lesion is removed by Flap 
endonuclease 1 (FEN1) and this reaction is stimulated by Proliferating Cell Nuclear 
Antigen (PCNA) and PARP1 (Caldecott, 2008). PCNA interacts with specialised 
polymerases such as Pol"/# or Pol! to extend and fill the gap by insertion of the 
correct nucleotides. The remaining nick is then sealed by DNA ligase 1 (LIG1). 
 
Patients with mutations in the BER protein Aprataxin present with a disorder called 
Ataxia-oculomotor apraxia 1 (AOA1). The clinical features of this syndrome include 
cerebellar atropy, ataxia and peripheral axonal neuropathy. A similar syndrome 
Spinocerebellar ataxia with axonal neuropathy 1 (SCAN1) has also been described 
where patients also show cerebellar atrophy and peripheral neuropathy. These 
patients were found to have mutations in Tyrosyl-DNA phosphodiesterase 1 (TDP1), 
PARP1 PARG 
XRCC1 
PNK 
APTX 
APE1 
LIGIII 
XRCC1 LIGIII 
Pol ! 
Short patch repair (1nt) 
PARP
1 
XRCC1 
LIGIII 
Pol ! 
Pol 
"/# 
FEN1 
Long patch repair (2-12 nt) 
XRCC1 
LIGIII 
PCNA 
LIGI 
Figure 1.5 Base excision repair 
 
Apurinic-apyrimidinic (AP) sites and single strand breaks are detected by 
poly(ADP-ribose) polymerase 1 (PARP1) which promotes accumulation of 
further repair factors. Poly(ADP-ribose) glycohydrolase (PARG) returns PARP1 
to its pre-activated state, allowing further detection of SSBs. End processing of 
any damaged termini is then performed by polynucleotide kinase (PNK), AP 
endonuclease (APE1) and Aprataxin (APTX). Flap endonuclease 1 (FEN1) 
removes the 5’ flap in long patch repair. Pol !, Pol" or Pol# fills in the gap and 
DNA ligase III(LIGIII) repairs the nick in short patch repair whilst DNA Ligase I 
(LIGI) repairs it in long patch repair. 
 
Figure adapted from Caldecott, 2008. 
AP site/SSB 
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a protein involved in the repair of DNA topoisomerase 1 (TOP1) associated SSBs 
(Caldecott, 2008).   
 
1.2.3 Nucleotide Excision Repair  
 
Nucleotide excision repair (NER) is the major repair pathway utilised for the 
removal of bulky lesions within the DNA that cause distortion of the DNA helix. 
These lesions include UV induced damage such as CPD’s and 6-4PPs, as discussed 
earlier, and also DNA adducts caused by agents such as aromatic amines 
(Nouspikel, 2009). There are two distinct pathways of NER; Global genome repair 
(GGR) and transcription coupled repair (TCR). The core processes are the same for 
each pathway and involve; damage recognition, assembly of the pre-incision 
complex, removal of the damaged strand by the introduction of incisions on either 
side of the lesion, and finally the filling in of the resulting gap followed by its 
ligation (Hanawalt et al., 2003) (Figure 1.6). 
 
Global genome repair (GGR) is the NER pathway used in non-coding or silent gene 
regions of the DNA. The DNA damage recognition step in this pathway involves UV-
damage DNA binding protein (UV-DDB1 and 2, also known as the XPE complex) 
and the DNA damage-binding protein XPC-HR23B (Cleaver et al., 2009). 
Transcription coupled repair (TCR) occurs in transcriptionally active regions of the 
genome and is detected by the stalling of RNA polymerases I and II (RNAPI/II). 
Cockayne Syndrome A (CSA) and Cockayne syndrome B (CSB) are then recruited 
to displace the RNA polymerase to allow repair to continue. Once the damage has 
been detected the pathways converge and lesions are dealt with in the same 
manner. Transcription factor-IIH (TFIIH) is composed of ten subunits including XPB, 
XPD, p62, p44, p34, p52, p8, Mat1, Cdk7 and CyclinH. It is recruited to the damage 
and unwinds the DNA by virtue of its helicase activity (Rastogi et al., 2010). RPA, 
XPA and XPG are then recruited, although the exact sequence of events is unclear. 
XPG cleaves the DNA around the damage site on the 3’ side, whilst XPF-ERCC1 
cleaves on the 5’ side. The damage is then removed and the repair patch is filled 
and ligated by the BER machinery (Cleaver et al., 2009). 
 
Mutations in proteins involved in nucleotide excision repair give rise to distinct 
clinical diseases; Xeroderma Pigmentosum (XP), Cockayne Syndrome (CS) and 
Trichothiodystrophy (TTD). These disorders have diverse clinical features that 
include developmental and neurological problems, dwarfism, microcephaly and 
mental retardation (Cleaver et al., 2009). 
Helix distorting damage  
RNAPI/
II 
CSB 
RNAPI/
II 
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DDB2 
DDB1 XPE 
XPC 
23B 
XPC 
XPD 
TFIIH 
XPB 
23B 
RPA 
XPD 
TFIIH 
XPG 
XPA 
ERCC1 
XPF 
3’ incision 5’ incision 
Transcription coupled repair Global genomic repair 
Common repair pathway 
Figure 1.6 Nucleotide excision repair 
 
Damage recognition by RNAPI/II (TCR) or XPC and XPE (GGR) is followed by 
recruitment of TFIIH which unwinds the DNA helix by the helicase activity of XPD. 
Cleavage of the damage site is then performed by the XPG (3’) and XPF-ERCC1 
(5’) nucleases. BER machinery can then refill and ligate the repair patch. 
 
Figure adapted from Cleaver et al, 2009. 
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1.2.4 Non-homologous End-joining 
 
Double strand breaks can arise in the cell, either directly through exposure to 
ionising radiation or indirectly through the collapse of stalled replication forks. Non-
homologous End–joining (NHEJ) is an error-prone process employed by the cell to 
ligate the ends of the DSB without the need for a homologous chromatid. This is 
particularly important in G1 where the sister chromatid is not available. DSBs in the 
DNA are recognised by the Ku70/80 heterodimer that binds to the DNA ends and 
recruits the DNA-dependent protein kinase catalytic subunit (DNA-PKcs). DNA-PKcs 
becomes activated through its interaction with the DNA and Ku. It phosphorylates 
Artemis as well as undergoing autophosphorylation. Artemis is a nuclease that 
resects the overhanging ends of the DNA in preparation for re-ligation. DNA 
polymerase µ (Polµ) fills in the gap and the ends are ligated by DNA Ligase IV/ X-
ray repair, complementing defective repair in Chinese Hamster (LIG4/XRCC4) in 
conjunction with XRCC4-like factor (XLF) (Lieber, 2010, Lieber and Wilson, 2010) 
(Figure 1.7).  
 
Patients with mutations in the NHEJ protein LIG4 display radiosensitivity, 
developmental delay and microcephaly (O'Driscoll et al., 2001). Radiosensitive 
severe combined immunodeficiency (RS-SCID), where patients exhibit severe 
immunodeficiency without developmental delay, is caused by mutations in Artemis 
(Moshous et al., 2001). 
 
1.2.5 Homologous Recombination 
 
Homologous recombination (HR) is the repair process that is preferentially used in 
the S and G2 phases of the cell cycle for the repair of DSBs, when a homologous 
sister chromatid is available. In order for HR to proceed, the ends of the DSB must 
be resected in a 5’ to 3’ direction. This resection is undertaken by Exonuclease1 
(Exo1) and the Mre11-Rad50-Nbs1 (MRN) complex (Ira et al., 2004). CtIP also 
works in conjunction with MRN to promote resection (Sartori et al., 2007). The 
single-stranded DNA (ssDNA) created by the resection activity then becomes 
coated with Replication protein A (RPA). This is then displaced by the Rad51 
protein, which forms filaments along the DNA. These regions initiate HR by invading 
the strand of the homologous sister chromatid to form a D-loop structure. DNA 
polymerase $ extends the DNA strand from the 3’ end, using the donor DNA strand 
as a template. Double Holliday junctions are then formed when the break end 
interacts with the displaced strand from the intact homologous chromatid. Holliday 
Ku 
DNA-PKcs 
DNA-PKcs 
Ku 
Artemis 
P P
Double strand break 
End binding 
End processing 
DNA-PKcs 
Ku 
Artemis 
Gap filling and ligation 
XRCC4 
LIG4 
Pol µ 
Figure 1.7 Non-homologous end joining of double strand breaks (DSBs). 
 
DSBs in the DNA are recognised by Ku which binds to the DNA ends and 
recruits DNA-PKcs. DNA-PKcs is activated through its interaction with the 
DNA and it phosphorylates itself and Artemis. Artemis resects the ends of 
the DNA in preparation for re-ligation. Pol µ fills in the gap and the ends are 
ligated by XRCC4/LIG4 in conjunction with XLF.  
 
Figure adapted from Lieber and Wilson, 2010. 
XLF 
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junctions are resolved by cleavage of strands by either BLM-Top3 or Mus81-Eme1 
nuclease complexes. The ends are then ligated yielding either crossover or 
noncrossover products (Mazón et al., 2010) (Figure 1.8). Cells from patients with 
Bloom’s syndrome, harbouring mutations in the RecQ helicase BLM, exhibit a high 
incidence of homologous recombination as evidenced by increased rates of sister 
chromatid exchanges (SCE’s) (Bartram et al., 1976). 
  
1.3 ATM AND ATR: REGULATORS OF THE DNA DAMAGE 
RESPONSE  
 
The main regulators of the DNA damage response are Ataxia telangiectasia 
mutated (ATM), Ataxia telangiectasia Rad3 related (ATR) and DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs). These proteins are members of the 
phosphoinositol 3-kinase like kinase (PIKK) family of protein kinases, which also 
includes mammalian target of rapamycin (mTOR), suppressor of morphogenesis in 
genitalia (SMG1) and transformation/transcription domain-associated protein 
(TRRAP) (Lempiäinen and Halazonetis, 2009). These proteins share a common 
domain structure (Fig 1.9), which is conserved within the PIKKs and but is distinct 
from other protein kinases. These domains are the FRAP-ATM-TRRAP (FAT) domain, 
the kinase domain (KD), the PIKK-regulatory domain (PRD) and the FAT-C-terminal 
(FATC) domain (Lempiäinen and Halazonetis, 2009). The FAT, PRD and FATC 
domains are involved in regulating the activity of the kinase domain through 
protein-protein interactions and post-translational modifications. These kinases 
predominately phosphorylate substrates at –S/T-QN- sites where a serine or 
threonine residue is followed by a glutamate (Shechter et al., 2004).  
 
1.3.1 ATM activation 
 
ATM and DNA-PKcs are activated by double strand breaks (DSBs), such as those 
induced by exposure to ionising radiation.  ATM is recruited to DSBs via an 
interaction with the Mre11-Rad50-Nbs1 (MRN) complex, whilst DNA-PKcs is 
recruited by an interaction with Ku70/80 (Lovejoy and Cortez, 2009). These 
associated proteins have DNA end binding properties, essential for correct PIKK 
localisation to the damage (Falck et al., 2005). 
 
In undamaged cells, ATM is present as an inactive dimer (Goodarzi et al., 2004). 
Upon DNA damage, ATM undergoes autophosphorylation at serine 1981 and the 
dimer dissociates into active monomers (Bakkenist and Kastan, 2003). This 
Mre11 
Nbs1 Rad50 
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Rad51 filament 
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Strand invasion 
Branch migration 
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Holliday Junction 
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Figure 1.8 Homologous Recombination 
 
DSB ends are resected by Exo1 and MRN nuclease yielding an ssDNA 
region that becomes coated with RPA. This is displaced by Rad51, mediated 
by BRCA2. Rad51 filaments promote strand invasion of the homologous 
chromatid. DNA synthesis by DNA polymerase ! extends the DNA strand. 
Holliday junctions are formed and resolved by BLM-Top3 or Mus81-Eme1 
nucleases. Ligation of the ends completes the reaction. 
 
Figure adapted from Sancar et al, 2004 
Figure 1.9 PIKK family domain structure 
 
See text for information on domain function. 
 
Figure adapted from Lempiainen and Halazonetis, 2009 
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phosphorylation is important to retain ATM at the damage site, although it is not 
required for its initial localisation (So et al., 2009). ATM is then recruited to the 
DSB via an interaction with the C-terminus of Nbs1 of the MRN complex, the initial 
sensor of the damage (Cerosaletti et al., 2006). ATM then phosphorylates histone 
H2AX to produce "H2AX and this phosphorylation recruits a mediator protein, 
mediator of DNA-damage checkpoint protein-1 (MDC1) to the break (Stewart et al., 
2003). H2AX can also be phosphorylated by DNA-PK in a redundant manner (Stiff 
et al., 2004). Phosphorylated MDC1 recruits further proteins to the break site such 
as the ubiquitin ligase RING-finger-protein-8 (RNF8) and RING-finger-protein-168 
(RNF168) (Mailand et al., 2007, Doil et al., 2009). RNF8 then ubiquitylates "H2AX, 
resulting in the recruitment of breast cancer susceptibility protein-1 (BRCA1) and 
p53 binding protein-1 (53BP1). RNF168 helps to maintain the ubiquitination of 
"H2AX and helps to stabilise the recruitment of BRCA1 and 53BP1 (Derheimer and 
Kastan, 2010). Thus, the ATM signalling cascade is critical to signal the presence of 
a subset of DSBs to further downstream repair processes such as non-homologous 
end-joining (NHEJ) or homologous recombination (HR) (Figure 1.10).  
 
Ataxia telangiectasia (A-T) (OMIM 208900) is an autosomal recessive DNA damage 
response disorder that arises due to mutations in ATM. Cell lines from these 
patients have defects in all cell cycle checkpoints, are sensitive to killing by ionising 
radiation and also show defects in the repair of a subset of DSBs (Riballo et al., 
2004). Clinical features of the disorder include progressive cerebellar ataxia, 
telangiectases, immune defects and cancer predisposition, however, unlike some of 
the other DNA damage response disorders that will be described later, AT patients 
do not display microcephaly (O'Driscoll and Jeggo, 2006).  
 
1.3.2 ATR activation 
 
ATR is activated in response to many kinds of DNA damage including base adducts, 
crosslinks, replication stress and persistent DSBs, where ssDNA regions are 
generated. However, it is primarily activated by the production of a common 
structure resulting from these different damage effects (Cimprich and Cortez, 
2008). The excision of pyrimidine dimers induced by UV irradiation, mediated by 
the nucleotide excision repair pathway (Branzei and Foiani, 2008), the stalling of 
replication forks where a lesion causes the polymerase and helicase to become 
uncoupled, the resection of the end of a DSB by nucleases (Jazayeri et al., 2006); 
all of these cellular processes generate a region of single-stranded DNA that is next 
Ub 
Figure 1.10  ATM-dependent recruitment of proteins to a DSB. 
ATM exists in the cell as an inactive dimer. Upon induction of a DSB, ATM 
undergoes autophosphorylation and forms active monomers. ATM and the 
MRN complex are then recruited to the break where ATM phosphorylates 
MRE11, NBS1 and H2AX. The phosphorylation of H2AX enables recruitment 
of MDC1. MDC1 is phosphorylated by ATM and recruits RNF8. RNF8 mono-
ubiquitinates !H2AX which results in the recruitment of 53BP1, BRCA1 and 
RNF168. RNF168 maintains the ubiquitination of !H2AX, stabilising 53BP1 
and BRCA1 at the break. 
 
Figure and legend adapted from Derheimer and Kastan, 2010. 
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to a region of double-stranded DNA with a 5’ primer end (Figure 1.11). This is the 
DNA structure that is thought to activate ATR (Cimprich and Cortez, 2008). 
 
When single-standed DNA (ssDNA) is detected in the cell it rapidly becomes coated 
with RPA. RPA is a heterotrimeric single-standed DNA binding complex that is 
composed of three subunits, RPA1 (70kD), RPA2 (32kD) and RPA3 (14kD). It plays 
important roles in DNA replication such as ssDNA stabilisation and replication 
initiation, as well as after DNA damage where it is essential for the assembly of 
signalling complexes onto damaged DNA (Namiki and Zou, 2006, Olson et al., 
2006). The N-terminal oligonucleotide-oligosaccharide fold (OB fold) domain of 
RPA1 directly binds to the N-terminus and two further domains of ATR-interacting 
protein (ATRIP), recruiting the ATRIP-ATR complex to ssDNA (Zou and Elledge, 
2003, Namiki and Zou, 2006, Ball et al., 2007). In cells, ATR exists in a stable 
complex with ATRIP and the expression of each protein is dependent on the other 
(Cortez et al., 2001). The structure and function of ATRIP will be discussed in more 
detail in Chapter 4. 
 
The Rad17-RFC2-5 clamp-loader complex is independently recruited to RPA-ssDNA, 
where it recruits and loads the Rad9-Hus1-Rad1 (9-1-1) complex onto the 
chromatin in the presence of a dsDNA-ssDNA junction (Zou et al., 2002), (Burrows 
and Elledge, 2008). DNA topoisomerase II binding protein 1 (TopBP1) is then 
recruited to the damage via an interaction with the C-terminal tail of Rad9 (Greer 
et al., 2003). Once all these proteins are assembled at the site of damage, an 
interaction between TopBP1 and both ATR and ATRIP stimulates ATR activation and 
the ATR kinase becomes fully active (Mordes et al., 2008). Threonine 1989 on ATR 
was recently identified as a marker for the active kinase (Nam et al., 2011). ATR is 
auto-phosphorylated at this site after damage and this is promoted by the presence 
of multiple ATR-ATRIP complexes on RPA-ssDNA (Liu et al., 2011). The 
phosphorylation was proposed to occur in trans along the RPA-ssDNA stretch. The 
T1989 phosphorylation then mediates the interaction of TopBP1 and ATR, resulting 
in full kinase activity.  
  
1.4 ATR-DEPENDENT SIGNALLING 
 
ATR has been shown to be essential for embryonic development. An elegant study 
demonstrated that ATR-/- embryos survive the earlier stages of development but 
die following implantation, at around day 7 postcoitem (Brown and Baltimore, 
2000). ATR+/- heterozygous mice survive for longer but greater numbers of these 
5’ 
5’ 
5’ 
5’ 
a) 
c) 
b) 
Figure 1.11 DNA structures that activate ATR 
 
a)  Single-stranded intermediate in nucleotide excision repair 
b)  End resection of double strand breaks 
c)   Regions of ssDNA generated during replication fork stalling 
 
Adapted from Cimprich & Cortez, 2008. 
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animals had died by 18 months than the control or ATM+/- animals. The ATR+/- 
animals also showed higher tumour incidence than controls upon post-mortem 
examination. In contrast to ATR, ATM-/- mice are viable but display growth 
retardation and are infertile (Xu et al., 1996). These studies demonstrate the 
essential nature of the ATR-dependent signalling pathway in development.  
 
Recent studies have produced further mouse models to aid our understanding of 
the consequences of deficient ATR function. In one study, ATR was down regulated 
in all tissues in adult mice by the use of Cre-technology (Ruzankina et al., 2007). 
Stem and progenitor cell depletion was observed in tissues with high replicative 
capacity and a loss of the capacity of these tissues to renew. There was little effect 
on post-mitotic brain tissue. Premature aging-related phenotypes such as hair 
greying and osteoporosis were also observed. This study therefore eloquently 
illustrates the importance of ATR not only in development but also in ongoing 
cellular proliferation.  In a further study, the ATR mutation that leads to aberrant 
splicing in the described ATR-Seckel patient (O'Driscoll et al., 2003) was engineered 
into a mouse model termed ATRs/s (Murga et al., 2009). The ATRs/s mice were born 
at sub-mendelian ratios and are phenotypically reminiscent of human Seckel 
syndrome, displaying severe growth retardation, microcephaly, receding foreheads 
and micrognathia. The mice did not survive beyond six months and also exhibited 
premature ageing related phenotypes such as hair greying and osteoporosis. 
Examination of embryonic fibroblast cells revealed an increased activation of the 
DNA damage response, as measured by H2AX phosphorylation, 53BP1 foci 
formation and chromosome breakage. It was proposed that this response was due 
to an increase in replication stress. When ATRs/s embryos were examined for the 
same replication stress indicators, the results were reproduced in vivo and also 
were shown to result in increased levels of apoptosis in the tissues examined.  
 
A recently conducted study has demonstrated the importance of ATR in neural 
development. An elegant system was utilised to reduce embryonic expression of 
ATR in mice from E10.5. Mice were born with Seckel like features such as growth 
retardation, reduced brain size and defects in brain development, but died about 7 
days later (Lee et al., 2012). Post mortem examination of the brain revealed 
decreased cellularity of the cortex and the corpus callosum. Increased DNA 
damage, as evidenced by H2AX phosphorylation, was detected in the external 
granule layer (EGL) of the cerebellum and the ganglionic eminence (GE) of the 
cortex. However, other parts of the brain were not affected, indicating that ATR is 
required for the maintenance of specific neuroprogenitor cells. It was proposed that 
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this is due to the rapid proliferation of these cells, which exerts a higher 
dependency on ATR signalling potentially due to higher levels of replicative stress in 
these cell populations.  
 
Once ATR has become fully activated as described in section 1.3.2 it can then 
phosphorylate many downstream targets to effect different cellular outcomes 
(Figure 1.12). Some important targets of ATR will be discussed in this section. 
 
1.4.1 H2AX 
 
The Histone H2A variant X (H2AX) can be phosphorylated by all the PIKKs as an 
early step in the DDR. It is phosphorylated on S139 in the C terminal tail and is 
then referred to as "H2AX (Fernandez-Capetillo et al., 2003). This modification 
stretches for megabases along the chromatin, surrounding the damage site 
(Rogakou et al., 1999). This is usually a DSB, formed either directly by external 
damage, after exposure to ionising radiation, or induced by processes such as 
recombination during meiosis or V(D)J recombination (Ward and Chen, 2001). 
Phosphorylation of H2AX has also been shown to be induced by the fragmentation 
of DNA during apoptosis (Rogakou et al., 2000). 
 
H2AX has also been shown to be phosphorylated in an ATR-dependent manner 
after exposure to UV or HU treatment and to form foci at replication forks during S 
phase (Ward and Chen, 2001). Further studies have demonstrated that ATR-
dependent, UV-induced H2AX phosphorylation is cell cycle phase independent and 
is triggered by the generation of DNA repair-induced intermediates, specifically 
those produced by the NER pathway of DNA repair (Hanasoge and Ljungman, 
2007).   
 
The phosphorylation of H2AX is important in order to recruit and retain further DDR 
mediator and effector proteins to damage sites such as BRCA1, 53BP1, MDC1, 
Rad51 and the MRN complex (Fernandez-Capetillo et al., 2003). H2AX-/- mice 
exhibit increased chromosomal instability, growth defects and defects in DNA repair 
(Bassing et al., 2002, Celeste et al., 2002), demonstrating the importance of H2AX 
in maintaining genome stability. After replication fork stalling, H2AX is also required 
for the induction of a p21-dependent cell cycle arrest (Fragkos et al., 2009). 
 
 
 
Figure 1.12 ATR–dependent signalling  
 
Stretches of ssDNA formed by the stalling of replication forks or excision of 
UV damage is rapidly coated with RPA. The rad17-rfc complex loads the 9-1-1 
complex onto the DNA. An interaction between TopBP1 and the tail of Rad9 
recruits TopBP1 to the damage site. ATRIP is recruited via an interaction with 
RPA, recruiting the ATR-ATRIP complex to the site. When ATR, ATRIP and 
TopBP1 are localised together ATR becomes fully activated. ATR can then 
phosphorylate downstream targets such as p53, BRCA1 and Chk1. 
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1.4.2 Chk1 
 
Checkpoint kinase 1 (Chk1) is an essential kinase that is phosphorylated by ATR 
both during an unperturbed cell cycle and in response to DNA damage (Liu et al., 
2000). ATR phosphorylates Chk1 on amino acids ser317 and ser345, resulting in its 
activation. It has been demonstrated that phosphorylation of ser345 is dependent 
on the initial phosphorylation of ser317, with speculation that this prior 
phosphorylation induces a conformational change in Chk1, allowing the second 
phosphorylation to occur (Wilsker et al., 2008). 
 
The efficient phosphorylation of Chk1 by ATR requires two other protein complexes. 
Claspin is a mediator protein that is found at the replication fork, binds to 
phosphorylated Rad17 (Wang et al., 2006) and interacts with Chk1 after DNA 
damage (Kumagai and Dunphy, 2000). The interaction of Claspin with Chk1 
requires three Chk1 binding motifs and the phosphorylation of Claspin on sites 
Thr916 and Ser 945/982 (Chini and Chen, 2006). The kinase responsible for these 
phosphorylation events is unknown, as these sites are not consensus sites for ATR. 
It is possible that Chk1 regulates itself in a positive feedback loop as it is able to 
phosphorylate Claspin on Thr916 in vitro (Chini and Chen, 2006). 
This Claspin-mediated Chk1 phosphorylation event is promoted by the association 
of Timeless-interacting protein (Tipin)-Timeless complexes and Tipin-Claspin 
complexes on stretches of RPA-ssDNA. The association of these protein complexes 
on the chromatin is facilitated by the interaction of Tipin with the 34kDa subunit of 
RPA (Kemp et al., 2010). 
 
Once Chk1 is phosphorylated it is released from the chromatin into the surrounding 
nuclear environment (Smits et al., 2006). It has been proposed that the 
phosphorylation of Ser317 on Chk1 is important for its release from the chromatin, 
whilst phosphorylation at Ser345 is important for the subsequent cellular 
relocalisation of Chk1 to the cytoplasm and centrosomes (Niida et al., 2007). The 
accumulation of Chk1 at the centrosome plays a role in preventing Cdk1 activation, 
thus controlling mitotic entry (Krämer et al., 2004). This mechanism will be 
discussed in detail in Chapter Three.  
 
Chk1-/- mice are embryonic lethal (Liu et al., 2000) before embryonic day 6.5, 
demonstrating that Chk1 is an essential kinase. Subsequent studies have revealed 
that phosphorylation of Chk1 at Ser345 may have an essential function as human 
cell lines harbouring this mutation could not be generated, although cell lines were 
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successfully created containing the Ser317 mutation (Wilsker et al., 2008). 
Exogenously expressed Chk1 mutated at Ser345 is also unable to rescue the Chk1 
lethal phenotype of knockout mouse embryonic cells. However Ser317 is 
dispensable for this function (Niida et al., 2007).  
 
Depletion of Chk1 also leads to replication fork slowing and stalling (Petermann et 
al., 2006), as well as an increase in the number of replication-associated DNA 
strand breaks (Syljuåsen et al., 2005). How Chk1 is involved in the regulation of 
replication is not clear. It is known to regulate origin firing during replication stress 
by inhibiting the activation of new replication factories (Ge and Blow, 2010). Chk1 
is also required to maintain the rate of replication fork progression during an 
unperturbed S phase, with speculation that its role lies in the stabilisation of 
replication forks (Petermann et al., 2006).  
 
1.4.3 53BP1 
 
p53-interacting protein 1 (53BP1) is a mediator protein that is involved in 
recombination, the activation of p53 (Harper and Elledge, 2007) and is rapidly 
recruited to sites of DNA damage, where it associates with "H2AX and serves as a 
scaffold to concentrate damage response proteins to the site (Sakasai and Tibbetts, 
2008). It is phosphorylated by ATM following ionising radiation and is recruited to 
DSB’s where it serves to amplify the ATM signal via the accumulation of the MRN 
complex (Noon et al., 2010). 53BP1 also plays a role in both the initiation of G2/M 
checkpoint arrest at low IR doses and the maintenance of checkpoint arrest after 
high IR doses (Shibata et al., 2010). Depletion of 53BP1 leads to checkpoint defects 
at low doses of IR as well as defects in DSB repair by NHEJ (Sakasai and Tibbetts, 
2008).  
 
The role of 53BP1 in the ATR-dependent signalling pathway is less clear. It has 
been shown that after induction of replication stress by UV or HU treatment, 53BP1 
is phosphorylated by ATR at several sites, as early as 15 minutes post treatment 
(Jowsey et al., 2007). It then localises to stalled replication forks, and this 
recruitment is partially dependent on both UBC13, a ubiquitin-conjugating enzyme 
and RNF8, an E3 ligase (Sakasai and Tibbetts, 2008). The formation of 53BP1 foci 
during S phase arrest is known to be dependent on both ATR and Chk1 (Sengupta 
et al., 2004). In this scenario, 53BP1 has an anti-recombinogenic role and recruits 
BLM (Bloom helicase protein) to HU-induced stalled replication forks. 53BP1 then 
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interacts with BLM and Rad51 in a Chk1 dependent manner and modulates Rad51 
to control HR at these sites of replication stress (Tripathi et al., 2008).   
 
Similar to its role in ATM signalling, 53BP1 is required for replication-independent 
ATR checkpoint activation following UV treatment, possibly by serving to amplify 
ATR signalling (Stiff et al., 2008). It was demonstrated that 53BP1 is recruited to 
sites of focused UV damage, independent of "H2AX, indicating that there may be 
different processes involved in the recruitment of 53BP1 to stretches of ssDNA to 
those for its recruitment to DSBs. 
 
1.4.4 Fanconi Anemia Pathway proteins 
 
The Fanconi Anemia (FA) pathway is critical for the repair of interstrand crosslinks 
(ICLs). These arise when the two strands of DNA become covalently linked due to 
the binding of agents such as Cisplatin, nitrous acid and aldehydes. ICLs are blocks 
to transcription and replication and therefore their removal is essential to maintain 
genome stability. The FA pathway is composed of at least fifteen different proteins. 
The FA core complex consists of eight FA proteins (FANCA/B/C/E/F/G/L/M) and two 
FA-associated proteins (FAAP24 and FAAP100). This complex forms an E3 ubiquitin 
ligase, the function of which is to monoubiquitinate two further FA proteins, 
FANCD2 and FANCI. Monoubiquitinated FANCD2 then becomes active and recruits 
Fanconi-associated nuclease 1 (FAN1) to the damage site. FANCD2 interacts with 
damage response proteins such as BRCA1, BRCA2 and FANCJ, which facilitate DNA 
repair via homologous recombination (Kee and D'Andrea, 2010). 
 
Crosstalk occurs between the FA pathway and the ATR pathway, possibly allowing 
coordination of checkpoint mechanisms with repair. ATR is required for the 
monoubiquitination of FANCD2 after damage and ATR deficient cells are 
hypersensitive to ICLs (Andreassen et al., 2004). ATR-ATRIP is required for the 
phosphorylation of FANCI and ATR has been shown to phosphorylate FANCI in vitro 
(Ishiai et al., 2008, Shigechi et al., 2012). FANCM and FAAP24 interact with a 
complex of ATR and HCLK2 and are required for activation of ATR-dependent S-
phase checkpoint responses (Collis et al., 2008).  
 
The FA pathway has also been shown to be important in the survival and 
maintenance of neural progenitors. FANCA-/- and FANCG-/- mice present with 
features such as microcephaly with abnormal development of the cortex (Sii-Felice 
et al., 2008).  
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Patients with mutations in the Fanconi Anemia proteins present with microcephaly, 
bone marrow failure and a high incidence of cancers. Cells from FA patients exhibit 
increased genomic instability in the form of hypersensitivity to ICL-inducing agents 
and increased chromosome aberrations (Kee and D'Andrea, 2010). 
 
1.4.5 BRCA1 
 
BRCA1 is a large protein that is involved in many cellular pathways, interacting with 
a variety of proteins including tumour suppressors, DNA repair proteins and cell 
cycle regulators. The N-terminal RING domain of BRCA1 confers E3 ubiquitin ligase 
activity, which is enhanced when BRCA1 is in complex with BRCA1-associated RING 
domain protein-1 (BARD1) (Wu et al., 1996). BRCT domains within BRCA1 mediate 
protein-protein interactions. BRCA1 plays multiple roles in HR by forming 
complexes with multiple proteins. BRCA1 in complex with Abraxas and Receptor-
associated protein-80 (RAP80) binds to DSBs and results in the ubiquitination of 
histones around the DSB (Wang et al., 2007). BRCA1 in complex with CtIP and the 
MRN complex mediates resection of the 5’ DNA end (Yun and Hiom, 2009). BRCA1 
in complex with BARD1 and TOPBP1 plays a role in the repair of replication-
associated damage (Greenberg et al., 2006) and may mediate ATR dependent 
checkpoint signalling, although its function here is not known (Roy et al., 2012).The 
recruitment of RAD51 to sites of DNA damage is also dependent on BRCA1 in 
complex with Partner and localiser of BRCA2 (PALB2) and BRCA2.  
 
The function of BRCA1 in checkpoint responses to DNA damage is not well 
understood. It is known that BRCA1 is required for ATM/ATR to phosphorylate 
particular targets in response to damage, such as facilitating the phosphorylation of 
p53 on ser15 (Foray et al., 2003). This phosphorylation is required for inducing 
transcription of p21, a CDK inhibitor, and results in activation of the ionising 
radiation induced G1/S checkpoint (Siliciano et al., 1997). How BRCA1 is precisely 
involved here is not known although depletion of BRCA1-BARD1 results in reduced 
p21 induction (Fabbro et al., 2004). Cells with deficient BRCA1, BARD1, RAP80 or 
Abraxas also exhibit defects in G2/M checkpoint activation following exposure to IR 
(Kim et al., 2006, Kim et al., 2007a, Kim et al., 2007b).  BRCA1 interacts with 
ATRIP phosphorylated at Ser239 and disruption of this interaction leads to G2/M 
checkpoint defects (Venere et al., 2007). 
 
 
 17 
1.4.6 p53 
 
p53 is a transcription factor that regulates the expression of a large number of 
genes involved in many cellular processes such as DNA repair, apoptosis, cell cycle 
progression, and cell senescence. Under unperturbed cell cycle conditions, p53 is 
degraded by the MDM2 ubiquitin ligase, rendering it functionally inactive. When 
cells are exposed to stress such as DNA damage, hypoxia, or oxidative damage, 
p53 levels accumulate due to the shut down of MDM2 mediated degradation (Hayon 
and Haupt, 2002). 
 
In response to UV-induced DNA damage or stalled replication forks, ATR 
phosphorylates p53 on Ser15. This causes the accumulation of p53 and results in 
increased transcription of p53 gene targets such as p21. This is a CDK inhibitor and 
contributes to the G2/M checkpoint by the direct inhibition of CDK by binding to 
CDK-Cyclin complexes (Boulaire et al., 2000). Gadd45 is another transcriptional 
target of p53 and is thought to inhibit the binding of CDK1 to cyclinB (Zhan et al., 
1999) p53 is also a transcriptional regulator of the 14-3-3 protein. This protein 
binds to CDK1, sequestering CDK1-CyclinB complexes in the cytoplasm and 
inhibiting mitotic entry.  
 
If DNA damage persists or is at a high level, the cell may undergo apoptosis. ATR 
phosphorylation of p53 can induce transcription of pro-apoptotic genes such as Fas, 
Bax, Puma and Noxa. These can activate the extrinsic death receptor apoptosis 
pathway, resulting in the assembly of the DIS-complex that is composed of Fas-
associated protein with death domain (FADD) and the pro-caspases 8 and 10. 
Activation of this pathway culminates in the digestion of the DNA by caspase-
activated DNase (CAD) and the inactivation of proteins by their degradation by 
caspases 3 and 7. The intrinsic mitochondrial apoptosis pathway is also activated 
resulting in the formation of an apoptosome composed of pro-caspase-9, Apoptotic 
protease activating factor-1 (Apaf-1) and cytochrome C. This complex also 
activates caspases resulting in DNA and protein degradation (Roos and Kaina, 
2012). 
 
1.5 ATR-DEPENDENT CHECKPOINTS 
 
Cell cycle checkpoints can be defined as a temporary delay or arrest of cell cycle 
progression in response to cellular stress (Sancar et al., 2004). These important 
cellular surveillance points are at the G1/S transition, intra S phase and the G2/M 
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transition. Additional checkpoints also exist that monitor the level of origin licensing 
(licensing checkpoint) (Shreeram et al., 2002), the fidelity of spindle assembly 
(spindle assembly checkpoint) (Rudner and Murray, 1996) and chromosome 
condensation and entry into mitosis (the antephase checkpoint) (Matsusaka and 
Pines, 2004). In this section I will discuss those checkpoints that are known to be 
dependent upon ATR signalling pathways.  
 
1.5.1 The Intra-S-phase checkpoint 
 
ATR plays an important role in the induction of S-phase checkpoints in response to 
replication stress. When a DNA polymerase encounters a block to replication, the 
helicase often continues to unwind the DNA and becomes uncoupled from the 
stalled polymerase. This results in the formation of a long stretch of single-stranded 
DNA that precedes the advancing fork (Paulsen and Cimprich, 2007). The 
generation of ssDNA causes the activation of ATR as described in section 1.3.2. 
Once activated, ATR initiates several cellular responses such as the phosphorylation 
and activation of Chk1. Chk1 then phosphorylates downstream targets such as 
Cdc25A, targeting it for ubiquitination and degradation by the Skp1/Cullin/F-box 
(SCF) complex (Busino et al., 2003). Cdc25A is then unable to remove the 
inhibitory phosphorylations at Threonine 14 and Tyrosine 15 of Cdk2, which is in 
complex with either CyclinA or CyclinE (Sebastian et al., 1993), resulting in 
inhibition of Cdk2 kinase activity (Falck et al., 2002). This prevents the loading of 
Cdc45 onto the chromatin, resulting in a down regulation of DNA replication by the 
inhibition of late firing origins (Costanzo et al., 2000, Mohammad et al., 2007). 
 
The activation of Chk1 can also lead to the inhibition of DNA elongation though the 
inhibition of tousled-like kinase (TLK1). TLK1 phosphorylates a chromatin assembly 
factor, Anti-silencing factor1 (Asf1). Upon DNA damage, TLK1 is inhibited resulting 
in dephosphorylation of Asf1 (Silljé and Nigg, 2001, Krause et al., 2003, Cook, 
2009). 
 
1.5.2 The G2/M checkpoint 
 
The G2/M checkpoint prevents cells that harbour DNA damage from undergoing 
mitosis and is activated by either ATM or ATR, depending on the damage detected 
(Sancar et al., 2004).  
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The control of entry into mitosis is governed largely by the activity of the Cdk1-
CyclinB complex. During normal cell cycle progression, the transcription of cyclinB1 
begins in S phase and rises to its peak in G2 phase (Lindqvist et al., 2009). Control 
of CyclinB protein levels is crucial as restriction of its availability limits the 
formation of Cdk1-CyclinB complexes. CyclinB shuttles between the nucleus and 
the cytoplasm. In S and G2 phase it is predominately found in the cytoplasm 
(Hagting et al., 1998, Toyoshima et al., 1998). As the centrosomes mature, in mid 
G2, CyclinB starts to accumulate there and by late G2, the highest concentration of 
CyclinB within the cell is located at the centrosomes (Jackman et al., 2003). This is 
the location, in human cells, where phosphorylated CyclinB can be detected first.  
 
CyclinB forms a complex with Cdk1 and in order for these complexes to become 
activated Threonine 161 in the T loop of Cdk1 must be phosphorylated. The Cdk-
activating kinase (CAK) mediates this phosphorylation when a threshold 
concentration of Cdk1-cyclinB complexes is reached (Tassan et al., 1994). Cdk1-
CyclinB complexes are also negatively regulated by inhibitory phosphorylations on 
T14 and Y15 of Cdk1 by the Wee1 and Myt1 kinases (Lindqvist et al., 2009). Active 
Cdk1-cyclinB complexes can regulate their own activity via positive feedback loops 
(Figure 1.13). Cdk1-cyclinB activation of the Cdc25 phosphatases can remove the 
inhibitory phosphorylation on T14 and Y15 of Cdk1, imposed by Wee1/Myt1. There 
are three Cdc25 isoforms present in mammalian cells; Cdc25A, Cdc25B and 
Cdc25C. Each of the isoforms can shuttle between the nucleus and the cytoplasm 
and all have also been found at the centrosome (Dutertre et al., 2004, Boutros et 
al., 2006, Busch et al., 2007, Bonnet et al., 2008, Shreeram et al., 2008). Polo-like 
kinase 1 (Plk1) and Aurora A kinase (AurA) also regulate Cdk1-cyclinB activity and 
will be discussed in detail in Chapter 6.  
 
The active Cdk1-CyclinB complexes build up steadily during G2 and translocate into 
the nucleus during mitotic entry. A further rapid activation of the majority of the 
Cdk1-CyclinB complexes takes place during the last thirty minutes before 
prometaphase, triggering mitotic entry (Lindqvist et al., 2007).  
 
The regulation of Cdk1-cyclinB activity has been proposed to be a switch-like 
bistable process (Lindqvist et al., 2007). Bistability in this context can be defined as 
the Cdk1-cyclinB complexes existing as either active, inactive or nearing one of 
these states. This system is also influenced by hysteresis which can be defined as 
the resistance of these stable states to change, for instance, once Cdk1-cyclinB is 
active it remains active and the cell is likely to enter mitosis, regardless of small 
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Figure 1.13 Cdk1-CyclinB control of mitotic entry 
 
a)  Feedback loops control activation of Cdk1-cyclinB complexes. Myt1 and 
Wee1 inhibit Cdk1-cyclinB activity whilst the Cdc25 phosphatases 
activate Cdk1. Once active Cdk1 can inhibit its inhibitors and activate its 
activators. Cdk1 also phosphorylates Bora, increasing its association with 
AurA and PLK1, leading to PLK1 activation. Active PLK1 increases Cdk1 
activation via Wee1 inhibition and Cdc25 activation. Centrosome 
maturation increases local concentrations of CyclinB through AurA and 
PLK1 activity. 
b)  Cdk1-CyclinB activation is triggered when complexes reach a threshold 
level in G2 and remain active until completion of mitosis 
 
Figure and legend adapted from Lindqvist, 2009. 
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fluctuations in Cdk1-cyclinB concentration (Lindqvist et al., 2009). In terms of 
mitotic entry this means that Cdk1-cyclinB activation will occur once a threshold of 
complexes is reached and that once the feedback loops maintaining this activation 
are initiated, they will remain active until mitosis is completed (Figure 1.13).  
 
The G2/M checkpoint initiated after UV damage is controlled by the same cyclin 
dependent kinases and has been shown to be ATR-dependent (Cliby et al., 1998). 
Upon detection of DNA damage, ATR is activated as previously described in section 
1.2.1.1 and phosphorylates downstream targets such as Chk1. Active Chk1 then 
phosphorylates Cdc25A at Serines 76 and 123 (Zhao et al., 2002, Donzelli et al., 
2004, Jin et al., 2008). Phosphorylation of Cdc25A at these and other sites, 
stimulates its ubiquitination via the Skp1/Cullin/F-box (SCF) proteins and target it 
for degradation (Busino et al., 2003). Chk1 also phosphorylates Cdc25C at Serine 
216, leading to its nuclear export via cytoplasmic sequestration by the 14-3-3 
protein (Peng et al., 1997). The phosphorylation of Cdc25B is also inhibited after 
DNA damage, via inhibition of AurA phosphorylation of the Ser323 site on Cdc25B. 
This phosphorylation event was shown to be Chk1 dependent (Cazales et al., 
2005). By controlling the access of Cdc25 proteins to Cdk1, Chk1 can downregulate 
Cdk1-cyclinB activation, thus stalling mitotic entry to allow repair to damaged DNA 
(Figure 1.14). The phosphorylation of PLK1 is also inhibited after DNA damage in an 
ATR/Chk1 dependent manner, inhibiting its kinase activity (Tsvetkov and Stern, 
2005). This will be discussed in detail in Chapter 6. 
 
1.5.3 Further ATR-dependent checkpoints 
 
Recent data has come to light that suggests that ATR may be involved in a 
checkpoint that monitors spindle assembly, independently of the Spindle Assembly 
checkpoint (SAC). Chromosome breakage was shown to induce ATR/ATM 
dependent phosphorylation of a centrosomal protein CEP63, displacing this protein 
from the centrosome. This leads to inhibition of spindle assembly and a delay in 
mitotic progression (Smith et al., 2009). 
 
1.6 ATR AND REPLICATION 
 
DNA replication is a particularly sensitive phase of the cell cycle when endogenous 
barriers such as DNA-protein complexes or other replication blocks, such as base 
damage, can cause replication forks to stall and potentially to collapse, resulting in 
the introduction of DSBs. Replication can also proceed slowly at specific points in 
Figure 1.14 ATR-dependent G2/M checkpoint arrest 
 
ATR is activated at regions of ssDNA. It then phosphorylates Chk1 at 
serines 317 and 345. Activated Chk1 phosphorylates Cdc25A, Cdc25B and 
Cdc25C, resulting in their inhibition via different mechanisms as shown. 
Inhibition of PLK1 kinase activity via Chk1 pathways also occurs. This 
results in Cdk1-CyclinB inhibition and delay to mitotic entry. Dashed lines 
indicate indirect relationships. Red lines indicate inhibition. Blue lines 
indicate activation. 
ATR 
Chk1 
Cdc25C 
Cdc25A 
Plk1 
Cdc25B 
SCF-mediated 
degradation 
Reduced activity 
at centrosome ? 
Reduced 
activity 
Cytoplasmic 
sequestration 
by 14-3-3 
Restrained Cdk1-CyclinB activity 
G2/M arrest 
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the genome, such as repetitive sequences, fragile sites and natural pause sites, 
increasing the probability of the introduction of replication errors (Branzei and 
Foiani, 2005). 
 
ATR and Chk1 are essential during unperturbed cell cycles. The loss of ATR or 
Chk1, even in the absence of damage, results in premature mitotic entry before the 
completion of replication, a phenotype termed ‘mitotic catastrophe’ (Cortez et al., 
2001, Niida et al., 2005). The role of ATR and Chk1 in unperturbed cell cycles is 
thought to be related to its DNA damage response functions of Cdk regulation and 
control of DNA replication (Cook, 2009). When replication forks stall, ATR is rapidly 
recruited to these sites and once activated, phosphorylates many downstream 
targets. The activation of the ATR-dependent response enables checkpoint 
activation, as discussed in section 1.5.2, down-regulation of late origin firing, 
stabilisation of the stalled replication forks and activation of processes required to 
restart collapsed replication forks (Paulsen and Cimprich, 2007). In this section, I 
will discuss each of these processes in turn.  
 
1.6.1 Origin licensing and origin firing 
 
The identification of mutations in the Origin Recognition Complex (ORC) in 
Microcephalic Primordial dwarfism patients (Chapters Five and Six) has highlighted 
the relationship between ATR signalling and origin licensing. It is important for the 
cell to have sufficient licensed origins to complete replication in a timely manner, 
but also important that licensing is restricted in order that each origin only fires 
once in S phase to avoid re-replication. If a cell enters S phase with too few 
licensed origins this could lead to fork stalling as forks have to travel a longer 
distance to complete replication. A ‘licensing checkpoint’ has been proposed that 
delays G1, ensuring that cells only enter S phase once they have a sufficient 
number of licensed origins (Ge and Blow, 2009).  
 
Origins become licensed once the pre-replication (preRC) complex has been 
assembled in G1. First the Origin Recognition Complex (ORC) binds to each origin. 
This is composed of six subunits, ORC1-6 and will be discussed in detail in Chapter 
5. Cdc6 and Cdt1 then associate with ORC and promote the loading of the Mini-
chromosome Maintenance complex (MCM) helicase. Once MCM is loaded at the 
origin it becomes licensed (Figure 1.15). At the G1/S transition, the activity of 
Cdc7/Dbf4 and cyclinE/Cdk2 then promote the association of Cdc45 and the GINS 
complex at origins that will fire.  
ORC binding 
CDC6 
CDT1 
CDC6 and CDT1 
recruitment 
MCM 
MCM recruitment and 
origin licensing 
ORC 
CDC45 
CDC45 
CDC45 
CDC45 
CDC45 loading 
Cdc7/Dbf4 
Replication initiation 
CDK2 
Figure 1.15 Pre-replication complex formation and the initiation of DNA 
replication 
 
ORC binds to replication origins and recruits CDC6 and CDT1. Recruitment of 
the MCM2-7 complex to ORC forms the pre-replication complex (pre-RC). At 
this point the origin becomes licensed. The pre-RC changes to a pre-initiation 
complex (pre-IC) with the recruitment of CDC45. The initiation of DNA 
replication is triggered by CDK2 and Cdc7/Dbf4 kinases. 
 
Figure adapted from Diffley and Labib, 2002. 
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When DNA damage is detected, the inhibition of Cdk2/CyclinE complexes by 
ATR/Chk1 dependent inhibition of the CDC25 phosphatases, prevents the 
association of Cdc45 and GINS with the pre-replication complexes on the 
chromatin, preventing further origin firing (Sancar et al., 2004). Chk1 also inhibits 
Cdc45 loading via inhibition of Cdc7/Dbf4, independently of Cdk2 activity (Liu et al., 
2006, Heffernan et al., 2007). Inhibition of Cdc45 loading is further achieved by the 
phosphorylation of Myeloid/lymphoid or mixed-lineage leukemia (MLL) by ATR. This 
stabilises MLL, resulting in its accumulation on the chromatin. Here it methylates 
histone H3 at lysine 4 at late replicating origins, inhibiting Cdc45 loading (Liu et al., 
2010). 
 
Upon UV exposure, Cdt1 is targeted for degradation by the SCF (Skp2) E3 ubiquitin 
ligase complex and by the Cul4, DNA Damage binding protein 1 (DDB1) with the 
adaptor protein Cdt2 (Nishitani et al., 2006). This UV-induced degradation can be 
inhibited by exposure to caffeine or the inhibition of Chk1 (Kondo et al., 2004), 
indicating that ATR-dependent signalling may play a role in Cdt1 regulation. 
 
Cdc6 is also ubiquitinated and degraded after DNA damage. Cdc6 interacts with the 
E3 ligase Huwe1. In vitro experiments indicate that Huwe1 ubiquitinates Cdc6 after 
exposure to UV irradiation and if the expression of Huwe1 is suppressed in cells, 
Cdc6 degradation is compromised (Hall et al., 2007). Cdc6 is also degraded in an 
APC/C dependent manner after exposure to ionising radiation (Petersen et al., 
2000, Duursma and Agami, 2005). After damage Cdc6 is also released from the 
chromatin, although the mechanism for this is unclear (Hall et al., 2007). It is 
possible that the chromatin association of Cdc6, mediated by its interaction with 
ORC, is regulated by ATR and prevents further assembly of preRCs in the presence 
of damage (Cook, 2009). 
 
1.6.2 Stabilisation of stalled replication forks 
 
The stabilisation of stalled replication forks is critical in order to prevent fork 
collapse and hence DSB formation, one of the most deleterious forms of DNA 
damage. Fork stabilisation ensures that the DNA polymerases Pol% and Pol# remain 
associated with the fork in order for replication to restart when possible (Paulsen 
and Cimprich, 2007). In Saccharomyces cerevisiae Mec1/ATR is recruited to the 
replication fork where it phosphorylates Mrc1 (Claspin in humans). This stabilises 
the MCM complex and halts DNA unwinding, preventing replication fork collapse 
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(Ben-Yehoyada et al., 2007). The mechanism for fork stabilisation in mammalian 
cells is not clear although the loss of both ATR and H2AX leads to increased 
chromosome translocation and chromatid breakage when replication is stalled 
(Chanoux et al., 2009). ATRIP interacts with MCM7 and ATR phosphorylates MCM2 
(Cortez et al., 2004) raising the possibility that ATR regulates MCM-mediated 
unwinding of the DNA at the replication fork, perhaps inhibiting this process after 
damage to prevent dissociation of the helicase from the polymerase.  
 
The long stretches of ssDNA that often form at replication forks are prone to 
rearrangement, resulting in the formation of aberrant structures that require 
intervention if replication is to be resumed. These structures are more likely to 
require some form of recombination repair, potentially resulting in base 
incorporation errors or the introduction of DSBs. ATR suppresses recombination by 
the phosphorylation of the RecQ helicases, Werner syndrome protein (WRN) 
(Ammazzalorso et al., 2010) and Bloom syndrome protein (BLM) (Tripathi et al., 
2008), promoting their recruitment to the replication fork. It is thought that these 
3’ to 5’ helicases act at replication forks to prevent the formation of aberrant 
structures, such as the ‘chicken-foot’ structure (Figure 1.16), which require the use 
of homologous recombination mechanisms to resolve them. WRN and BLM deficient 
cells exhibit an increased rate of sister chromatid exchanges and an increase in 
aberrant replication intermediates, demonstrating their importance in this process 
(Paulsen and Cimprich, 2007).  
 
There is increasing evidence that the Fanconi Anemia (FA) complex proteins also 
play a role in the stabilisation of stalled replication forks, particularly where 
interstrand cross-links occur.  
 
 
1.7 THE CENTROSOME 
 
ATR and other DNA damage response proteins have been detected at the 
centrosome in recent years (Zhang et al., 2007) and the importance of this 
organelle in damage response signalling is increasingly evident. In this section I will 
discuss aspects of centrosome biology and the relationship of the centrosome with 
the DNA damage response. 
 
 
Figure 1.16 Chicken-foot DNA structure 
 
Stalling of replication forks can lead to fork reversal and the formation 
of a ‘Chicken-foot’ DNA structure. These structure require homologous 
recombination for their resolution. 
 
Pericentriolar material 
Centriole 
centrosome 
Figure 1.17 The centrosome 
 
a)  The centrosome indicating centrioles and pericentriolar material 
b)  Immunofluoresence image of mitotic cell showing centrosomes in green 
a) 
b) 
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1.7.1 The centrosome in cell division 
 
The centrosome is a tiny (1-2µM) organelle that is comprised of two centrioles 
surrounded by a cloud of pericentriolar material (PCM) (Figure 1.17). The 
centrosome is thought to be composed of hundreds of proteins, including many 
coil-coil proteins such as Pericentrin, that serve as docking modules for the 
recruitment of further protein to the centrosome. The PCM contains "-tubulin ring 
complexes ("TURCs) that nucleate the microtubules. In mammalian cells, the 
centrosome therefore plays a crucial role, acting as a microtubule-organising centre 
(MTOC). A key function of the centrosome is the formation of a functional bipolar 
mitotic spindle to ensure that chromosomes are segregated accurately during 
cytokinesis (Doxsey et al., 2005). As each daughter cell receives one centrosome 
during mitotic division, the centrosome must be duplicated once each cell cycle. 
Centrosomal duplication is coupled with the initiation of DNA replication, linking the 
‘centrosome cycle’ with the nuclear cell cycle (Figure 1.18). If centrosomes do not 
duplicate correctly or fail to separate, monopolar spindles can be formed which are 
unable to undergo cytokinesis (Figure 1.19b). These cells either activate a p53 
dependent checkpoint, leading to arrest and cell death, or in the absence of p53 
continue to cycle and become polyploid (Uetake and Sluder, 2004, Fukasawa, 
2007). Defects in centrosome maturation, a process where centrosomes increase in 
size and microtubule nucleating capability, (Lee and Rhee, 2011) can also result in 
an inability to form proper bipolar spindles. If centrioles split prematurely, or 
centrioles are overduplicated during interphase, supernumary centrosomes can be 
created, often leading to the formation of multipolar spindles (Figure 1.19.c). Cells 
with tripolar spindles can enter cytokinesis but are likely to become severely 
aneuploid (Fukasawa, 2007), whilst cells with more than 3 poles are similar to cells 
with monopolar spindles and either do not enter cytokinesis or continue to cycle 
and become polyploid. An increase in the number of centrosomes does not always 
result in multipolar spindles. A process termed ‘centrosome clustering’ can occur 
where extra centrosomes are organised into two spindle poles. The cell thus forms 
‘psuedo-bipolar spindles’ and can undergo cytokinesis (Krämer et al., 2011). In 
cancer cells this strategy may increase genomic instability, as there can be an 
increased incidence of low-level chromosome mis-segregation (Silkworth et al., 
2009). This is because a single kinetochore is more likely to attach to more than 
one spindle pole during mitosis, an event termed ‘merotelic attachment’, resulting 
in a lagging chromosome at anaphase (Ganem et al., 2009). There is a strong 
association between centrosome abnormality and the incidence of aneuploidy in 
cancer (Wang et al., 2004). 
I 
G1/S 
G2/M 
M to A 
Figure 1.18 The centrosome cycle 
 
Centrosome duplication is coupled with the initiation of DNA replication, 
linking the centrosome cycle (red) with the nuclear cycle (blue). This is 
achieved through the use of the common regulatory proteins, Cdks. Cell 
cycle mechanisms requiring centrosomes are shown in red. 
 
Figure adapted from Doxsey et al, 2005. 
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Figure 1.19 The centrosome in cell division 
 
a)  The centrosome in normal mitosis. Duplicated centrosomes disengage 
and migrate to opposite poles of the cell, resulting in a bipolar spindle. 
b)  Centrosomes fail to disengage during G2, resulting in a monopolar 
spindle and either cell arrest leading to death, or polyploidy. 
c)  Supernumary centrosomes due to centrosome overduplication, 
fragmentation or premature disengagement. Multipolar spindles are 
formed resulting in aneuploidy, arrest or polyploidy.  
 
Figure adapted from Fukusawa, 2007 
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The role of the centrosome in asymmetric cell division such as during brain 
development is currently emerging. The position of the centrosome in neural 
progenitor cells is critical for maintaining the balance between symmetric and 
asymmetric cell division, an important factor in determining brain size (as discussed 
in section 1.1). In the first embryonic division of neuroblasts, astral microtubules 
emanating from the centrosome interact with sites formed on the apical membrane 
of the epithelium. This results in the positioning of the spindle in an apicobasal 
orientation, which is maintained by the centrosome through subsequent divisions 
(Knoblich, 2010) .  
 
Centrosome positioning is also important in the neuronal migration processes of 
brain development. Cortical neurons migrate to the cortical plate in a stepwise 
process. The leading process extends forward followed by movement of the 
centrosome into the leading process. The nucleus then translocates towards the 
centrosome and the cycle repeats (Higginbotham and Gleeson, 2007). Defects in 
neuronal migration have been documented in the olfactory bulb of Pericentrin 
mutant mice (Endoh-Yamagami et al., 2010) and in Human lissencephaly patients 
with mutations in LIS1 (Dobyns et al., 1993). Both of these proteins are located at 
the centrosome.  
 
1.7.2 The centrosome in cell cycle control 
 
Involvement of the centrosomes in cell cycle control was demonstrated by 
experiments where centrosomes were removed from the cell by microsurgery or 
ablated by laser treatment. These cells fail to initiate DNA replication and remain 
arrested in G1 (Hinchcliffe et al., 2001, Khodjakov and Rieder, 2001). One 
mechanism that has been proposed to induce this G1 arrest is the existence of a 
centrosome checkpoint that monitors the structural integrity of the centrosomes, 
arresting the cells via a p53/p38 dependent pathway (Mikule et al., 2007). An 
alternative hypothesis is that the removal of the centrosome results in the 
elimination of the centrosomal Cdk2-CyclinE complexes, which are required for the 
initiation of DNA replication (Matsumoto and Maller, 2004). CyclinE contains a 
centrosomal localisation sequence (CLS) that is required for its localisation to the 
centrosome. CyclinE centrosomal localisation is required for the initiation of DNA 
replication within the nucleus, linking the nuclear and centrosome cycle together 
(Ferguson and Maller, 2010). Cdk2-CyclinE also has a key role in the initiation of 
centrosome duplication (Lacey et al., 1999), an event that coincides with the 
 26 
initiation of DNA replication. Whether the G1/S centrosomal checkpoint pathways 
proposed above are targeted by the DNA damage response is yet to be defined.  
 
A role for the centrosome in G2/M checkpoint regulation has also been described. 
The initial activation of Cdk1-CyclinB in an unperturbed cell cycle occurs at the 
centrosome (Jackman et al., 2003). This activation of Cdk1-CyclinB, mediated by 
the Cdc25 phosphatases, can be inhibited by Chk1, a fraction of which is also 
localised at the centrosome. DNA damage causes the accumulation of Chk1 at the 
centrosome and loss of the kinase activity of Chk1 at this location results in G2/M 
checkpoint defects (Krämer et al., 2004, Löffler et al., 2007). This element of 
centrosomal checkpoint control will be discussed in detail in Chapter Three. 
 
There is, therefore, increasing evidence that centrosomes play an important role in 
cell cycle control alongside their role in mitotic spindle organisation. Centrosomes 
have been proposed to act as a ‘molecular scaffold’, enabling an increase in the 
local concentration of proteins and thus reducing non-specific interactions (Doxsey 
et al., 2005). The role of the centrosome in the DNA damage response is also 
increasingly compelling with more studies detecting proteins that function in the 
DNA damage response at this organelle.  
 
1.7.3 Centrosomes and Cilia formation 
 
A further function of the centrosome is the formation of the primary cilia. In non-
dividing cells the centrioles migrate to the cell surface. At this location the mother 
centriole (the older of the centriole pair) forms a basal body that directs cilia 
formation. The exact mechanism behind basal body formation is currently unclear. 
Primary cilia have important functions in development including maintenance of 
left-right symmetry and a role in an important signalling pathway called sonic-
hedgehog signalling. Defects in cilia formation or signalling cause a range of human 
diseases termed ‘ciliopathies’. Clinical features of these diseases include 
polydactyly, brain malformation, situs inversus and polycystic kidney disease (Nigg 
and Raff, 2009). 
 
1.8 MICROCEPHALIC PRIMORDIAL DWARFISM DISORDERS 
 
Mutations in centrosomal proteins are increasingly being identified in many diseases 
where microcephaly is a prominent clinical feature. In this section I will discuss a 
range of microcephalic primordial dwarfism disorders (see Table 1) and highlight 
DISORDER 
OMIM 
NO. DDR-DEFECT 
NEUROLOGICAL 
PHENOTYPE 
Seckel syndrome  
(SS) 
210600 606744 
608664 613676 
ATR signalling Moderate to 
severe mental 
retardation 
Nimegen 
Breakage 
syndrome 
251260 ATM and ATR 
signalling and 
Artemis-ATM-
dependent DSB 
repair 
Moderate mental 
retardation 
Primary  
Microcephaly 
(MCPH1) 
251200 ATR-dependent 
checkpoint 
activation 
Moderate mental 
retardation 
Fanconi Anaemia 227646 Response to 
cross-linking 
agents 
Normal 
Xeroderma 
Pigmentosum  
(XP-A) 
278700 Nucleotide 
excision repair 
and ATR 
signalling 
Mild to moderate 
mental 
retardation 
LIG4 606593 Non-homologous 
End Joining 
Normal to mild 
mental 
retardation 
XLF/Cernunnos-
SCID 
611291 Non-homologous 
End Joining 
Normal to mild 
mental 
retardation 
Bloom syndrome 210900 Unregulated 
homologous 
recombination 
Mild to moderate 
mental 
retardation 
Cockayne 
syndrome 
Nucleotide 
excision repair 
Severe mental 
retardation 
Microcephalic 
Osteodysplastic 
Primordial 
Dwarfism II 
210720 ATR signaliing?? Mild mental 
retardation 
Meier-Gorlin 
syndrome 
224690 ATR signalling?? Mild mental 
retardation 
BPES? 
MDLS? 
WBS? 
ATR 
haploinsuffiency 
Table 1 Microcephalic Primordial Dwarfism disorders 
Adapted from (O'Driscoll & Jeggo, 2008). 
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the relationship between the clinical features observed, the DNA damage response 
and the centrosome.  
 
1.8.1 Seckel Syndrome 
 
Seckel syndrome (SS) (OMIM 210600) was first described by Helmut Seckel in 
1960 (Seckel, 1960). It is an autosomal recessive genetic disorder that is clinically 
and genetically heterogenous with at least four different genetic susceptibility loci 
identified to date. It is characterised by severe intrauterine growth retardation, 
proportionate dwarfism and marked microcephaly with moderate to severe mental 
retardation. Patients were originally described as ‘bird-headed dwarfs’ due to the 
striking facial appearance conferred by a small head, beak like nose and a receding 
lower jaw (Figure 1.20) (Majewski and Goecke, 1982). Patients also display some 
skeletal abnormalities such as fifth finger clinodactly, thoracic kyphosis, ivory 
epiphysis and delayed ossification (Børglum et al., 2001). No clear link between SS 
and cancer incidence has been defined, although a small number of patients have 
presented with acute myeloid leukaemia (Hayani et al., 1994) and osteosarcoma 
(Faivre et al., 2002).  
 
The first genetic defect identified in SS was a hypomorphic, synonymous mutation 
in ATR (O'Driscoll et al., 2003) at SCKL1 locus 3q22.1-q24. This mutation was 
shown to affect the splicing of the gene and ATR protein expression was 
dramatically reduced but crucially, not totally abolished (Figure 1.20b). Patient cell 
lines were shown to be defective in ATR-dependent damage responses such as 
H2AX phosphorylation following exposure to UV irradiation.  
 
Further Seckel patient cell lines were subsequently examined and found to harbour 
defects in ATR-dependent signalling (Alderton et al., 2004), although no further 
mutations in ATR were identified. All lines examined had defects in UV-induced 
G2/M checkpoint activation, displayed supernumerary mitotic centrosomes and 
showed high levels of fragmented DNA following treatment with hydroxyurea to 
induce replication fork stalling. This phenotype was termed ‘nuclear fragmentation’ 
and these cells were proposed to be of late S/early G2 origin. The cells were found 
to stain for prophase markers such as the lamin B1 nuclear envelope, but did not 
stain for mitotic markers such as phospho-histone H3 (ser10). The cells were also 
examined using the TUNEL assay but were found not to be apoptotic. It was 
proposed that these cells arose from a failure to recover from replication fork 
stalling coupled with a premature entry into prophase due to the lack of a 
ATR 
Patient Control 
Figure 1.20 ATR-Seckel patient presenting with bird-like facial 
features. 
 
a)  Patient described in O’Driscoll et al, 2003. 
b)  Western blot showing reduced but not absent ATR protein 
expression 
a) b) 
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functional G2/M checkpoint (Alderton et al., 2004). The nuclear fragmentation 
phenotype could be corrected by the introduction of wild type ATR cDNA into the 
ATR-S patient cells, confirming that ATR inactivation was responsible for this 
cellular phenotype.  
 
Recently, we identified a new subset of Microcephalic Primordial Dwarfism (MPD) 
patients with Microcephalic osteodysplastic primordial dwarfism, type II (MOPDII) 
who were shown to harbour mutations in the Pericentrin (PCNT) gene, which maps 
to chromosome 21q22.3 (Griffith et al., 2008). These cell lines also display defects 
in ATR-dependent signalling. The identification of this novel genetic defect provided 
the first example of a defect in a structural centrosomal protein resulting in defects 
in DNA damage response signalling and will be discussed in full in chapter three.  
 
Subsequently, mutations in CENPJ mapping to chromosome 13q12.2 (SCKL4, OMIM 
613676) have also been described in one consanguineous SS family. A homozygous 
mutation in intron 11 of the CENPJ gene was detected, causing aberrant splicing 
and the production of three mutant transcripts (Al-Dosari et al., 2010).  Mutations 
in CENPJ have also been identified in Primary Microcephaly patients (Bond et al., 
2005, Gul et al., 2006, Darvish et al., 2010). It has been speculated that these 
mutations may only affect transcripts expressed in the brain, whereas the mutation 
found in the SS family may also affect transcripts involved in proliferation 
throughout the body (Al-Dosari et al., 2010), resulting in the different clinical 
phenotypes. CENPJ is also a centrosomal protein that plays a key role in 
maintaining centrosome integrity (Cho et al., 2006), in mitotic spindle nucleation 
(Hung et al., 2000) and is thought to be involved in cell cycle control (Chen et al., 
2006). 
 
A further subset of SS patients with mutations in the CEP152 gene on chromosome 
15q21.1-q21.2 has also been identified (Kalay et al., 2011). It was demonstrated 
that CEP152 has an important role in maintaining genomic integrity, although an 
involvement in ATR-dependent signalling was not directly investigated (Kalay et al., 
2011). CEP152 is another centrosomal protein that has been shown to act as a 
scaffold to recruit and retain other proteins at the centrosome (Cizmecioglu et al., 
2010). Mutations in CEP152 have also been identified in Primary Microcephaly 
patients (MCPH4) (Guernsey et al., 2010). 
 
SS patients with genetic susceptibility loci mapped to chromosome 18p11-q11 
(SCKL2, OMIM 606744) were recently discovered to harbour point mutations in 
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CTIP (Qvist et al., 2011). This gene encodes a protein that has known functions in 
DNA repair. CtIP localises at DSBs and interacts with the MRN complex to promote 
the resection of the break ends (Sartori et al., 2007). This results in a region of 
ssDNA that rapidly becomes coated with RPA, leading to ATR activation. In the SS 
patients examined, a mutated C-terminally truncated form of the CtIP protein is 
expressed that impairs the processing of the DSB, reducing the formation of RPA-
ssDNA. This results in reduced ATR activation and a hypersensitivity to DNA 
damage (Qvist et al., 2011).  
 
Other SS genetic susceptibility loci have been mapped to 14q21-q22 (SCKL3, OMIM 
608664) but no mutations have yet been discovered in these patients.  
 
1.8.2 Microcephalic Osteodysplastic Primordial Dwarfism (Type II) 
 
Microcephalic osteodysplastic primordial dwarfism, type II (MOPDII) (OMIM 
210720) is clinically similar to SS but is regarded as a distinct disorder. Severe pre 
and post-natal growth retardation is a common feature but distinct clinical features 
of MOPDII include disproportionate limbs, a normal head size at birth which 
progresses to true, disproportionate microcephaly and distinct skeletal features 
such as bony dysplasia and loose-jointedness which are also progressive with age 
(Hall et al., 2004). There is also an increased likelihood of vascular problems in 
MOPDII patients, such as aneurysms and moyamoya disease, which can be 
potentially life-threatening (Hall et al., 2004). Moyamoya disease is an idiopathic 
disorder of the blood vessels supplying the brain. Narrowing of the blood vessels 
occurs which can result in cerebral ischaemia. This manifests in patients as 
seizures, haemorrhage, aneurysms and stroke (Brancati et al., 2005). 
 
Mutations in the PCNT gene have been identified in MOPDII patients (Rauch et al., 
2008), prompting speculation that the PCNT-Seckel patients identified are actually 
PCNT-MOPDII patients. However, this conclusion was based on clinical findings and 
genotyping alone (Willems et al., 2010). Examination of ATR-dependent signalling 
in these cell lines may help to define whether a genotype-phenotype impact can 
distinguish between these two syndromes, and is important in view of the need to 
monitor the vascular problems observed in MOPDII patients. This will be discussed 
further in Chapter Three.  
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1.8.3 Meier-Gorlin Syndrome 
 
Meier-Gorlin Syndrome (MGS) (OMIM 224690) is also referred to as Ear-Patella-
Short stature syndrome. It is an autosomal recessive disorder with clinical features 
including pre- and post-natal growth retardation, absent patella (kneecaps) and 
microtia (small ears). Patients may also manifest other clinical features such as 
microcephaly, small mouth, skeletal abnormalities and micrognathia (abnormal 
smallness of the jaws) (Faqeih et al., 2005). 
 
Recently, mutations in components of the pre-replication complex, including ORC1, 
ORC4, ORC6, CDC6 and CDT1, have been identified in a group of MGS patients. 
ORC1 was also found to be mutated in a subset of Seckel Syndrome patients and 
will be discussed in Chapter 5. ORC1 is known to be located at the centrosome 
where it plays a role in control of centrosome duplication (Hemerly et al., 2009). 
Cell lines from MGS patients have been shown to display defects in ATR-dependent 
damage response signalling (See Chapter 5 and 6). 
 
1.8.4 Primary Microcephaly 
 
Autosomal recessive primary microcephaly is a genetic disorder characterised by 
the presentation of microcephaly (at least 3 standard deviations below the mean) 
accompanied by mild to moderate mental retardation. Patients do not show any 
other clinical features, such as skeletal abnormalities, which are common in the 
other disorders described above. This disorder is genetically heterogeneous with at 
least seven loci identified to date. These are summarised in Table 2. Approximately 
one third of MCPH cases have not yet been linked to one of these loci, indicating 
that more genes may still await identification (Thornton and Woods, 2009).  Most of 
the mutations that cause MCPH lead to either a dramatic reduction in the level of 
protein present or are functionally null (Nicholas et al., 2009). All of the proteins 
identified thus far are localised at the centrosome, further demonstrating the 
importance of this organelle in neurogenesis.  
 
The first molecular defect to be identified in primary microcephaly patients was 
Microcephalin (Jackson et al., 2002). Microcephalin encodes a BRCT domain 
containing protein (MCPH1), which has been shown to play a variety of roles in cell 
cycle progression and DNA damage response pathways. It has been demonstrated 
to localise to foci induced by DNA damage by binding to "H2AX (Wood et al., 2007) 
OMIM I.D LOCUS GENE OCCURANCE 
MCPH1 251200 8p23 MICROCEPHALIN Rare 
MCPH2 604317 19q12 WDR62 10% 
MCPH3 604804 9q33.3 CDK5RAP2 Rare 
MCPH4 604321 15q21.1 CEP152 Rare 
MCPH5 608716 1q31 ASPM 50% 
MCPH6 608393 13q12.2 CENPJ Rare 
MCPH7 612703 1p32 STIL Rare 
Table 2  MCPH genes 
(Adapted from Thornton & Woods, 2009) 
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and is required for the recruitment of many downstream DNA damage response 
proteins (Wu et al., 2009).  
 
MCPH1 patient cells display defects in ATR-dependent G2/M checkpoint activation 
and Cdc25A stabilisation (Alderton et al., 2006). It was demonstrated that 
Microcephalin plays an important role in the regulation of mitotic entry via the 
regulation of Cdk1. Patient cells exhibit a premature chromosome condensation 
(PCC) phenotype that correlates with dramatically reduced levels of phosphorylated 
Y15-Cdk1 in late S and G2 phases of the cell cycle. Subsequent studies have 
demonstrated that Microcephalin interacts with Pericentrin in order to recruit Chk1 
to the centrosome and this may be important for the timely control of mitotic entry 
(Tibelius et al., 2009).  
 
Mutations in ASPM (Abnormal Spindle Microcephaly associated) are the most 
common cause of primary microcephaly (Thornton and Woods, 2009). ASPM 
localises to the spindle poles during mitosis and is involved in the organisation of 
the spindle and its positioning within the cell (Higgins et al., 2010). It is highly 
expressed during the period of rapid expansion of the cerebral cortex in the mouse 
brain (Bond et al., 2002) and is then down-regulated at the point where the 
divisions switch from symmetric proliferation to asymmetric (Fish et al., 2006). In 
the absence of ASPM, cells prematurely switch to asymmetric division due to an 
increase in the number of cells that bypass the apical membrane (Figure 1.1) (Fish 
et al., 2006). Mutations in mouse ASPM revealed defects in the ability of the protein 
to localise to the midbody, resulting in microcephaly and a striking loss of germ 
cells (Pulvers et al., 2010).  
 
Mutations in Cdk5Rap2 and CENPJ were also identified in primary microcephaly 
patients (Bond et al., 2005). CDK5RAP2 is involved in recruitment of gamma 
tubulin ring complexes ("TURC) to the centrosome via an interaction with 
Pericentrin (Buchman et al., 2010), aids in the maintenance of centrosome 
cohesion (Graser et al., 2007) and regulates the assembly of microtubules (Fong et 
al., 2009). It is expressed in the embryonic mouse brain and its depletion leads to a 
reduction in the proportion of apical progenitor cells, which have the capacity to 
self-renew, and an increase in the proportion of basal progenitor cells, which tend 
to differentiate. There was also an increased level of apoptosis observed in 
Cdk5Rap2 deficient mouse embryos (Buchman et al., 2010). 
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1.9 AIMS 
 
The aim of this thesis was to carry out a functional characterisation of SS patient 
cell lines to gain insight into the underlying genetic defects. Based on a previous 
finding that multiple SS patient cell lines display ATR-dependent G2/M checkpoint 
defects, I aimed to examine ATR-dependent DNA damage responses in multiple, 
genetically uncharacterised, SS patient cell lines. In order to attempt to identify the 
underlying genetic defects in these patients, a two-pronged approach was 
undertaken. Firstly, the analysis of ATR-dependent signalling was assessed by the 
use of assays to determine if there are defects in upstream or downstream 
signalling events. This enables a determination of the likely position of the genetic 
defect within the ATR signalling pathway. Secondly, patient samples from large 
families with multiple affected members were sent to collaborating genetics 
laboratories to include in genetic mapping studies. Once genetic defects were 
identified, a characterisation of the impact of mutations was undertaken in order to 
gain insight into both the genetic and molecular basis underlying SS and related 
Microcephalic primordial dwarfism disorders. 
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CHAPTER TWO 
 
MATERIALS AND METHODS 
 
2.1 TISSUE CULTURE  
 
2.1.1 Cell lines 
 
Lymphoblastoid cell lines (LBLs) used were wild-type (WT; GM2188), ATR-Seckel 
(ATR-S; DK0064) and Ataxia Telangiectasia-mutated (ATM; GM03189D), obtained 
from the Coriell Cell Repository (New York, NJ). Patient LBLs and primary 
fibroblasts were derived from patients with informed consent. PCNTE220X-/- (CV1559, 
affected), PCNTE220X-/+ (CV1584, unaffected brother of CV1559), PCNTS629fs-/- 
(CV1576, affected), PCNTS629fs-/+ (CV1582, unaffected mother of CV1576) and 
PCNTC1990fs-/- (12061, affected) (Griffith et al., 2008). CV1720 was derived from an 
affected patient with mutations in ATRIP, CV1780 was derived from unaffected the 
father of CV1720 and CV1783 was derived from the unaffected mother of CV1720 
(Ogi et al, 2012 in submission). ORC1LE127G-/- (CV1759, affected), ORC1LE127G-/+ 
(CV1794, unaffected father of CV1759) and ORC1LE127G-/+  (CV1795, unaffected 
mother of CV1759) (Bicknell et al., 2011b). CDC6T323R-/- (13107 affected), 
ORC4Y174C-/- (18380 affected), CDT1R462Q + Y520X (20792 affected) and ORC6F86X + Y232S 
(20744 affected) (Bicknell et al., 2011a). LBLs were cultured in RPMI 1640 medium 
supplemented with 15% fetal calf serum (FCS), 1% penicillin/streptomycin and 1% 
L-Glutamine.  
 
Primary fibroblasts used were WT (1BR3 and 48BR), ATR-Seckel (F02-98), 42552 
(PCNT C1990fs-/-), ASB (PCNTE220X-/-) and AJ620 (ORC1-P4 R105Q/R720Q). Primary 
fibroblasts were cultured in MEM medium supplemented with 15% fetal calf serum 
(FCS), 1% penicillin/streptomycin and 1% L-Glutamine.  
 
HeLa and MG63 cell lines were cultured in MEM medium supplemented with 10% 
fetal calf serum (FCS), 1% penicillin/streptomycin and 1% L-Glutamine. 
 
All cell lines were grown at 37°C in 5% CO2 incubators. All tissue culture reagents 
were supplied by Gibco, Invitrogen. 
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2.1.2 Treatment with DNA-damaging agents 
 
UV irradiation was performed using a UV-C source (0.5J/m2/s).               
!-irradiation was performed with a 137Cs source at a dose rate of ~2Gy/min. 
Hydroxyurea was obtained from Sigma-Aldrich (Poole, UK). 
 
2.2 IMMUNOFLUORESENCE AND MICROSCOPY 
 
2.2.1 Standard Immunofluoresence 
 
LBLs were swollen in 75mM KCL for five minutes and then cytospun onto poly-L-
lysine coated slides. The cells were then fixed in 3% paraformaldehyde (PFA), 2% 
sucrose for ten minutes. Cells were permeabilised using 0.2% Triton-X100 for 30 
sec followed by extensive washing with phosphate buffered saline (PBS). Cells were 
blocked with 2% bovine serum albumin (BSA) in PBS for ten minutes prior to 
incubation with primary antibody (Table 3) (1:100, 40 min). Secondary antibodies 
(1:200, 20 min) used were FITC, Cy3 or TRITC conjugated and were obtained from 
Sigma-Aldrich. Nuclei were counterstained with DAPI. Images were captured with a 
Zeiss axioplan fluorescent microscope using Simple PCI software.  
 
2.2.2 Centrosomal immunofluoresence 
 
LBLs were swollen in 75mM KCL for five minutes and then cytospun onto slides. The 
cells were then fixed in 3% PFA, 2% Sucrose for ten minutes followed by extensive 
PBS washing. Cells were then fixed using ice cold 70% methanol for 1 min followed 
by extensive PBS washing. Cells were permeabilised using 0.2% Triton-X100 for 45 
sec followed by extensive washing with PBS. Cells were blocked with 2% BSA in 
PBS for ten minutes prior to incubation with primary antibody (1:100, 40 min). 
Secondary antibodies (1:200, 20 min) used were FITC, Cy3 or TRITC conjugated 
and were obtained from Sigma-Aldrich. Nuclei were counterstained with DAPI. 
Images were captured with a Deltavision microscope using Softworx software. 
Quantification of centrosomal signal was achieved using ImageJ software. 
 
2.2.3 UV-induced G2/M checkpoint arrest 
 
LBLs were seeded into complete medium and incubated for 2-4 hrs prior to 
irradiation with 5J/m2 UV-C or 3gy IR. Cells were then cultured for a further two 
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hours in complete medium before harvesting, or for 24hr in complete medium with 
the addition of 1.5µM Nocodazole (Sigma). Cells were pelleted, swollen in 75mM 
KCL for five minutes and then fixed in Carnoys fixative (Methanol:Acetic Acid, 3:1). 
Nuclei were stained with DAPI and slides were prepared using a cytospin. The 
mitotic index was then determined for each cell line by counting at least 500 cells. 
A decrease in the number of mitotic cells was taken as indicative of activation of 
the G2/M checkpoint. 
 
2.2.4 Supernumerary mitotic centrosomes 
 
LBLs were incubated for 24hrs in complete medium supplemented with 1.5µM 
nocodazole and processed for immunofluorescence microscopy with anti-! tubulin 
antibodies. The number of centrosomes present in 50-100 mitotic cells was scored 
for each cell line. 
 
2.2.5 HU-induced 53BP1 foci formation 
 
LBLs were untreated or treated with 5mM Hydroxyurea for 2hr. Cells were then 
washed once in PBS and slides prepared using a cytospin. Cells were fixed in 3% 
PFA, 2% Sucrose for ten minutes followed by extensive PBS washing. Slides were 
then stained using the standard immunofluoresence techniques described above 
using an anti-53BP1 primary antibody. Cells with > 5 53BP1 foci were counted as 
positive and the percentage of positive cells was assessed for each cell line.  
 
2.2.6 HU-induced H2AX phosphorylation 
 
LBLs were untreated or treated with 5mM Hydroxyurea for 2hr. Cells were then 
washed once in PBS and slides prepared using a cytospin. Cells were fixed in 3% 
PFA, 2% Sucrose for ten minutes followed by extensive PBS washing. Slides were 
then stained using the standard immunofluoresence techniques described above 
using an anti-!H2AX primary antibody. Cells with pan-nuclear !H2AX staining were 
counted as positive and the percentage of positive cells was assessed for each cell 
line. 
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2.2.7 Replication fork stability assay 
 
Cells were labelled with CldU (50µM) for 20 min, pelleted and washed in PBS, 
followed by incubation in complete medium supplemented with 10µM Aphidicolin 
(Sigma) for 2 hr. Cells were then pelleted and swollen in 75mM KCL plus 100µM IdU 
for ten minutes to allow fork reinitiation and IdU incorporation. Cells were then 
fixed in Carnoys fix and slides prepared using a cytospin. Cells were permeabilised 
and then incubated in 2.5M HCL for 40 min to denature the DNA. Cells were then 
blocked in 2% BSA/PBS for 1hr prior to primary antibody incubation (Both at 
1:100, 4 C, overnight). The CldU label was detected with a TRITC-conjugated 
secondary antibody and the IdU label detected with a FITC-conjugated antibody. 
Nuclei were counterstained with DAPI. Images were captured with a Zeiss axioplan 
fluorescent microscope using Simple PCI software. The percentage of cells with 
both red and green labels was scored. 
 
2.2.8 DNA fibre analysis 
 
Cells were labelled with IdU (25µM) for 20 min at 37°C and then pulse-labelled with 
CldU (250µM) for 20 min. Cells were then washed twice with ice-cold PBS and were 
resuspended in ice-cold PBD at a concentration of 0.5 to 1 x106 cells/ml. A 2µL drop 
of cell suspension was placed in the centre of the top quarter of a microscope slide. 
The drop was left to dry at room temperature for 7 min. 7.5µL of spreading buffer 
(200mM Tris-HCL pH7.5, 50mM EDTA, 0.5% SDS) was added to the drop and 
mixed by gentle stirring with a pipette tip. This was incubated for a further 5 min at 
room temperature. The slide was then tilted to an angle 10-20° to the horizontal by 
raising the top end by approximately 0.75cm, in order for the drop to run to the 
bottom of the slide in 4 min. The slide was then air-dried and fixed in 
methanol/acetic acid 3:1 for 10 min. For immunostaining of DNA fibres, slides were 
washed twice with water for 5 min and then denatured using 2.5M HCL for 1 hour. 
Slides were rinsed twice with PBS-Tween (0.1%) and then incubated in blocking 
solution (PBS/1% BSA/0.1% Tween) for 30 min. Primary antibody incubation with 
mouse anti-BrdU to detect IdU incorporation and rat anti-BrdU to detect CldU 
incorporation was performed overnight at 4°C. Slides were washed twice with PBS-
T. Slides were incubated with secondary antibodies for 30 min at 37°C in a humid 
chamber. Slides were then washed 5 x 2min with PBS-T. To detect single-stranded 
DNA slides were incubated with mouse anti-ssDNA (polydT) antibody for 30 min at 
37°C in a humid chamber. Slides were washed 5 x 2 min with PBS-T and then 
incubated with mouse secondary antibody for 30 min at 37°C in a humid chamber. 
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Slides were then washed 5 x 2 min with PBS-T and mounted using Prolong Anti-
Fade Gold (Molecular Probes). Images were captured with a Deltavision microscope 
using Softworx software. Fibres were analysed according to (Maya-Mendoza et al., 
2007). 
 
2.3 PROTEIN TECHNIQUES 
 
2.3.1 Whole Cell Extracts (WCE) 
 
Cell pellets were either stored at -80°C or directly lysed in 50-100uL of lysis buffer 
(50mM Tris-HCL pH7.5, 120mM NaCl, 0.5% NP-40, 1mM DTT, 1mM NaF, 1mM !-
Glycerophosphate, 0.2mM PMSF and protease inhibitor cocktail from Sigma) for 1hr 
on ice. Cell lysates were centrifuged for 2 min at 13000rpm at 4°C. The supernatant 
was transferred to a clean, cold eppendorf tube. The protein concentration was 
then determined using Bradford Protein Assay reagent (Bio-Rad Laboratories) at a 
UV absorbance of 595nm. Extracts were either stored at -80°C or directly boiled in 
2x SDS loading buffer (5% SDS, 10% Glycerol, 10% !-mercaptoethanol, 125mM 
Tris-HCL ph6.8 and 0.2% bromophenol blue) and loaded onto SDS-PAGE gels. 
 
2.3.2 Chromatin extraction 
 
1 x 107 cells were untreated or irradiated with 20J/m2/s UV-C and incubated for 1hr 
in complete medium. Cells were then washed in PBS and resuspended in 100µL 
hypotonic buffer. Lysates were incubated on ice for 15min and then pelleted. The 
supernatant (soluble fraction) was removed and retained. The remaining pellet was 
washed once in hypotonic buffer before resuspension in 100µL hypertonic buffer. 
After incubation on ice for a further 15 min, the chromatin extract was pelleted and 
resuspended in 100µL of 2x High SDS loading buffer. The samples were then 
sonicated and 10µL resolved by SDS-PAGE for western blotting. 
 
2.3.3 Chromatin Fractionation 
 
LBLs (1 x 107) were washed with PBS and once with 1 ml low salt buffer (LSB). 
Pelleted cells were resuspended in six times the packed cell volume of LSB + 0.1 
mM MC-LR and 1 x protease inhibitor cocktail, and immediately centrifuged for 10 
min at 10,000 rpm (supernatant = S10). The pellet was gently resuspended (by 
tapping, but not pipetting, to prevent chromatin decondensation) in a volume (V) of 
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high-salt buffer (HSB: 50 mM Tris-HCl [pH 8.0], 5% [v/v] glycerol, 1 mM EDTA, 10 
mM MgCl2, 400 mM KCl, 1x protease inhibitors and 0.1 mM MC-LR) equal to 0.25 V 
of LSB used to lyse the cells. Samples were immediately centrifuged for 10 min at 
10,000 rpm (supernatant = P10). The pellet was then resuspended in nuclease 
buffer (same V as HSB) containing 10 U/ml MNase and incubated at 37°C for 10 
min. Samples were then centrifuged for 5 min at 10,000 rpm (supernatant = C1). 
The pellet was resuspended in nuclease buffer (V same as used for HSB) containing 
100 U/ml MNase and incubated at 37°C for 45 min before an equal V of 
solubilization buffer (nuclease buffer + 2% [v/v] NP-40, 2% [v/v] Triton X-100, 
600 mM NaCl) was added. Samples were vortexed briefly and centrifuged for 5 min 
at 10,000 rpm (supernatant = C2). The remaining pellet was resuspended in 
solubilization buffer (same V as HSB) and an equal V of denaturing buffer (50 mM 
Tris [pH 6.8], 1% [v/v] SDS, 100 mM DTT, 10% glycerol) before brief sonication, 
boiling for 5 min, and centrifuging at 10,000 rpm for 5 min (supernatant = C3) 
(Goodarzi et al., 2008). 
 
2.3.4 SDS-PAGE and Western Blotting 
 
Whole cell extracts (50µg) or chromatin extracts (5-10µL) were resolved by SDS-
PAGE (Laemelli method) before transfer onto either HyBond 0.45uM PVDF (GE 
Healthcare) or 0.2uM Protran nitrocellulose membranes (Whatman). Membranes 
were blocked in either 5% BSA or 5% non-fat milk in Tris-buffered saline plus 0.1% 
Tween-20 (TBS-T) for 1hr. Membranes were then probed with primary antibody in 
5%BSA/TBS-T overnight at 4 C. Membranes were washed with TBS-T, 3 times for 
ten minutes. Membranes were then probed with HRP-conjugated secondary 
antibodies followed by three further TBS-T washes. Signal was then detected using 
either Pierce ECL Detection Reagents or ECL plus detection reagents (GE 
Healthcare). 
 
2.3.5 Cdc25A stability assay 
 
Cells were either untreated or irradiated with 10J/m2/s UV-C and then incubated in 
complete medium with 100µg/ml cycloheximide for 20 min. Cells were pelleted and 
resuspended in WCE extraction buffer in the continued presence of cycloheximide. 
50µg WCE was resolved using SDS-PAGE and western blotted with anti-cdc25A 
antibodies (Alderton et al., 2006). 
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2.4 Plasmids 
 
pCMV ATRIP WT plasmid was obtained from David Cortez. pCGT ORC1 WT plasmid 
was obtained from Andrew Jackson. pcDNA3 ATR WT plasmid was obtained from 
Anthony Carr. 
 
 
2.5 Site-directed mutagenesis 
 
The Quikchange Lightning Site-Directed mutagenesis kit (Stratagene) was used to 
incorporate patient mutations into WT plasmids. Details of primers used for site-
directed mutagenesis are shown in Table 4. 
 
2.6 Complementation analysis 
 
LBL cultures were either untransfected or transfected with 1µg of appropriate cDNA 
using GeneJuice transfection reagent (Novagen/Merck Chemicals), according to the 
manufacturers instructions. Transfections were repeated 24hr and 48 hr later. 
Cultures were therefore transfected three times in total. Cultures were then 
subjected to G2/M checkpoint analysis as described in section 2.2.3. 
 
2.7 Fluorescence-activated cell sorting (Facs) analysis of S-phase 
progression 
 
LBLs were pulse-labelled with 50µM BrdU for 30 min and then incubated in the 
presence of 0.2µg Colcemid for 6hr to prevent mitotic exit. Samples were collected 
at 0,2,4 and 6hr post BrdU label and were fixed in 70% ice-cold Ethanol. Cells were 
then treated with 2M HCL for 30 min followed by incubation in 0.1M Sodium 
Tetraborate for 2 min. Cells were washed with PBS/1%BSA and then incubated with 
fluorescein isothiocyanate (FITC)-conjugated monoclonal anti-BrdU (Becton 
Dickinson) for 30 min. Cells were washed with PBS/1%BSA and then 
counterstained with 10 µg/ml propidium iodide with 0.5 mg/ml RNase in PBS for 15 
min prior to Facs analysis. Cells were gated to eliminate any doublets and then the 
BrdU labeled population gated and quantified. The rate of S-phase progression was 
calculated as the loss of cells from the early S-phase compartment.  
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2.8 Small interfering RNA studies 
 
HeLa or MG63 cells were transfected with 10nM of siRNA duplex using siPort NeoFX 
transfection reagent according to the manufacturers instructions (Ambion, UK). The 
oligonucleotides used were Invitrogen StealthTM duplexes, designed using an 
invitrogen algorithm (https://rnaidesigner.invitrogen.com/rnaiexpress/index.jsp).  
 
Oligos used were: PCNT sense: UCACAAUCAGUGACCACCAACCGGA.  
        ORC1 sense: CGUAUGUUGCUAAAUUGCUUGAGUU 
        CEP192 sense: GAGACUCCUACGGUGUCCAUUCAAG 
 
The control oligonucleotide was ON-TARGETplus siCONTROL Non-targeting siRNA 
#2 (Dharmacon). 
 
 
 
 
 
Antibody Details Supplier 
 
Identifier 
53BP1 Rabbit polyclonal Bethyl BL181 
ATR Goat polyclonal Santa Cruz N19 
ATRIP Rabbit polyclonal Bethyl A300-095A 
Aurora A Mouse monoclonal Abcam Ab13824 
Phospho Aurora A 
(Thr288) 
Rabbit monoclonal Cell signalling S3079 
BrdU (detects IdU) Mouse monoclonal BD 
Biosciences 
Clone B44 
BrdU (detects CldU) Rat polyclonal Abcam Clone 
BU1/75 
FITC-BrdU Mouse monoclonal BD 
Biosciences 
347583 
Cdc25A Mouse monoclonal Abcam DCS120 + 
DCS121 
Cdc25A Mouse monoclonal Santa Cruz F6 
Cdc25B S230  B Ducommon   
Chk1 phospho ser317 Rabbit polyclonal Cell signalling 2344S 
Chk1 Rabbit polyclonal Santa Cruz FL476 
hCLK2 Rabbit polyclonal Abcam Ab65082 
FANCD2 Rabbit polyclonal Novus NB-100-182 
HDAC1 Rabbit polyclonal Abcam Ab19845 
Histone H3 Rabbit monoclonal Abcam Y173 
HP1 Rabbit polyclonal Santa Cruz FL191 
Gamma H2AX Mouse monoclonal Upstate 05-636 
Gamma Tubulin Rabbit polyclonal Sigma T5192 
Gamma Tubulin  
(GTU-88) 
Mouse monoclonal Abcam Ab11316 
Kap1 Rabbit polyclonal Abcam Ab10484 
Mcm2 Goat polyclonal Santa Cruz N19 
ORC1 Goat polyclonal N 
terminal 
Santa Cruz N17 
ORC1 Rabbit polyclonal C 
terminal 
Santa Cruz H80 
ORC2 Rabbit polyclonal Santa Cruz H300 
Pericentrin Rabbit polyclonal Abcam  Ab4448 
Phospho PLK1 (Thr210) Rabbit polyclonal Cell signalling S5472 
PLK1 Mouse monoclonal Abcam Ab14210 
ssDNA Mouse monoclonal Millipore MAB3034 
Timeless Rabbit polyclonal Abcam Ab72458 
Secondary antibodies    
Anti-mouse IgG1-A546 Goat Invitrogen A21123 
Anti-rat A488 Chicken Invitrogen A21470 
Anti-Mouse IgG2a-A647 Goat Invitrogen A21241 
    
Anti-mouse FITC Goat Sigma F0257 
Anti-rat TRITC Rabbit Sigma T5778 
Anti-rabbit Cy3 Sheep Sigma C2306 
    
Anti-goat HRP Polyclonal rabbit Dako P0449 
Anti-rabbit HRP Polyclonal swine Dako P0217 
Anti-mouse HRP Polyclonal goat Dako P0447 
Table 3 Antibodies 
Target Primer sequence 
ATRIP C2229T-F GTCAGCATGCTCATCTGAGGGCTTCCTGATG 
ATRIP C2229T-R CATCAGGAAGCCCTCAGATGAGCATGCTGAC !
Table 4 SDM primers 
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CHAPTER THREE 
 
RESULTS I: Mutations in Pericentrin (PCNT) cause 
Microcephalic Primordial Dwarfism 
 
3.1 INTRODUCTION 
 
A splicing mutation in ATR was identified in a Seckel Syndrome patient in our 
laboratory (O'Driscoll et al., 2003) and subsequent analysis of further Seckel 
syndrome patient cell lines showed defects in ATR-signalling but without mutations 
in ATR (Alderton et al., 2004). Two large, consanguineous families of Middle 
Eastern origin were therefore selected for further study in order to attempt to 
identify further genetic defects underlying Seckel syndrome. Two children from 
family 1 were clinically diagnosed with Seckel syndrome, whilst family 2 had one 
affected child. The lymphoblastoid (LBL) cell lines from one affected child plus one 
parent from each family were assessed for UV-induced G2/M checkpoint defects, 
nuclear fragmentation and supernumary centrosome phenotypes. They were then 
included in a genetic mapping study in order to identify potential causative gene 
candidates. Using this approach we identified mutations in the Pericentrin (PCNT) 
gene, which maps to chromosome 21q22.3, in collaboration with Andrew Jackson’s 
group at the MRC Human Genetics Unit in Edinburgh. I will present data in this 
chapter to show that the identification of this novel genetic defect provided the first 
example of mutations in a structural centrosomal protein causing a defect in DNA 
damage response signalling. 
 
Mutations in PCNT were also identified in a group of patients diagnosed with 
Microcephalic Osteodysplastic Primordial Dwarfism Type II (MOPDII) (Rauch et al., 
2008b). These patients are similar to Seckel syndrome in that the clinical features 
include microcephaly and severe growth retardation. Distinct clinical features of 
MOPDII include disproportionate limbs and distinct skeletal features such as bony 
dysplasia and loose-jointedness that are progressive with age. The microcephaly in 
these patients presents as a normal head size at birth which progresses to true, 
disproportionate microcephaly (Hall et al., 2004). There is also an increased 
likelihood of vascular problems in MOPDII patients, such as aneurysms and 
moyamoya disease, which can be potentially life-threatening (Hall et al., 2004). 
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Further clinical evaluation of the PCNT-Seckel patients described here resulted in 
their reclassification as MOPDII patients (Willems et al., 2010).  
Pericentrin (PCNT) is a large 360kd coiled-coil protein that exists in multiple 
isoforms (Flory and Davis, 2003). It is an integral component of the pericentriolar 
material of the centrosome and acts as a scaffold, transporting proteins to the 
centrosome via an interaction with Dynein and anchoring them there (Purohit et al., 
1999). Depletion of PCNT results in disruption of centrosome structure and defects 
in organization of the spindle (Doxsey et al., 2005b). One of the important 
functions of PCNT is therefore to anchor !Tubulin ring complexes (!TURCs) at the 
centrosome, thereby providing sites for microtubule nucleation (Takahashi et al., 
2002, Zimmerman et al., 2004). 
 
PCNT has been shown to interact with a diverse range of proteins including Protein 
kinase A (Diviani et al., 2000) and Protein kinase C (Chen et al., 2004). 
Subsequent to publication of data included in this chapter, CDK5RAP2 (Buchman et 
al., 2010), CHK1 and Microcephalin (MCPH1) (Tibelius et al., 2009) were all found 
to interact with PCNT. CDK5RAP2 and MCPH1 are both centrosomally localised 
proteins that are mutated in some Primary Microcephaly patients (Jackson et al., 
2002, Bond et al., 2005).  NEK2 kinase is sequestered by PCNT at the centrosome, 
preventing premature splitting of the centrosomes before late G2 phase (Matsuo et 
al., 2010). 
 
In recent years, the centrosome has increasingly been demonstrated to be an 
important cellular site for the control of cell cycle progression, with evidence for 
roles in G1 to S phase progression, G2 to M phase progression and metaphase to 
anaphase transition (Doxsey et al., 2005b). Initial findings regarding the 
importance of the centrosome for control of mitotic entry were provided from 
reports that the earliest detection of active Cdk1-CyclinB1 complexes occurred at 
the centrosome during prophase (Jackman et al., 2003). Chk1 was reported to 
inhibit Cdk1 activity when both proteins were present at the centrosomes in 
interphase cells. This inhibition of Cdk1/Cyclin B1 prevents the progression of cells 
from G2 to mitosis. Chk1 was found to be absent from the centrosomes of mitotic 
cells, allowing the cells to progress from G2 to mitosis (Krämer et al., 2004a). It 
was elegantly demonstrated that targeting wild type Chk1 to the centrosome via 
fusion with a PACT (pericentrin-AKAP450 centrosomal targeting) domain prevented 
activation of Cdk1 and resulted in polyploidy and multiple centrosomes. Targeting 
of kinase-dead Chk1 to the centrosome resulted in premature activation of Cdk1 
and premature mitotic entry (Krämer et al., 2004a). Chk1 inhibition also activated 
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Cdk1 associated with the centrosome and resulted in premature mitotic entry. The 
inhibition of mitotic entry was found to be via a Chk1-Cdc25B mechanism, rather 
than a direct effect of Chk1 on Cdk1. Cdc25A (Shreeram et al., 2008), Cdc25B 
(Dutertre et al., 2004), and Cdc25C (Bonnet et al., 2008) have all been reported to 
localize to the centrosome. Cdk1 is also recruited to the centrosome via an 
interaction with the CEP63 protein (Löffler et al., 2007a). 
 
The Kramer laboratory then went on to demonstrate that DNA damage causes the 
accumulation of phosphorylated Chk1 at the centrosome (Löffler et al., 2007b). 
They concluded that the accumulation of total Chk1 at the centrosome was 
ATM/ATR independent, however, the accumulation of phosphorylated Chk1 at the 
centrosome was dependent on ATR/ATM (Löffler et al., 2007a). Whether this 
phosphorylation of Chk1 by ATM/ATR occurs at the centrosome or in the nucleus 
was not established. The authors then targeted kinase-dead Chk1 to the 
centrosome using the PACT domain and observed a G2/M checkpoint defect after 
UV irradiation (Löffler et al., 2007a). 
 
PCNT is highly expressed in mouse embryo cells and is localized at the base of 
primary cilia. It was shown in PCNT mutant mice that PCNT is required for the 
assembly of cilia of olfactory neurons but not for global cilia formation (Miyoshi et 
al., 2006). PCNT has been shown to interact with intraflagellar transport proteins, 
depletion of which result in PCNT mislocalisation and inhibition of primary cilia 
formation (Jurczyk et al., 2004). Disruption of the primary cilia structure is 
associated with a range of disorders termed ‘Ciliopathies’, where phenotypes 
include polycystic kidney disease, pre and post axial polydactyly, and skeletal and 
neurodevelopmental disorders (Duldulao et al., 2010). 
 
A PCNT mutant mouse engineered with a two base pair deletion in exon 31, 
resulting in a frame-shift at codon 2214 has recently been described by Endoh-
Yamagami and colleagues (Endoh-Yamagami et al., 2010). Homozygote mice 
display progressive embryonic growth retardation and a high incidence of perinatal 
lethality. Both homozygous and heterozygous embryos had smaller brains than 
their wild type counterparts. Another penetrant feature of the PCNT homozygous 
mice is preaxial polydactyly, a phenotype that is associated with the ciliopathy 
Joubert syndrome (Duldulao et al., 2010).  
 
Finally, a role for PCNT in glucose regulation has been demonstrated. PCNT is 
expressed in primary mouse pancreatic islet and insulinoma cells where it 
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associates with insulin granules. Depletion of PCNT results in a loss of intracellular 
insulin (Jurczyk et al., 2010). Premature diabetes with severe insulin resistance has 
been noted in patients with PCNT mutations (Huang-Doran et al., 2011).  
 
The aim of this chapter was to carry out an in-depth functional characterisation of 
consanguineous Seckel syndrome patient cell lines to enable identification of novel 
genetic defects using gene-mapping techniques. Once a genetic defect had been 
identified an investigation into how it impacts on the ATR-dependent DNA damage 
response was conducted. 
 
3.2 RESULTS 
 
3.2.1 Mutations in Pericentrin in Microcephalic Primordial Dwarfism 
patients  
 
Two families within our panel of Seckel Syndrome patient cell lines were of great 
interest as they were both large and consanguineous (Figure 3.1a). This makes 
them ideal candidates for genetic mapping studies where data from large numbers 
of genetically dissimilar individuals greatly increases the power of the study (Jin et 
al., 2004). The patients displayed microcephaly and short stature, following 
intrauterine growth retardation (Figure 3.1b). In family 1 the patient (subsequently 
identified as E220X-/-) had a receding forehead with a high nasal bridge and 
prominent nose. An MRI scan revealed atrophy of the white matter and thinning of 
the corpus callosum. There was some developmental delay at 8 months of age with 
the patient unable to sit unaided. The facial features were thought to not entirely fit 
with a diagnosis of Seckel syndrome, although features common in Seckel 
syndrome patients such as fifth finger clinodactyly were present (Personal 
communication; Dr Nouriya Al Sanna). The patient from family 2 (S629fs) also had 
a prominent nose, small ears and a receding forehead. A deep voice with small 
‘broken’ teeth was also observed. Skeletal surveys on all patients were normal 
(Griffith et al., 2008). 
 
After confirming the ‘Seckel status’ of the patients by G2/M checkpoint assay and 
supernumary mitotic centrosome assessment, DNA was sent to our collaborators 
for further study.  The MRC Human Genetics Unit in Edinburgh performed an SNP-
microarray genome-wide homozygosity scan at 50kbp resolution, using Affymetrix 
chips, on the two families (Griffith et al., 2008). Using this approach they identified 
a novel Seckel locus between markers rs1598206 and rs2330591 on chromosome 
Figure 3.1 Family pedigrees of PCNT mutated patients 
 
a) Pedigrees of families with PCNT mutations. Asterix shows patients 
included in genome-wide SNP genotyping and linkage analysis 
 
b) 13 year old patient with PCNT mutation showing growth retardation 
and microcephaly when compared to her 11 year old unaffected sibling 
(Family two).  
 
Images adapted from Griffith and Walker, Nature Genetics, 2008. 
 
b) 
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21q22.3-qter. This region spans 2.9 Mbp of DNA and contains 55 known Refseq 
genes. Within this region was a gene encoding a centrosomal protein Pericentrin 
(PCNT). Due to the consistent observation of supernumary mitotic centrosomes as 
a cellular phenotype of Seckel syndrome patients (Alderton et al., 2004), and an 
established link between centrosomal gene mutation and primary microcephaly 
phenotypes (Zhong et al., 2005), PCNT was considered to be a potential Seckel 
syndrome candidate gene. Sequencing of PCNT in each family revealed mutational 
changes. 
 
A homozygous nonsense mutation (E220X) was identified in family 1 (Saudi 
Arabian) (CV1559). A homozygous single base-pair deletion (S629fs) was identified 
in family 2 (Kuwait) (CV1576). This deletion causes a frameshift and is thought to 
result in a premature protein truncation after an additional 65 amino acids. A 
further patient was then identified with a homozygous single base-pair insertion 
(C1190fs), which again results in a frameshift (12061) (Figure 3.2a).  
 
3.2.2 PCNT expression is reduced in PCNT mutated patient cell lines 
 
The levels of PCNT protein expression in each patient were examined by 
immunoblotting in order to verify the impact of the mutational change and to 
determine whether any residual protein could be detected (Figure 3.2b). Two bands 
of the correct predicted sizes were detected in control cell extracts that were not 
present in any patient cell line extracts. The levels of PCNT protein are therefore 
significantly disrupted by the mutations described, although the possibilty that 
residual protein is present cannot be excluded. Indeed, further work in our 
laboratory on patient primary fibroblasts has found that residual protein can be 
detected when these cells are examined using immunofluorescence with anti-
pericentrin antibodies (T. Stiff, personal communication). This is perhaps 
unsurprising, as a structural centrosomal protein would be predicted to be essential 
for cell viabilty. Indeed, disruption of the PCNT gene in mice by the use of gene 
trap technology leads to embryonic lethality. Affected embryos display severe 
intrauterine growth retardation and microcephaly (Delaval and Doxsey, 2010). 
 
3.2.3 PCNT mutated cells display a defective UV-induced G2/M 
checkpoint but a proficient IR-induced G2/M checkpoint 
 
ATR-Seckel cells have previously been shown to display a defective G2/M 
checkpoint response both 24 hours (Alderton et al., 2004) and 2 hours (Stiff et al., 
Family 1 
E220X (CV1559) 
Family 2 
S629fs (CV1576) 
C1190fs 
(12061) 
Figure 3.2 PCNT protein schematic and expression levels 
 
a)  Schematic of Pericentrin showing protein structure  and the position of 
mutations found in the patients. 
b)  Levels of PCNT expression were examined by resolving whole cell 
extracts from WT, ATR-Seckel (ATR-S), unaffected heterozygous relative 
(E220X+/-, S629fs+/-) and PCNT-mutated cell lines (E220X-/-, 
S629fs-/- and C1190fs-/-) on 6% SDS-PAGE gel followed by transfer 
onto nitrocellulose membrane. Membranes were then probed with a 
PCNT antibody. ATR was used as a loading control. 
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2008) post UV irradiation. PCNT mutated cell lines were examined for their ability 
to activate G2/M checkpoint arrest at 2 hours after treatment with UV, reflecting a 
replication-independent arrest, and also 24 hours after treatment with UV, 
reflecting cells that may have progressed through both S phase and G2 phase 
before arresting. The patient cell lines examined failed to arrest effectively after 
exposure to UV at either time point post irradiation, similar to the response seen in 
ATR-Seckel patient cell lines and in contrast to wild-type cell lines (Figure 3.3 a, b). 
PCNT mutated cells are therefore compromised in their ability to activate ATR-
dependent signaling in response to UV damage, resulting in a defective checkpoint 
response. This result demonstrated a surprising link between mutation in a core 
centrosomal structural protein and defects in the ATR-dependent signaling 
pathway.  
 
In order to assess whether PCNT is required for activation of the ATM signaling 
pathway, PCNT mutated cells were examined for the ability to activate a G2/M 
checkpoint arrest after exposure to ionizing radiation, which introduces double-
strand breaks into the DNA. PCNT mutated cells arrested normally following IR 
induced damage, in contrast to ATM mutant cell lines (Figure 3.4), indicating that 
PCNT is required for ATR-dependent pathway function but is not specifically 
required for ATM-dependent damage responses.  
 
3.2.4 PCNT depletion in HeLa cells recapitulates the defective UV-
induced checkpoint phenotype observed in PCNT mutated patient 
cell lines 
 
In order to confirm the requirement for PCNT in ATR-dependent signaling, PCNT 
was depleted in HeLa cells using siRNA oligonucleotides. Cells were then irradiated 
with either UV or ionizing radiation and the G2/M checkpoint response examined 2 
hrs later. The G2/M checkpoint response to UV irradiation was defective whilst the 
cellular response to ionizing radiation was normal (Figure 3.5). These results 
correspond to those observed in the patient cell lines and confirm that PCNT is 
specifically required for ATR-dependent signaling responses, but not ATM-
dependent ones.  
 
3.2.5 H2AX is phosphorylated normally in PCNT mutated cells 
 
 
The phosphorylation of H2AX is a key upstream step in both the ATR and ATM 
signaling pathways and is important for the recruitment of proteins such as 53BP1, 
Figure 3.3 PCNT mutated cells display a defective UV-induced G2/M 
checkpoint  
 
a)  WT, ATR-S, unaffected heterozygous relative and PCNT mutated cell lines 
were examined for G2/M checkpoint arrest, 2hrs after treatment with 5J/
m2 UV irradiation. A decrease in the number of mitotic cells was taken as 
indicative of a G2/M arrest.  
b)  The same cell lines were examined for G2/M checkpoint arrest, 24hrs 
after treatment with 5J/m2  UV irradiation and in the presence of 1.5µM 
nocodazole.  
 
Graphs a represents the mean of three independent experiments. Graph 
b represents the mean of two independent experiments.  
The error bars represent the standard deviation. 
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Figure 3.4 PCNT mutated cells display a proficient IR-induced G2/M 
checkpoint  
 
WT, ATM, ATR-S, unaffected heterozygous relative and PCNT mutated cell 
lines were examined for G2/M checkpoint arrest, 2hrs after treatment with 
3Gy IR irradiation. A decrease in the number of mitotic cells was taken as 
indicative of a G2/M arrest.  
 
The graph represents the mean of three independent experiments. 
The error bars represent the standard deviation. 
 
Figure 3.5  RNAi Depletion of PCNT in HeLa cells impairs ATR-dependent G2/M 
arrest 
 
a) Hela cells were either untransfected, mock transfected (mock) or exposed 
to Control or PCNT siRNA oligonucleotides for 72hrs. Cells were then examined 
for G2/M arrest 2hrs after exposure to 5J/m2 UV or 3 Gy IR. A decrease in the 
number of mitotic cells was taken as indicative of a G2/M arrest. Graph 
represents the mean of three independent experiments. Error bars represent 
the standard deviation. 
 
b) Western blot confirming PCNT depletion. ATR was used as a loading control. 
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MDC1 and BRCA1 to the site of the damage (Fernandez-Capetillo et al., 2003). The 
ability of PCNT mutated cells to phosphorylate H2AX following exposure to 
hydroxyurea was examined. This ATR-dependent phosphorylation was normal in 
patient cell lines, similar to wild-type controls and in contrast to ATR-Seckel cells 
(Figure 3.6). This indicates that ATR kinase is functional and able to phosphorylate 
a key upstream substrate in these cells. 
 
3.2.6 Chk1 is phosphorylated normally in PCNT mutated cells 
 
In order to further delineate at which point in the ATR signaling pathway PCNT 
could be functioning, the phosphorylation of Chk1 after UV irradiation was 
examined.  Patient cells were assessed for their ability to phosphorylate Chk1 at 
ser317 after exposure to UV irradiation using western blotting and were shown to 
phosphorylate this key checkpoint kinase normally. PCNT depleted HeLa cells were 
then also examined, and Chk1 was again phosphorylated normally in the absence 
of PCNT (Figure 3.7). These results indicate that PCNT is dispensable for the 
phosphorylation of Chk1 at ser317 in the ATR-dependent response to UV 
irradiation. 
 
3.2.7 Total Chk1 levels at the centrosome are reduced in PCNT 
mutated patient cell lines 
 
As Chk1 has been shown to localize to the centrosomes of interphase cells (Krämer 
et al., 2004b), and PCNT is known to recruit proteins to the centrosome (Diviani et 
al., 2000), we speculated that PCNT might be required to anchor Chk1 to the 
centrosome.  
PCNT mutated patient fibroblasts were examined for Chk1 levels at the centrosome 
using a previously characterised monoclonal antibody for total Chk1 (Krämer et al., 
2004b). Over 15% of cells in the PCNT mutated lines had a total absence of Chk1 
signal, in contrast to below 5% of cells in WT and ATR-Seckel control cell lines 
(Figure 3.8). These results indicate a requirement for PCNT to localize Chk1 to the 
centrosome of these cells. This observation was subsequently published by Tibelius 
et al in 2009. 
 
 
 
 
 
 
Figure 3.6  H2AX phosphorylation is normal in PCNT mutated cells. 
 
WT, ATR-S, unaffected heterozygous relative and PCNT mutated cell lines were 
untreated (UNT) or exposed to 5mM Hydroxyurea (HU) and incubated at 37°C 
for 2hr. Phosphorylation of H2AX on ser139 was detected using 
immunofluoresence with specific antibodies. The percentage of cells staining 
positively for H2AX phosphorylation was determined for each cell line. The graph 
represents the mean of three independent experiments. Error bars represent the 
standard deviation. 
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Figure 3.7  UV-induced Chk1 phosphorylation is normal in PCNT mutated 
patient cell lines and PCNT depleted lines. 
 
a)  Lymphoblastoid patient cell lines were treated with 5J/m2 UV and cell 
pellets harvested 1hr later.  Whole cell extracts were then resolved on a 
8% SDS-PAGE and transferred onto a PVDF membrane. Membranes were 
then probed with an anti-phospho Chk1 (ser317) antibody. Total Chk1 
levels were used as a loading control.  
b)  Hela cells were either untransfected (Unt), mock transfected (mock) or 
exposed to Control (Cont) or PCNT siRNA oligonucleotides for 72hrs. 
Cells were then treated with 10J/m2 UV and cell pellets harvested 1hr 
later. Whole cell extracts were then resolved on a 8% SDS-PAGE and 
transferred onto a PVDF membrane. Membranes were then probed with 
an anti-phospho Chk1 (ser317) antibody. Total Chk1 levels were used as 
a loading control.  Extracts were immunoblotted for PCNT to confirm 
depletion.  
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Figure 3.8  PCNT mutated cells display reduced levels of Chk1 at the 
centrosome 
 
a)  Patient primary fibroblasts (WT: 48BR, 1BR3; PCNT mutated: E220X-/-, 
C1190fs-/-; ATR Seckel: F02-98) were stained using techniques to 
identify the centrosomal pool of Chk1 (green). Centrosomes were 
identified by co-staining with a !-tubulin marker (red). The percentage of 
cells with a total absence of Chk1 signal at the centrosome was 
evaluated. The graph represents the mean of three independent 
experiments. Error bars represent the standard deviation.  
b)  Immunoflurescent images showing 1BR3 control cell with Chk1 (green) 
and !-tubulin (red) signal overlap and PCNT-Seckel cell with only red !-
tubulin  signal. 
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3.2.8 Cdc25A degradation is normal in PCNT mutated cells 
 
 
As Chk1 was phosphorylated normally in PCNT mutated cells, but its localization to 
the centrosome was compromised, downstream targets of Chk1 were further 
examined in order to establish whether Chk1 function is normal in these cells. 
 
After damage Cdc25A is phosphorylated by Chk1 at multiple sites including serine 
123 (Mailand et al., 2002). These phosphorylations target the phosphatase for 
ubiquitin-proteasome mediated degradation via the Skp1/Cul1/F-box (SCF) 
complex (Busino et al., 2003), resulting in a G2/M arrest. The stability of Cdc25A 
during the cell cycle or after damage can therefore be monitored by the addition of 
cycloheximide to culture media, in order to prevent new protein synthesis and thus 
visualize the degradation of the cellular pool of Cdc25A. This Chk1-dependent 
degradation process has previously been shown to be defective in ATR-Seckel cells 
(Alderton et al., 2006). PCNT mutated patient cells were examined for their ability 
to degrade the Cdc25A phosphatase during normal cellular growth. In WT and PCNT 
mutated lines, Cdc25A was degraded normally in contrast to ATR-Seckel cells 
(Figure 3.9). HeLa cells depleted of PCNT and treated with UV irradiation, also 
displayed normal degradation of Cdc25A, confirming the result observed in the 
patient cell line. This result indicates that Chk1 dependent degradation of Cdc25A is 
normal in the PCNT mutated lines and that this is therefore not a contributing factor 
in the loss of the G2/M checkpoint in these cells.  
 
 
3.2.9 PCNT mutated cells display reduced levels of Cdc25B pS230 at 
the centrosome 
 
The inhibitory phosphorylation of S230 on Cdc25B by Chk1 has been demonstrated 
to occur during normal cell growth (Löffler et al., 2006). The phosphorylation at 
ser230 was detected at the centrosome as well as in the cytoplasm and was 
demonstrated to inhibit the activity of Cdc25B, although the mechanism for this is 
unclear (Schmitt et al., 2006).  
 
In order to assess if the reduced levels of Chk1 detected at the centrosome in PCNT 
mutated cells resulted in a reduction in the phosphorylation of a Chk1 target 
protein, the level of phosphorylated S230 Cdc25B present at the centrosomes was 
examined in PCNT mutated primary fibroblast cells using a previously characterised 
antibody (Schmitt et al., 2006). The percentage of PCNT mutated cells with a total 
Figure 3.9  Cdc25A stability is normal in a PCNT mutated patient cell line 
and PCNT depleted line. 
 
a)  WT, ATR-Seckel (ATR-S) and PCNT mutated (E220X-/-) LBL lines were 
treated with 100 ug/mL Cycloheximide for 20 min and cell pellets were 
then harvested in the continued presence of cycloheximide. Whole cell 
extracts were resolved on a  10% SDS-PAGE gel and transferred onto 
PVDF membrane. Membranes were probed with antibodies against 
Cdc25A. Actin was used as a loading control.  
b)  Hela cells were either untransfected (Untrans), mock transfected 
(mock) or exposed to Control (Cont) or PCNT siRNA oligonucleotides for 
72hrs. Cells were treated with 10J/m2 UV and then incubated in 100ug/
mL cycloheximide for 20 min. Cell pellets were then harvested in the 
continued presence of cycloheximide. Whole cell extracts were resolved 
on a  10% SDS-PAGE gel and transferred onto nitrocellulose 
membrane. Membranes were probed with antibodies against Cdc25A. 
Actin was used as a loading control. Extracts were also immunoblotted 
to confirm PCNT depletion, using ATR as a loading control. 
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Figure 3.10  PCNT mutated cells display reduced levels of Cdc25B pS230 at 
the centrosome 
 
a)  Patient primary fibroblasts fibroblasts (WT: 48BR, 1BR3; PCNT 
mutated: E220X-/-, C1190fs-/-; ATR Seckel: F02-98) were stained 
using techniques to identify the centrosomal pool of Cdc25B 
phosphoS230 (red). Centrosomes were identified by co-staining with a 
!-tubulin marker (green). The percentage of cells with a total absence 
of Cdc25B pS230 signal at the centrosome was evaluated. The graph 
represents the mean of three independent experiments. Error bars 
represent the standard deviation.  
b)  Immunoflurescent images showing a 1BR3 control cell with Cdc25B 
pS230 (red) and !-tubulin (green) signal overlap and a PCNT-mutated 
cell with only green !-tubulin  signal. 
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absence of pS230 Cdc25B at the centrosome was approximately 15% in contrast to 
less than 5 % in WT and ATR-Seckel control lines (Figure 3.10). This reduction in 
Cdc25B phosphorylation is comparable to the reduction of Chk1 signal observed at 
the centrosome (Figure 3.8). This result suggests that the reduction in Chk1 signal 
at the centrosome in these cells results in a reduction in the phosphorylation of its 
downstream target. The biological relevance of this is however unclear, as no 
changes to Cdc25B pS230 signal could be detected after exposing cells to DNA 
damage (data not shown) and this aspect of signalling warrants further 
investigation.  
 
PCNT mutated primary fibroblast cells were then subjected to PCNT-siRNA 
treatment for 72 hours to deplete any residual protein remaining. These cells were 
then examined for pS230 Cdc25B levels at the centrosome using the same antibody 
as Figure 3.10. This treatment significantly increased the number of cells with a 
total absence of pS230 Cdc25B signal (Figure 3.11), confirming that loss of Chk1 
from the centrosome due to PCNT depletion impacts on downstream 
phosphorylation events at the centrosome. This data was subsequently 
independently demonstrated and published by Tibelius and authors in 2009 
(Tibelius et al., 2009). 
 
3.2.10 53BP1 foci formation in response to replicative stress is 
impaired in PCNT mutated cells 
 
The formation of 53BP1 foci at sites of replication stress is known to be dependent 
on both Chk1 and ATR (Sengupta et al., 2004, Tripathi et al., 2008). ATR-Seckel 
cells have previously been shown to exhibit reduced 53BP1 foci formation following 
treatment with hydroxyurea (Alderton et al., 2006). 53BP1 foci formation was 
therefore examined in PCNT mutated LBLs, following treatment with hydroxyurea to 
stall replication forks, as a readout for the activity of the Chk1 kinase, and also to 
determine if the lack of a key centrosomal protein has an impact on replication 
stress signalling.  
Strikingly, both PCNT mutated and ATR-Seckel cells display impaired 53BP1 foci 
formation capability following replication stress (Figure 3.12). This is in contrast to 
wild-type and unaffected parental control lines where foci formed as expected. This 
result indicates that the signalling that is required to target 53BP1 to replication-
stress induced damage is impaired in PCNT mutated cells. It further suggests that 
defects in centrosomal structure may impact upon events at the replication fork.  
 
Figure 3.11  PCNT-mutated cells display a further reduction in levels of 
Cdc25B pS230 at the centrosome, following depletion of residual PCNT 
expression.  
 
Residual PCNT expression in patient primary fibroblasts was depleted by 72hr 
PCNT siRNA incubation. Cells were stained using techniques to identify the 
centrosomal pool of Cdc25B phosphoS230 (red). Centrosomes were identified 
by co-staining with a !-tubulin marker (green). The percentage of cells with a 
total absence of Cdc25B pS230 signal at the centrosome was evaluated. The 
graph represents the mean of two independent experiments. Error bars 
represent the standard deviation.  
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Figure 3.12 53BP1 foci formation in response to replication stress is impaired 
in PCNT-mutated cells. 
 
WT, ATR-S, unaffected heterozygous relative and PCNT-mutated cell lines were 
exposed to 5mM hydroxyurea for 2hr. 53BP1 foci were examined using 
immunofluoresence with a specific antibody. The percentage of cells with more 
than 5 foci was determined for each cell line. The graph represents the mean 
of three independent experiments. Error bars represent the standard 
deviation. 
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3.2.11 Stalled replication forks in PCNT mutated cells recover 
normally after replication stress 
 
The recovery of stalled replication forks after Aphidicolin-induced replication arrest 
is ATR and Chk1 dependent (Feijoo et al., 2001, Stiff et al., 2005). This recovery 
can be monitored by labelling replication forks with a deoxyuridine analogue, 
Chlorodeoxyuridine (CldU), stalling replication forks by treatment with aphidicolin 
and the labelling recovering forks with a second deoxyuridine analogue, Iodouridine 
(IdU). Each label can then be detected using immunofluoresence techniques and 
the percentage of recovered forks determined by scoring the overlay of red and 
green signal. ATR-Seckel cells have been shown to exhibit defects in the ability to 
recover from stalled replication forks (Stiff et al., 2005), implicating ATR-dependent 
signalling in their stabilisation. PCNT mutated cells were therefore assessed for the 
ability to recover stalled replication forks following replication stress, particularly as 
53BP1 foci formation in these cells was shown to be impaired (Figure 3.12). In 
wild-type and PCNT mutated cells, forks recovered from the replication block to the 
same extent, in contrast to ATR-Seckel cells which displayed defects in fork 
recovery (Figure 3.13). This result demonstrates that HU-induced stalled replication 
forks in PCNT mutated cells are stabilised normally. It is possible that the 
centrosomal pool of Chk1 is therefore not required for the functions of Chk1 that 
are related to replication. This result further suggests that the clinical features 
observed in these patients are not due to increased genomic instability due to the 
collapse of stalled replication forks.  
 
3.3 DISCUSSION 
 
In this chapter I have demonstrated that mutations in PCNT, a structural 
centrosomal protein, result in defects in ATR-dependent damage response 
signalling. I have shown that the mutations identified in PCNT result in some 
cellular phenotypes associated with Seckel syndrome such as supernumerary 
mitotic centrosomes and a UV-induced G2/M checkpoint defect. However, the 
upstream steps in the ATR signalling pathway, such as H2AX phosphorylation, are 
not defective in these cells. I have also shown that mutations in PCNT result in 
reduced Chk1 localisation to the centrosome, resulting in reduced Chk1 dependent 
phosphorylation of Cdc25B at the centrosome.  
 
By studying PCNT mutated patient cell lines, a structural centrosomal protein has 
been implicated in the ATR-dependent DNA damage response for the first time. The 
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Figure 3.13  Recovery of stalled replication forks is normal in PCNT-mutated 
patient cell lines. 
 
WT, ATR-S, E220X-/- and E220X+/- LBLs were labelled with CldU for 20 min to 
label replication forks. Cells were then pelleted, washed and incubated with 
APH for 2 hr to stall ongoing forks. Cells were pelleted and swollen in KCL plus 
IdU for ten minutes to allow fork reinitiation and IdU incorporation. Replication 
recovery is monitored by the overlap of CldU (red) and IdU (green) labelling. 
The graph represents the mean of three independent experiments. Error bars 
show the standard deviation.  
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evidence to link defects in ATR signalling with the clinical features displayed by the 
patients is compelling. Two genes have now been linked to Seckel syndrome by this 
laboratory: ATR and PCNT.  
 
At the same time that Seckel sydrome patients harbouring PCNT mutations were 
reported, mutations in PCNT were also reported to cause another genetic syndrome 
Majewski Osteodysplastic Primordial Dwarfism Type II (MOPDII) (Rauch et al., 
2008a). These patients also present with microcephaly and extreme pre and post-
natal growth retardation. Interestingly these patients are born with a 
proportionately normal head circumference, which then progresses to true 
microcephaly after birth (Hall et al., 2004). Mental retardation in these patients 
appears to be less marked than in Seckel patients (Rauch et al., 2008b). It will be 
interesting to obtain further MOPDII patient cell lines in order to analyse the ATR-
dependent damage response in these patients and perform a genotype/phenotype 
analysis of PCNT mutations. This could determine whether all the PCNT mutations 
observed result in ATR-dependent damage response defects and whether this 
correlates with severity or frequency of clinical features in the patients.  
 
Willems et al. (2010) undertook a retrospective analysis of clinical data and 
concluded that PCNT-Seckel patients had been mis-diagnosed and could actually be 
classified as MOPDII patients, based on clinical features such as skeletal 
abnormalities, facial features and intellectual disability (Willems et al., 2010). 
However it appears that head circumference at birth was not examined in this 
study. As MOPDII is defined by proportionate head size at birth, progressing to a 
relative microcephaly after one year (Galasso et al., 2008) is this clinical feature 
critical for distinction between the two disorders? A clinical distinction, if there is 
found to be one, could be argued as essential due to the extra surveillance required 
of MOPDII patients due to the occurrence of vascular problems, such as Moyamoya 
disease (Hall et al., 2004). This is a disease leading to constriction of blood vessels 
in the brain that can lead to hemorrhage. These vascular problems can result in 
death. Perhaps further investigation of ATR-dependent signalling in these cell lines, 
as suggested above, could provide further insight and allow these disorders to be 
distinguished by the use of a diagnostic test. 
 
There are currently two proposed models for the function of PCNT in cell division.  
The first model proposed to explain the function of PCNT is that the lack of this 
protein results in centrosome structural defects, resulting in defects in mitotic 
spindle assembly and orientation. Examination of MOPDII patients harbouring PCNT 
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patients revealed various mitotic defects, such as disorganized microtubules, 
incorrect orientation of metaphases and disorganized cytokinesis, in 71% of 
fibroblast cells (Rauch et al., 2008b). The reduction of gamma-tubulin at the 
centrosome observed in our PCNT mutated patients (Griffith et al., 2008) could also 
result in defective microtubule nucleation and disruption of mitotic spindle assembly 
(Takahashi et al., 2002, Doxsey et al., 2005a). Disruption of spindle assembly may 
result in the formation of multipolar spindles and therefore lead to aneuploidy or 
cell death during mitosis (Figure 3.14a). Interestingly, all cell lines examined with 
defects in ATR-dependent signaling show a nuclear fragmentation phenotype, 
postulated to be a result of premature mitotic entry due to failure of G2/M 
checkpoint activation in the presence of replication associated damage (Alderton et 
al., 2004). Defects in spindle orientation were observed in PCNT-MOPDII patients 
(Rauch et al., 2008b). PCNT depletion leads to loss of astral microtubules 
(Zimmerman et al., 2004), which are known to be important for proper orientation 
of the spindle (Toyoshima and Nishida, 2007). Defects in spindle orientation can 
lead to a shift from symmetric division to asymmetric division, resulting in an 
overall decrease in the progenitor stem cell population (Cox et al., 2006) (See 
Introduction). 
 
The second model is that indicated from the data presented in this chapter.  
Reduction in the level of PCNT at the centrosome results in a defective ATR-
dependent G2/M checkpoint response to UV damage (Figure 13.4b). This is due to 
reduced levels of Chk1 at the centrosome, which in normal circumstances is 
anchored there via an interaction with PCNT (Tibelius et al., 2009). The lack of local 
Chk1 concentration at the centrosome contributes to a failure to inhibit the Cdc25-
dependent activation of Cdk1-CyclinB1 complexes, and a resultant failure to inhibit 
unscheduled mitotic entry. This is demonstrated by reduced levels of Ser230 
phospho Cdc25B at the centrosome observed in PCNT mutated patient cell lines. 
However, this phenotype is not observed in all cells, suggesting that this pathway 
may act redundantly, perhaps with the other Cdc25 proteins. The lack of a G2/M 
checkpoint in these cells may reduce the overall number of cells during embryonic 
development due to an increase in mitotic catastrophe, as damaged cells enter 
mitosis inappropriately. This increased cell death could potentially contribute to the 
short stature and microcephaly observed in the patients. 
 
The role of PCNT in the formation of the primary cilia could also potentially 
contribute to the clinical features displayed by PCNT-Seckel patients. The primary 
cilium is anchored in place by a modified centrosome called the basal body 
Figure 3.14 Models of PCNT function at the centrosome.  
 
a) Centrosome defects result in spindle defects resulting in multipolar spindles 
and cell death. Loss of astral microtubules results in spindle orientation 
defects, increasing asymmetric cell division and resulting in reduced cell 
numbers. Figure adapted from Delaval and Doxsey, 2009. 
b) UV or HU induced DNA damage results in activation of ATR kinase which 
then phosphorylates downstream targets such as Chk1. This phosphorylation 
is required for the accumulation of Chk1 at the centrosome. PCNT anchors 
Chk1 to the centrosome preventing activation of Cdk1-Cyclin B via the CDC25 
proteins, and preventing progression into mitosis. In the absence of Chk1 at 
the centrosome cells do not arrest at the G2/M checkpoint. 
Figure adapted from Griffith and Walker, Nature Genetics, 2008 
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(Duldulao et al., 2010). The cilia have recently been shown to play important roles 
in major signaling pathways and also in brain development (Lee and Gleeson, 
2011). There are some overlapping features between ciliopathies and Seckel 
syndrome such as skeletal defects, polydactyly and some degree of mental 
retardation. Recent data from our laboratory indicate that PCNT mutated patients 
do exhibit some defects in cilia formation and function (T. Stiff, data not shown). 
It appears that HU-induced stalled replication forks are stabilized effectively in 
PCNT mutated cells, however the deficiency in 53BP1 foci formation after HU 
treatment implies that the signalling cascade from stalled forks may be 
compromised. It is possible that 53BP1 is activated by Chk1 at the centrosome 
before relocating to stalled replication forks, or that an unknown factor is required 
for Chk1 to signal efficiently to 53BP1, and this may occur via the centrosome. 
53BP1 depletion in human cells results in a partial defect in the intra S-phase 
checkpoint and a defect in the G2/M checkpoint response to low doses of IR 
(Jowsey et al., 2007). Although the G2/M checkpoint in the PCNT mutated lines was 
proficient after 3 Gy IR, an examination of the G2/M checkpoint response to low 
doses of irradiation could be informative to see if the defects in 53BP1 foci 
formation observed impacts upon these checkpoints. 
 
Further investigation of the regulation of S-phase events is warranted in PCNT 
mutated cells. Interestingly, centrosomal localisation of Cyclin E has been shown to 
occur in mammalian cells from G1 through S phase (Matsumoto and Maller, 2004) 
and centrosomal localization of Cyclin E/Cdk2 is required for the initiation of DNA 
synthesis (Ferguson and Maller, 2010). These studies indicate that indeed the 
centrosome plays a role in the regulation of S phase events, as well as in G2/M 
checkpoint regulation. It is possible that PCNT is involved in the initiation of DNA 
replication or intra S-phase checkpoint induction. As ATR also has important roles in 
replication, which may impact on the clinical features observed in Seckel patients, 
an investigation of the role of PCNT in replication dynamics could be informative. 
 
In conclusion, in this chapter I have shown that mutations in PCNT, in patients with 
microcephalic primordial dwarfism, result in defects in the ATR-dependent damage 
response. This provides the first description of a connection between a structural 
centrosomal protein and DNA damage response signaling.  
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CHAPTER FOUR 
 
RESULTS II: Mutations in ATRIP cause Seckel 
Syndrome 
 
4.1 INTRODUCTION 
 
Seckel syndrome (SS) patient cell lines received by our laboratory are screened for 
ATR-dependent G2/M checkpoint arrest and supernumary mitotic centrosomes. 
Immunoblotting of proteins already established as genetic defects causal in 
Primordial Dwarfism syndromes, such as ATR and PCNT, is carried out. This enables 
the identification of patients with known genetic defects in order to help with 
genetic counselling of families, but also provides functional cellular data to aid with 
inclusion of patients in ongoing genetic mapping studies.  
 
LBL cells were obtained from a consanguineous family of Saudi-Arabian origin with 
a clinical diagnosis of SS in one patient (CV1720) (Figure 4.1). The patient 
displayed severe microcephaly and short stature with a receding forehead and a 
prominent nose. There was some dental crowding with micrognathia. The patient 
had small ear lobes and fifth finger clinodactyly. A skeletal survey revealed a 
delayed bone age. An MRI scan of the brain showed generalised atrophy of the 
cerebrum. The pituitary was an unusual shape with an absent fossa (See Table 5). 
Extracts from LBL cell line CV1720 were therefore resolved by SDS-PAGE and 
immunoblotted with antibodies against ATR and PCNT. A decreased level of ATR 
was observed in the patient extracts compared to WT (Figure 4.2). Blots were 
reprobed to assess ATRIP protein levels, as ATR and ATRIP proteins are dependent 
on each other for stability (Cortez et al., 2001). ATRIP protein levels were also 
markedly decreased in the patient extracts (Figure 4.2). 
  
To determine if causal mutations in ATR or ATRIP could account for the decrease in 
protein level observed, samples were sent for sequencing to our collaborator in 
Japan, Tomoo Ogi. No mutations were detected in ATR in any of the samples 
tested. However, two mutations were identified in ATRIP that were also present as 
heterozygous changes in the parents (Figure 4.3).  
 
 ATRIP-SS ATR-S 27-4BI 19-8BI 
Ethnicity Gujarati-Indian 
(consanguineous) 
Pakistani 
(consanguineous) 
English 
 
English 
Birth.     
OFC (cm) 
Wgt (Kg) 
Hgt  (cm) 
 
27.1 
2.06 
NR 
 
24 (-8SD) 
1.1 (-3SD) 
NR 
 
NR 
1.15 
36 
 
24.2 
0.77 
NR 
Age.                    
OFC 
Wgt                 Hgt 
14mts 
-9SD  
-5SD 
-5SD 
9yrs 
-12SD 
-3.3SD 
NR 
20mts 
-10SD 
-8SD 
-8SD 
4.5yrs 
-10SD 
-7SD 
-8SD 
Face Micrognathia, 
receding forehead, 
prominent nose. 
Micrognathia, 
receding forehead, 
prominent nose.  
Micrognathia, 
prominent nose, 
hypoplastic alae 
nasi, low set 
columella, short 
palpebral fissures. 
Micrognathia, 
blepharophimosis, 
short palpebral 
fissures. High 
anterior hairline. 
Teeth Dental crowding. Dental crowding and 
malocclution. 
4 teeth at 20 
months. 
Dental crowding. 
Ears Small lobes. Posteriorly rotated 
with absent lobes. 
Small, round, low 
set with poorly 
formed antihelix 
tragus & antitragus. 
Absent lobes. 
Small ears with 
absent lobes 
Hands Bilateral 5th finger 
clinodactyly. 
Multiple ivory 
epiphysis. 
Small, tapering 
fingers. 
Bilateral 5th finger 
clinodactyly. 5th 
metacarpels appear 
short.  
Skeletal 
Survey 
Delayed bone age 
(wrist & hips), 
symmetric dwarfism. 
Microcrania with 
fuse sutures. Mild 
thoracic kyphosis. 
Ribs angulated 
posteriorly. Narrow 
iliac blades, cox 
valga and minor 
subluxation of the 
hips.  
NA. Symmetric 
dwarfism. Small 
patellae. No joint 
hypermobility or 
kyphoscoliosis. 
NA. Symmetric 
dwarfism. Small 
patella. Marked hip 
& shoulder 
flexibility. No 
kyphosis. 
Endocrinology Normal IGF1, TFT, 
LH, FSH & cortisol. 
NA NA NA 
MRI 14mts:generalised 
cerebral atrophy. 
Delayed myelination 
in the anterior limb of 
the internal capsule. 
Pituitary present but 
of unusual shape 
with absent fossa.  
NA NA 2yrs: abnormal 
gyration in posterior 
aspect of the 
cingulated gyrus 
extending into the 
parietal occipital 
region. Hypoplastic 
corpus collasum. 
Other NR Developmental 
delay. Walked at 
7yrs.  
NR Developmental 
delay. Sat at 15mts, 
walked at 3yrs 
10mts. High pitched 
voice, asthma, 
multiple chest 
infections, feeding 
difficulties-reflux 
(gastrostomy fed).  
NR; not recorded. NA; not assessed. 
Table 5. ATR-ATRIP Seckel clinical features. Adapted from Ogi et al, 2012. 
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a) 
b) 
Figure 4.1 ATRIP patient pedigree and features 
a)  Pedigree of ATRIP family 
b)  ATRIP-S patient brain scan showing generalised cerebral atrophy 
I:1        I:2 
II:1      II:2                II:3        II:4 
III:1     III:2                                        III:3     III:4                            III:5      III:6 
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Loading 
PCNT 
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Figure 4.2 ATRIP and ATR expression is reduced in CV1720 patient cells 
Levels of ATRIP and ATR expression were examined by resolving whole cell 
extracts from WT, ATR-S and CV1720 (ATRIP-S) cell lines on 6-8% SDS-PAGE 
gels followed by transfer onto nitrocellulose membranes. Membranes were 
then probed with a ATR or ATRIP antibody. The loading control was taken from 
a non-specific band. 
* R760X * Intron change 
Father – intron change – not reported SNP 
Mother - R760X 
Figure 4.3 ATRIP protein schematic and mutations identified 
a)  Schematic of ATRIP protein showing positions of mutations identified in 
CV1720 patient.  
b)  C2278T mutation present in patient and mother only. 
c)  Exon 1 to 3 RT-PCR showing two PCR products in CV1720 patient. 
Sequence of smaller fragment showing exon 2 loss in CV1720 patient. 
a) 
b) 
c) 
1 791 764 108 217 
Coiled - coil 
domain ATR-interacting  
domain 
390 
RPA-ssDNA 
interacting 
domain 
TopBP1 interacting domain 
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Sequencing of genomic DNA identified a heterozygous point mutation in exon 12, 
C2278T (Figure 4.3b). This change produced a stop codon, predicted to result in a 
truncated protein R760X. This mutation was detected as a heterozygous change in 
the mother but was not present in the father.  
 
To investigate the impact of this mutational change, qPCR was performed using 
allele specific primers. Primer pairs P1 and P3C were used to selectively amplify the 
WT C2278 allele, whilst primer pairs P2 and P3C were designed to amplify only the 
mutated C2278T allele. The WT qPCR product was detected in all samples whilst 
the C2278T product was detected only in the patient and the mother. The WT and 
C2278T mRNA products were expressed at near equal levels in the mother, 
indicating that nonsense mediated decay (NMD) of the mutant C2278T transcript 
does not occur (Figure 4.4a). 
 
Sequencing of introns 1 and 2 from the family material identified a novel mutational 
change in intron 2. This change was positioned 13bp from the intron-exon 
boundary of exon 2 and was present in the patient and the father but not the 
mother. The change was not a reported SNP. Therefore further investigation of the 
impact of this mutational change was performed. Both laboratories carried out RT-
PCR analysis of the exon 1 to 3 region of ATRIP. Amplification of exons 1 to 3 
produced a smeared PCR product with two distinct size products, a 458bp product 
that corresponds to full length exon1-3, and a smaller fragment of 325bp (Figure 
4.3c and data not shown).  Sequencing of these RT-PCR products revealed that the 
smaller product contained exon 1 directly spliced to exon 3 but missing exon 2. 
This suggested that mis-splicing is occurring in the patient cells, possibly due to the 
intron change detected.  
 
The mutation leading to the production of a mis-spliced RT-PCR product in the 
patient results in the deletion of exon 2 of ATRIP. Exon 2 codes for a region of 
ATRIP including amino acids 108 to 137 of the coiled-coil domain. This domain has 
been shown to be important for oligomerisation of ATRIP and also to be required for 
Chk1 phosphorylation (Ball and Cortez, 2005). If the mutant mRNA is translated 
into a protein with a defective coiled-coil domain then this could impact on protein 
function.  
 
Further primers were designed to the exon 2/3 boundary (P4) and within exon 3 
(P6C) to selectively amplify the correctly spliced mRNA. A primer pair with one 
primer designed to the exon 1/3 boundary (P5) and one within exon 3 (P6C, as 
a) 
b) 
Figure 4.4 Quantitative PCR analysis of ATRIP mutant alleles 
a) Selective quantitative amplification of the WT or 2278C>T ATRIP alleles.  
Primers located in ATRIP exon 12 and 13 were designed to selectively amplify 
the WT (c.2278C) (P1 and P3C) versus the mutated (c.2278C>T) (P2 and 
P3C) alleles. The WT PCR product is shown in blue and the c.2278C>T PCR 
product in red. The exon 12 mutated allele is only observed in the patient and 
mother cDNA whilst the WT allele is observed in the patient, mother and 
father cDNA although the level is reduced in the patient and mother.  
b) qRT-PCR analysis of ATRIP splicing variants from patient CV1720 and 
parental cells. qRT-PCR analysis of the level of the normally spliced 
(encompassing exons 1- 2-3) and the aberrantly spliced (!exon2) ATRIP cDNA 
in the patient and parent cells. PCR primers were designed at the exon2-
exon3 or exon1-exon3 boundaries to selectively amplify the splicing variants. 
Transcripts from HPRT1 were used as a quantification control. The correctly 
spliced transcript from the paternal allele of the patient (wild type c.2278C, 
blue fraction in the cumulative bar labelled, 'patient', at the left panel) was 
estimated to be ~25% of the normal level.  
Figure and legend from Tomoo Ogi. 
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above) were used to selectively amplify the mis-spliced mRNA product. Similar 
levels of correctly spliced mRNA were detected in all samples, however, the mis-
spliced mRNA product was more abundant in both the patient and the father 
(Figure 4.4b).  
 
Further qPCR experiments were conducted to clarify if the mis-spliced mRNA 
product, predicted to generate an out of frame cDNA, is subject to NMD. 
Fluorescent Cycleave PCR probes were designed and qPCR conducted in the 
absence or presence of Puromycin, an antibiotic that prevents NMD. Allele specific 
probes were designed to distinguish between the WT and the C2278T alleles (Figure 
4.5). In the mother the WT and C2278T allele products were detected at equal 
levels, regardless of the presence or absence of Puromycin. This further confirms 
that the C2278T allele product is not subject to NMD. In the patient, the WT allele 
product was reduced compared to the mutant allele in the absence of puromycin 
but was detected at equal levels in the presence of puromycin. These results 
indicate that the mRNA from the paternal allele in the patient is subject to NMD, 
due to aberrant splicing. No changes in either allele product could be detected in 
the father, likely due to any changes being below the threshold of detection for this 
assay.  
 
All of the above work on mutational analysis was conducted by Tomoo Ogi. 
 
ATRIP, a protein of approximately 85 kDa, was identified in ATR 
immunoprecipitates and ATR and ATRIP were found to be mutually dependent on 
each other for their stability (Cortez et al., 2001). It was proposed that ATR/ATRIP 
exists in cells in a stable complex and that depletion of ATRIP produced the same 
G2/M checkpoint defects as observed with depletion of ATR. It was also shown that 
ATR could phosphorylate ATRIP (Cortez et al., 2001). Two splice variants of the 
protein were detected. A splice variant resulting in loss of exon 11 was 
subsequently shown to be expressed at levels of less than 5% of the full length 
mRNA, and the expressed protein is unable to bind to ATR and therefore is unlikely 
to have any biological function (Ball et al., 2005). 
 
When ssDNA is created in the cell, such as by damage or stalling of replication 
forks, the single stranded region is swiftly coated with RPA. Recruitment of 
ATR/ATRIP to ssDNA is dependent on an interaction between RPA and ATRIP (Zou 
and Elledge, 2003). The region of ATRIP that functions as an RPA-ssDNA binding 
domain includes the first 107 amino acids. This domain was shown to be essential 
for localising ATRIP at ssDNA sites within the nucleus as ATRIP lacking this domain 
Figure 4.5  The mis-spliced paternal allele is subject to nonsense mediated 
mRNA decay (NMD).  
Cycleave-qPCR confirmed that the ATRIP c.2278C>T mutant allele was 
expressed exclusively in the patient and the mother. The ATRIP exon12-13 
fragment was amplified with a PCR primers P7/P8 as shown in the figure. A 
set of fluorescent probes were used to distinguish the WT versus c.2278C>T 
allele (probe1 and probe2, respectively). In the patient, the paternal mRNA 
transcript level (emerald lines) is low because of NMD (top left). Puromycin 
treatment eliminated the NMD and the paternal transcript level returned to 
the normal level.  
Figure and legend from Tomoo Ogi 
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was mainly confined to the cytoplasm. However, no nuclear localization signal has 
been identified in this domain (Ball et al., 2005). Further investigation revealed that 
there are multiple sites within ATRIP that are able to interact with RPA-ssDNA. The 
region containing amino acids 218 to 390 was also mapped as an RPA-ssDNA 
interacting domain (Namiki and Zou, 2006). 
ATRIP oligomerises in cells independently of ATR and this oligomerisation is 
mediated by the coiled-coil domain of ATRIP from amino acid 108 to 217 (Ball and 
Cortez, 2005).The oligomerisation of ATRIP is required for the formation of stable 
ATR/ATRIP complexes and the coiled coil domain is essential for effective ATR 
dependent Chk1 phosphorylation (Ball and Cortez, 2005). An ATR-interacting 
domain was also determined to reside at the C-terminal region of ATRIP (Ball et al., 
2005). When ATRIP mutants lacking the C-terminal domain were constructed and 
expressed in cells, recruitment of ATR to damage was prevented and defects in 
ATR-dependent phosphorylation of Chk1 were observed (Falck et al., 2005). These 
results indicated that in order for ATR to be recruited to ssDNA, a functional 
interaction between ATR and ATRIP is required (Falck et al., 2005). As similar 
motifs exist in ATM and DNA-PK, facilitating their interaction with Nbs1 and Ku 
respectively, it was postulated that this conserved domain serves as a ‘kinase-
docking module’ that is required for a more stable interaction between these 
binding partners with multiple interaction sites (Falck et al., 2005).  
 
Topoisomerase binding protein 1 (TopBP1) stimulates ATR kinase activity through 
binding to the ATR/ATRIP complex. This binding is dependent on ATRIP (Kumagai et 
al., 2006). The region on ATRIP that interacts with TopBP1 was identified as amino 
acids 203-348, adjacent to the coiled coil domain (Mordes et al., 2008). This ATRIP 
‘regulatory region’ is conserved in the yeast protein Ddc2 and mutations within this 
region result in sensitivity to replication stress in both yeast and human cells 
(Mordes et al., 2008). 
 
ATRIP also interacts with minichromosome maintenance 7 (MCM7) possibly 
facilitating the phosphorylation of MCM2 by ATR (Cortez et al., 2004). This function 
of ATRIP could be important for targeting of ATR to replication fork associated 
damage.  
 
ATRIP is phosphorylated by Cdk2 on Serine 224, but this phosphorylation is not 
required for ATRIP to bind to RPA, localise to damage sites or bind to ATR. 
However, phosphorylation of ATRIP S224 is required for effective G2/M checkpoint 
responses at later times following exposure to IR. (Myers et al., 2007). 
! "#!
 
In yeast Rad26-ATRIP, an important function for a conserved c-terminal motif was 
recently uncovered. Herring and colleagues discovered that this motif is required 
for a microtubule-associated damage response but not an overall damage 
response. Loss of Rad26-ATRIP resulted in sensitivity to microtubule toxins, 
segregation errors and a failure to delay mitotic entry in the presence of 
microtubule damage (Herring et al., 2010).  
 
The aim of this chapter was to identify the genetic defect in CV1720 patient cells. 
Once the mutational changes in ATRIP were identified, an important aim was to 
examine how these mutational changes impact on protein expression, function and 
the ATR-dependent damage response.  
 
4.2 RESULTS 
 
4.2.1 Timeless and hCLK2 protein levels are normal in CV1720 
patient cell line 
 
Timeless protein and hCLK2 protein levels in CV1720 LBL extracts were examined 
by immunoblotting to determine if a reduction in either of these protein levels could 
be a cause of the reduced ATR/ATRIP protein levels detected in this cell line. 
Timeless is a circadian protein that interacts with ATR/ATRIP and depletion of 
Timeless by siRNA results in defects in Chk1 phosphorylation (Unsal-Kaçmaz et al., 
2005). HCLK2 is another circadian protein that interacts with ATR/ATRIP and 
TopBP1 (Collis et al., 2007, Rendtlew Danielsen et al., 2009). It was reported that 
this interaction helps to stabilise ATR protein. Neither protein was reduced by a 
significant amount in CV1720 LBL extracts (Figure 4.6) therefore they were 
considered not likely to be mutated and were excluded from further analysis.  
 
4.2.2 Further assessment of ATR and ATRIP protein levels in 
CV1720 and parental cell lines 
 
In order to further assess the extent of protein depletion in CV1720 LBLs, extracts 
were prepared from WT and CV1720 cells and loaded in increasing amounts on 
SDS-PAGE gels for immunoblotting analysis. When 100µg of extract was loaded, an 
amount at which the WT protein level was saturated, minimal ATRIP protein could 
be detected in the patient (Figure 4.7a). Increasing the amount of extract loaded 
Timeless 
Loading 
WT ATR-S CV1720 
WT ATR-S CV1720 
hCLK2 
Loading 
a) 
b) 
Figure 4.6  Timeless and hCLK2 expression are normal in CV1720 patient cells 
Levels of Timeless and hCLK2 protein expression were examined by resolving 
whole cell extracts from WT, ATR-S and CV1720 (ATRIP-S) LBL cell lines on 
8% SDS-PAGE gels followed by transfer onto nitrocellulose membranes. 
Membranes were then probed with a Timeless or hCLK2 antibody. The loading 
control used was a non-specific band. 
25       50       75      100 25      50      75     100    ug WCE
WT CV1720 
ATRIP 
Loading - Mcm2 
25       50        75   25         50       75           ug WCE   
ATR 
Loading -  Mcm2 
WT CV1720 
a) 
b) 
Figure 4.7 ATRIP and ATR protein levels are dramatically reduced in CV1720 
patient cells  
Levels of ATRIP and ATR expression were examined by resolving increasing 
amounts of whole cell extracts from WT and CV1720 (ATRIP-S) LBL cell lines 
on 6- 8% SDS-PAGE gels followed by transfer onto nitrocellulose membranes. 
Membranes were then probed with either ATR or ATRIP antibody. The loading 
control used was Mcm2. 
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corresponded with increasing levels of ATR protein in the patient, although the 
levels were still much reduced compared to WT (Figure 4.7b).  When parent cell 
lines were examined, both ATR and ATRIP levels were reduced by approximately 
50% in each parent (Figure 4.8). This corresponds with the genetic analysis of 
heterozygous mutations in each parent and suggests that each mutation impacts 
on ATRIP stability, and therefore also ATR stability. Quantification of ATRIP and ATR 
protein levels from at least three independent immunoblotting experiments is 
shown in Figure 4.9. 
 
4.2.3 Assessment of the ATR-dependent DNA damage response in 
CV1720 patient cells 
 
Due to the observed reduction in ATR protein levels, CV1720 patient cells were 
assessed for the response to damage induced by UV or HU using several assays to 
examine ATR-dependent DNA damage responses. The phosphorylation of H2AX is a 
key upstream step in both the ATR and ATM signalling pathways and is important 
for the recruitment of proteins such as 53BP1, MDC1 and BRCA1 to the site of the 
damage (Fernandez-Capetillo et al., 2003). The phosphorylation of H2AX after UV 
irradiation or HU treatment is ATR-dependent (Ward and Chen, 2001). The 
formation of 53BP1 foci at sites of replication stress is known to be dependent on 
both Chk1 and ATR (Sengupta et al., 2004, Tripathi et al., 2008). ATR-Seckel cells 
have previously been shown to exhibit reduced H2AX phosphorylation and reduced 
53BP1 foci formation following treatment with hydroxyurea (Alderton et al., 2006). 
Therefore these ATR-dependent phosphorylation responses were examined in 
CV1720 patient cells. H2AX phosphorylation and 53BP1 foci formation responses 
were defective in CV1720 cells, similar to ATR-S cells and in contrast to the WT. 
These results demonstrate that ATR is not functional in this cell line and is not able 
to phosphorylate key target proteins (Figure 4.10).  
 
Supernumary mitotic centrosomes are also a common phenotype that we have 
observed in SS cell lines (Alderton et al., 2004). CV1720 patient cells were 
therefore examined and found to display supernumary mitotic centrosomes, to a 
similar level to the ATR-S cells (Figure 4.10).  
 
ATR-dependent modification of target proteins was also compromised in CV1720 
cells with reduced phosphorylation of Chk1 following exposure to UV (Figure 
4.11a,b) and reduced monoubiquitination of FANCD2 following exposure to HU 
(Figure 4.11c).  
50   75   100    50   75  100   50    75   100       ug WCE 
                   CV1780          CV1783 
WT              (father)          (mother) 
ATRIP 
Mcm2 
a) 
b) 
ATR  
Mcm2 
WT   CV1720  CV1780  CV1783  
Figure 4.8 ATRIP and ATR protein levels are reduced in CV1780 and CV1783 
heterozygous parental cells  
a)  Levels of ATRIP protein expression were examined by resolving increasing 
amounts of whole cell extracts from WT and CV1720 parental LBL cell 
lines (CV1780 and CV1783) on 8% SDS-PAGE gel followed by transfer 
onto nitrocellulose membrane. Membranes were then probed with an 
ATRIP antibody. The loading control used was Mcm2. 
b)  Levels of ATR protein expression were examined by resolving whole cell 
extracts from WT, CV1720 (ATRIP-S) and CV1720 parental 
(CV1780;CV1783) LBL cell lines on 6& SDS-PAGE gel followed by transfer 
onto nitrocellulose membrane. Membranes were then probed with ATR 
antibody using Mcm2 as a loading control. 
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Figure 4.9 Quantification of ATRIP and ATR protein levels 
At least three western blots were scanned and protein levels of ATRIP (a) 
and ATR (b) were quantified in WT, ATR-S, ATRIP-S (CV1720) and ATRIP-S 
parental (CV1780;CV1783) LBLs using SimplePCI software. Data shown is 
arbitrary units. Error bars represent the standard deviation. 
b) 
a) 
Figure 4.10 The ATR-dependent DNA damage response in CV1720 patient 
cells 
a) CV1720 patient cells display supernumary mitotic centrosomes. Cells were 
treated with nocodazole for 24hrs to increase the number of mitotic cells. 
Centrosomes were then examined by immunofluorescence using antibodies 
to !-tubulin. The number of cells containing more than two centrosomes was 
assessed. b) ATR-dependent H2AX phosphorylation is defective in CV1720 
patient cells. WT, ATR-S and CV1720 (ATRIP-S) cell lines were treated with 
5mM Hydroxyurea and incubated at 37°C for 2hr. Phosphorylation of H2AX 
on ser139 was detected using immunofluoresence with specific antibodies. 
The percentage of cells staining positively for H2AX phosphorylation was 
determined for each cell line. c) 53BP1 foci formation in response to 
replication stress is defective in CV1720 cells. WT, ATR-S and CV1720 
(ATRIP-S) cell lines were exposed to 5mM hydroxyurea for 2hr. 53BP1 foci 
were examined using immunofluoresence with a specific antibody. The 
percentage of cells with more than 5 foci was determined for each cell line. 
Each graph represents the mean of three independent experiments. Error 
bars represent the standard deviation. 
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Figure 4.11 ATR dependent modification of target proteins is defective in 
CV1720 patient cells 
a)  Chk1 is not phosphorylated effectively in CV1720 patient cells. WT, and 
CV1720 (ATRIP-S) LBL cells were treated with 5Jm-2 of UV. Chk1 
phosphorylation was assessed by immunoblotting with specific 
antibodies. Total Chk1 levels are used as a loading control.  
b)  ATR dependent FANCD2 monoubiquitination is defective in CV1720 
patient cells. WT, ATR and CV1720 (ATRIP-S) LBL cells were treated with 
3mM HU for 1hr. FancD2 ubiquitination was assessed by immunoblotting 
using specific antibodies.  
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These results all clearly show that ATR is unable to efficiently phosphorylate its 
targets in CV1720 patient cells and that CV1720 patient cells display phenotypes 
that are typical of Seckel syndrome patient cells. 
 
 
4.2.4 CV1720 patient cells fail to activate the ATR-dependent G2/M 
checkpoint 
 
ATR-Seckel cells have previously been shown to display a defective G2/M 
checkpoint response both 24 hours (Alderton et al., 2004) and 2 hours (Stiff et al., 
2008) post UV irradiation. CV1720 patient cells were examined for their ability to 
activate an ATR-dependent G2/M checkpoint arrest, 24 hours after irradiation with 
UV. The patient cell line examined failed to arrest effectively after exposure to UV, 
similar to the response seen in ATR-S patient cell lines and in contrast to wild-type 
cell lines (Figure 4.12a). CV1720 patient cells are compromised in their ability to 
activate an ATR-dependent checkpoint in response to UV damage. 
 
4.2.5 The G2/M checkpoint defect in CV1720 patient cells can be 
complemented by transfection with WT ATRIP cDNA 
 
To confirm that the reduced expression of ATRIP in CV1720 patient cells causes an 
ATR-dependent G2/M checkpoint defect and to investigate further if the ATRIP 
C2278T (R760X) mutational change results in a loss of G2/M checkpoint control, 
the C2278T mutation was incorporated into WT ATRIP cDNA using site directed 
mutagenesis.  
 
Wild type control, ATR-S and CV1720 patient cells were then transfected with either 
WT ATRIP, or mutant ATRIP-R760X DNA plasmids and examined for the ability to 
activate an ATR-dependent G2/M checkpoint arrest, 24 hours post UV irradiation 
(Figure 4.12b). Transfection with WT ATRIP rescued the G2/M checkpoint defect in 
both ATR-S and ATRIP-S cells, probably as the additional ATRIP available to the 
cells enabled residual ATR protein to be stabilised more effectively. Transfection 
with mutant ATRIP-R760X failed to fully rescue the G2/M checkpoint defect in 
either the ATR-S or CV1720 patient cells.  These results demonstrate that the 
reduced level of ATRIP in the patient cell line cause the G2/M checkpoint defect 
observed and that the mutant ATRIP-R760X protein is not able to restore ATRIP 
checkpoint function in these cells. 
 
 
Figure 4.12 CV1720 patient cells fail to activate the ATR-dependent G2/M 
checkpoint 
a)  WT, ATR-S, unaffected heterozygous relative and CV1720 (ATRIP-S) cell 
lines were examined  for  G2/M checkpoint  arrest, 24hrs after  treatment 
with 5J/m2 UV irradiation and in the presence of 1.5µM nocodazole. A 
decrease in the number of mitotic cells was taken as indicative of a G2/M 
arrest.  
b)  WT, ATR-S and CV1720 (ATRIP-S) cells were transfected with WT ATRIP or 
mutant ATRIP-R760X DNA plasmids and examined for ATR-dependent 
checkpoint arrest, 24hrs after exposure to 5Jm2 UV and in the presence of 
1.5µM Nocodazole. A decrease in the mitotic index is indicative of G2/M 
checkpoint arrest.  
Graphs represent the mean of three independent experiments. Error bars 
represent the standard deviation. 
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4.2.6 R760X ATRIP impairs ATR-ATRIP protein interaction 
 
The C2278T mutational change detected in ATRIP was predicted to result in a 
truncation of ATRIP at R760X, resulting in a loss of the C terminal of the protein. 
This region of ATRIP has previously been shown to be required for interaction of 
ATRIP with ATR and its loss results in defects in ATR recruitment to ssDNA and 
Chk1 phosphorylation (Falck et al., 2005). We therefore reasoned that R760X 
ATRIP would not interact with ATR as efficiently as the WT protein. 
 
To investigate if the C2278T mutational change in ATRIP results in an inactivating 
mutation, the C2278T mutation was incorporated into ATRIP WT cDNA using site 
directed mutagenesis. HA-tagged WT or R760X ATRIP was then co-transfected with 
WT ATR cDNA in HEK293T cells. Immunoprecipitation with HA-agarose was 
performed and then the level of ATR binding to ATRIP assessed by western blotting 
(Figure 4.13). The amount of ATR present in samples transfected with R760X ATRIP 
was significantly lower than that observed in WT ATRIP transfected samples. This 
result indictates that the R760X mutation reduces binding of the mutant ATRIP to 
ATR. The immunoprecipitation work was conducted in Tomoo Ogi’s laboratory. 
 
In conclusion, in this chapter I have shown that the mutations identified in ATRIP in 
this SS patient result in reduced protein levels and therefore impact on ATR 
stability, resulting in reduced protein levels of ATR. This leads to defects in ATR-
dependent signalling such as reduced phosphorylation of ATR target proteins such 
as Chk1 and a failure to activate the G2/M checkpoint after UV exposure.  
 
4.3 DISCUSSION 
 
Mutations in ATR were first identified in a single SS family in 2003 but since that 
time no further patients with mutations in ATR had been identified. The results in 
this chapter identify mutational changes in ATRIP as a further cause of SS. In this 
chapter I have shown that the mutational changes detected in ATRIP lead to 
reduced expression of ATRIP protein, resulting in reduced expression of ATR. This is 
not unexpected, as each protein is known to be dependent on the other for its 
stability (Cortez et al., 2001). However, this finding had previously not been 
verified in vivo. I have shown that the defect in ATRIP expression results in 
defective ATR-dependent damage response signalling and contributes to a defective 
ATR-dependent G2/M checkpoint response. I have also shown that the R760X 
mutation is not able to rescue the ATR-dependent G2/M checkpoint defect, 
Figure 4.13 R760X ATRIP impairs ATR-ATRIP protein interaction 
Crude lysates were prepared from HEK293T cells either mock transfected 
(lane 1), transfected with WT (lane 2) or R760X mutated (lane 3) ATRIP 
cDNA (HA-tagged) together with ATR cDNA. Extracts were 
immunoprecipitated with agarose-conjugated rabbit anti-HA-tag antibody 
(MBL). Interactions were detected by immunoblotting with antibodies against 
ATR (top panel) and HA-tag (ATRIP, bottom panel).  
Figure and legend from Tomoo Ogi. 
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confirming that this mutational change is impacting in the patient. These 
observations are also important as they confirm, in patient cells, the in vitro 
experiments showing that ATR and ATRIP are mutually dependent for stability and 
therefore the importance of ATRIP for ATR-dependent signalling. 
 
The clinical features of SS are heterogenous and there is considerable overlap 
between SS and other Microcephalic primordial dwarfism disorders such as 
Majewski Osteodysplastic Primordial Dwarfism type II (MOPDII) and Meier-Gorlin 
syndrome (MGS). Clinical features that are common to all of these disorders are 
microcephaly and primordial dwarfism, however there are further clinical features, 
which can be used to distinguish between each of these disorders. Therefore the 
identification of further patients with ATR/ATRIP defects is useful to define clinical 
features of Seckel syndrome and potentially further discriminate between these 
disorders. At the same time as our ATRIP patient was identified, two further ATR 
patients were also identified with compound heterozygous mutations in ATR (G. 
Stewart, Figure 4.14). Details of the clinical features of all ATR patients, including 
the original 2003 patient (O'Driscoll et al., 2003) and the ATRIP patient described 
here, are shown in Table 5.  
 
ATR-ATRIP Seckel patients can be defined as having extreme microcephaly and 
short stature, microtia (small ears), micrognathia (small receding chin) and dental 
crowding. Skeletal abnormalities in the newly described patients are also more 
severe than in the original ATR patient, highlighting a possible role for ATR in bone 
development. Bone abnormalities were also observed in a mouse model engineered 
to contain the splicing mutation from the original ATR patient (Murga et al., 2009). 
Clinical features such as small patellae and absent earlobes present in the newly 
identified ATR patients are also characteristic features of MGS. However, the 
microcephaly and growth delay noted in MGS patients tends to be less marked than 
in the Seckel patients (Table 6). The ATRIP-Seckel patient described here also had 
some brain abnormalities such as generalised atrophy of the cerebellum and an 
unusually shaped pituitary gland with an absent fossa. These features could reflect 
problems in brain development in utero, with the pituitary defects possibly 
contributing to the growth abnormalities observed, although levels of hormones 
measured in the patient were normal (Table 5). 
 
These observations raise the possibility that MGS and Seckel are the same 
syndrome, with defects in ATR signalling, and that the clinical spectrum of these 
primordial dwarfism disorders are simply wider than previously acknowledged. 
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Figure 4.14 Newly identified ATR patients 
a) ATR-Seckel patient 27-4BI 
b) ATR-Seckel patient 19-8BI 
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Mutations identified in components of the origin recognition complex have been 
identified in MGS patients and are described in this thesis. ATR-signalling pathway 
function is also examined in these patients and will also be discussed later. The 
overlapping clinical features observed in these patients could reflect the 
requirement for both ATR and replication proteins in ensuring genome stability 
during the rapid phase of replication during embryonic development.  
 
In summary, in this chapter I have shown that mutations in ATRIP result in reduced 
protein levels of both ATRIP and ATR, causing defects in ATR-dependent DNA 
damage response signalling. The identification of further ATR/ATRIP patients is 
useful in allowing further definition of the clinical features of this MPD disorder.  
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CHAPTER FIVE 
 
RESULTS III: Mutations in ORC1L cause Microcephalic 
Primordial Dwarfism 
 
5.1 INTRODUCTION 
 
DNA replication is initiated from sequences within the genome termed replication 
origins. In bacteria and yeast these are sites of specific nucleotide sequences whilst 
in humans and higher organisms this is not the case, although an AT-rich sequence 
is preferable for pre-replication complex binding (Vashee et al., 2003). How origins 
are defined in the human genome is not completely understood but epigenetic 
factors are thought to be important (Takeda and Dutta, 2005). Origins are licensed 
for replication in G1 phase of the cell cycle by the assembly of a multiple protein 
pre-replication complex (preRC) (Cook, 2009). The first protein of the preRC to 
bind to the origin is the Origin Recognition Complex (ORC1-6). The binding of ORC 
to the chromatin then recruits the further licensing factors CDC6, and CDT1. The 
MCM2-7 complex is a presumptive replicative protein helicase that is then loaded 
onto the chromatin to complete preRC assembly. Licensing of the origin is 
considered complete once the MCM helicase has been loaded onto the chromatin 
(Nishitani and Lygerou, 2002). 
 
ORC is composed of six subunits, ORC1 to ORC6, of which ORC1 is the largest 
(Vashee et al., 2001). ORC1 is the only subunit of the complex that contains a 
bromo-adjacent homology (BAH) domain, a highly conserved domain amongst 
mammals.  The BAH domain has been shown to be important for both protein 
stability and for the binding of ORC1 to the chromatin (Noguchi et al., 2006). 
 
In human cells ORC1 levels are thought to fluctuate in a cell cycle specific manner, 
whilst the levels of subunits ORC2-5 remain constant throughout the cell cycle. In 
quiescent cells, early S-phase arrested cells and mitotic cells, ORC1 is present at a 
basal level. The cellular level of ORC1 protein begins to increase in early G1, rising 
to a maximal level, 10 fold higher than the basal, after 9 hours (G1/S) (Tatsumi et 
al., 2003). ORC1 is then selectively degraded during S phase returning to a basal 
level. However, in hamster cells and some human tumour cell lines, the levels of 
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ORC1 remain constant throughout the cell cycle (Okuno et al., 2001, Li and 
DePamphilis, 2002, McNairn et al., 2005). 
 
The human ORC complex is assembled in an ordered fashion with ORC2 and ORC3 
first binding to each other and recruiting ORC5. ORC4 and ORC1 are then recruited 
in an ATP-dependent manner (Siddiqui and Stillman, 2007). This complex then 
binds to the chromatin in an ORC1 dependent manner. The binding of ORC1 to the 
chromatin is dependent on ORCA, a recently identified WD-repeat protein (Shen et 
al., 2010). A further ORC subunit, ORC6 interacts weakly with the ORC2-5 complex. 
 
In human cells ORC1 is stably bound to the chromatin in G1 phase, as part of the 
preRC (Ohta et al., 2003).  Upon entry into S phase, ORC1 dissociates from the 
chromatin and is then polyubiquitinated by the SCF/Skp2 complex during S phase 
(Méndez et al., 2002). It is then degraded via proteolysis. The dissociation of ORC 
leads to disassembly of the pre-replication complexes (Siddiqui and Stillman, 
2007), helping to prevent inappropriate origin refiring. During mitosis the 
hyperphosphorylation of ORC1 by Cdk1/CyclinA prevents the binding of ORC1 onto 
the chromatin, thus preventing assembly of preRC’s until mitosis is completed (Li et 
al., 2004). The binding of ORC1 to the chromatin is then restored during the 
transition between mitosis and the following G1 (Méndez et al., 2002). 
 
Additional non-replicative roles for ORC have also been described. The ORC 
complex interacts with HP1 via the BAH domain of ORC1. HP1 associates with 
heterochromatin and localises to centromeres and telomeres, is involved in 
silencing of transcription at these heterochromatic regions and has a critical 
function in heterochromatin formation and maintenance (Kwon and Workman, 
2008). Depletion of ORC1 results in loss of HP1 from heterochromatic foci 
suggesting a role for ORC1 in the maintenance of constitutive heterochromatin 
(Prasanth et al., 2010). 
 
Many of the ORC subunits have been found to localise to the kinetochores and 
knockdown of ORC2 results in mitotic defects suggesting a role for ORC in spindle 
attachment to kinetochores, possibly coordinating this with the completion of 
replication (Prasanth et al., 2002, Prasanth et al., 2004).  
 
Sister chromatid cohesion is directly mediated by ORC in the budding yeast by a 
mechanism that is independent of cohesin (Suter et al., 2004). In Xenopus extracts 
pre-replication complexes are required for recruitment of cohesin to the chromatin, 
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thus ORC is indirectly required for this process in this system (Takahashi et al., 
2004).  
 
ORC1 has been demonstrated to control centrosome numbers by the prevention of 
centriole reduplication (Hemerly et al., 2009). The duplication of centrosomes is 
Cyclin E dependent but the duplication of centrioles is dependent on Cyclin A 
(Hanashiro et al., 2008). It was suggested that Cdk2-CyclinA-dependent 
localisation of ORC1 to the centrosomes prevents Cdk2-CyclinE-dependent 
reduplication of centrosomes during late G1 and early S phase, when levels of 
Cyclin E in the cell are still high (Hemerly et al., 2009).  
 
ORC1 has also been shown to have a role in the induction of apoptosis, when in an 
unbound and unmodified form. ORC1 can trigger apoptosis via the Caspase-3 
pathway, when it is not in complex with the other ORC subunits, when it is 
ubiquitinated in S phase or phosphorylated in M phase, and when it accumulates in 
a perinuclear location (Saha et al., 2006). 
 
In this chapter, patient cell lines from a consanguineous Saudi-Arabian family of 
nine members were examined for ATR-dependent UV-induced G2/M checkpoint 
activation and the presence of supernumary mitotic centrosomes, in order to 
confirm the Seckel syndrome status of the proband and to direct further studies 
towards the identification of the underlying genetic defect. The family were then 
included in a genetic mapping study in collaboration with Andrew Jackson’s group 
at the MRC Human Genetics Unit in Edinburgh, in order to identify potential 
causative gene candidates.  This approach lead to the identification of mutations in 
ORC1L in this family, segregating as expected for an autosomal recessive disorder. 
Further screening identified another three microcephalic primordial dwarfism 
families harbouring ORC1 mutations. 
 
5.2 RESULTS 
 
5.2.1 Clinical features of MPD family 1 
 
A consanguineous Saudi-Arabian family of nine, in which two children had 
Microcephalic Primordial Dwarfism (MPD) with a clinical diagnosis of SS, were 
referred to our laboratory for investigation into the underlying genetic defect. Both 
patients displayed marked growth retardation, severe microcephaly and additional 
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clinical features such as small ears (Patients P1 and P2, Table 7). Both patients 
were judged to be of normal intellect. These clinical features, common in SS, are 
overlapping with Meier-Gorlin Syndrome (MGS), which has been discussed in the 
introduction to this thesis.  
 
5.2.2 Mutations in ORC1L identified in MPD family 1 
 
Cells from patient P1 were confirmed to possess UV-induced G2/M checkpoint 
defects (see section 5.2.7) and were then sent to our collaborators in the MRC 
Human Genetics Unit in Edinburgh. Here they performed genome-wide genotyping 
on the consanguineous Saudi-Arabian family of nine members, using Affymetrix 
Genechips. The MRC Human Genetics Unit analysed SNP genotypes and performed 
multipoint linkage analysis to identify a region of homozygosity on chromosome 
1p32. This region was then refined using microsatellite markers to a 15.6-cM region 
between D1S706 and D1S2890, containing 105 annotated genes (Bicknell et al, 
2011). Several candidate genes were sequenced including RAD54L and STIL but no 
pathogenic mutations were identified. Sequencing of ORC1 identified a homozygous 
A>G mutation in exon 4 resulting in an amino acid substitution, E127G in patient 
P1 (subsequently referred to as ORC1-P1) and patient P2. Further screening 
revealed mutations in ORC1 in four other MPD families (Figure 5.1, Table 7). Many 
of the mutations identified were within the BAH domain of ORC1 (Figure 5.2a). 
There is currently no crystal structure for human ORC1 so the mutations were 
modelled into the crystal structure from the chicken polybromo BAH domain and 
the yeast Sir3 BAH domain (Figure 5.2b) using the Phyre server. The mutations 
identified were predicted to cause loss of protein folding (F89S), and loss of 
protein-protein interaction sites (R105Q). The mutation E127G was not thought to 
affect protein folding or interactions directly, although the loss of charge caused by 
the mutation could potentially cause some protein interaction loss (personal 
communication: Anthony Oliver). 
 
5.2.3 ORC1 protein expression is reduced in ORC1-P1 patient cell 
lines 
 
Cells from patient ORC1-P1 (E127G) were pre-treated with increasing levels of 
protease inhibitor for 30 minutes and pellets obtained. These were then separated 
into a soluble fraction and an insoluble fraction that contained chromatin bound 
proteins. Reduced levels of ORC1 were revealed in both the soluble and insoluble 
fractions examined, indicating that the mutations in the BAH domain of ORC1 in 
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BAH = Bromo adjacent homology 
AAA+ = ATP binding domains 
Cdc6 = interaction domain 
RXL motif = Cyclin binding 
BAH AAA+ Cdc6 
Putative NLS 
RXL motif 
* * * * *
*  = mutations found in ORC1 Seckel patients 
1)  E127G 
2)  F89S 
3)  R105Q/R720Q 
4)  R105Q/691X 
5)  R105Q 
Figure 5.1 ORC1 patient and mutations identified 
a)  Schematic of ORC1 showing protein domains and position of mutations 
found in ORC1 patients. 
b)  ORC1-P1 patient picture and clinical measurements from two patients 
a) 
b) 
ORC1-P1 ORC1-P4 
Height 85.5 (-4.5) 94 (-5.3) 
Weight 9.6 (-5.9) 10.9 (-6.6) 
OFC 42 (-7.1) 46.2 (-5.4) 
Height in cm, weight in kg, OFC in cm 
standard deviations below mean in brackets 
Human      EGDDDENPYVAKLLELFEDDSDPPPKKRARVQWFVRFCEVPA  
Chimpanzee EGDDDENPYVAKLLELFEDDSDPPPKKRARVQWFVRFCEVPA  
Dog        EGDDDENPYVAKLVELFEDDSEPHSKKRARVQWFIRFCEVPV  
Mouse      QGEDNKKPYVAKLIELFQNGAEVPPKKCARVQWFVRFLEIPV  
Rat        QGEDNQKPYVAKLIELFENGSEVPPKKYARVQWFVRFCEIPI  
 
 
Human      CKRHLLGRKP-GAQEIFWYDYPACDSNINAETIIGLVRVIP     
Chimpanzee CKQHLLGRKP-GAQEIFWYDYPACDSNINAETIIGLVRVIP 
Dog        SKRHLLGRKP-AAQEIFWYDYPACNSNINAETIIGRVQVVA   
Mouse      SKRHLLGRSP-PAQEIFWYDCSDWDNKINVETIIGPVQVVA 
Rat        PKRHLLGRRP-SAQEIFWYDCSDCDNDIHVETIIGPVQVVA  
89 
105 127 
Figure 5.2 ORC1 BAH domain and mutation modelling 
a) Alignment of ORC1 orthologs showing BAH domain of ORC1 and position of 
mutations in this region 
b) Phyre server modelling of ORC1 BAH domain mutations. Personal 
communication, Anthony Oliver !""#$%%&&&'()*')+,'+-'.-'/0%#!1234
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this patient results in reduced protein stability, consistent with a previous study 
(Noguchi et al., 2006). Pre-treatment with MG-132, a proteosome inhibitor that 
reduces the degradation of ubiquitinated proteins (Tsubuki et al., 1996), had no 
effect on protein levels indicating that increased protein degradation is not a factor 
in the reduced protein expression observed. A reduction in the level of ORC2 bound 
to the chromatin was also observed, indicating that the assembly of the preRC onto 
chromatin is impaired (Figure 5.3a,b). Parental cell lines exhibited a partial 
reduction in the level of ORC1 bound to the chromatin (Figure 5.3c). Micrococcal 
nuclease digestion of chromatin fractions revealed a dramatic reduction in the 
levels of ORC1 tightly bound to the chromatin (Figure 5.3d). The levels of ORC2 
and MCM2 bound to the chromatin in these fractions was also markedly reduced, 
further demonstrating a reduced ability to efficiently form preRC’s in these cells 
(Figure 5.3d). Examination of fibroblasts from the ORC1-P4 patient (R105Q/R720Q) 
by immunoblotting showed normal ORC1 protein levels but a decrease in the 
amount of chromatin-bound ORC1 and ORC2 (Figure 5.3e). This result suggests 
that the mutations detected in ORC1L in this patients result in a decreased ability of 
ORC1 protein to bind to the chromatin and a reduced ability for the ORC complex to 
assemble onto the chromatin.  
 
 
5.2.4 ORC1-P1 cells exhibit defects in S-phase progression 
 
The reduced ability to form preRC’s on the chromatin suggested that origin 
licensing and origin firing might be compromised in these cells. We reasoned that if 
cells from the patient are not able to replicate efficiently, this could be a plausible 
explanation for the growth retardation and microcephaly phenotypes observed. This 
could be of increased importance during development, where cell cycle phases are 
often shorter than in somatic cells (Takahashi et al., 1995).  Data generated in our 
laboratory indicated that ORC1 deficient cells do not activate replication origins 
efficiently. ORC1-P4 cells were examined for replication licensing capacity using an 
assay that measures the requirement for cellular ORC to license a viral replication 
origin (episomes from Epstein-Barr virus) to enable its replication (Dhar et al., 
2001) and were found to have drastically reduced capacity to initiate replication 
from this origin (Bicknell et al., 2011b).  
 
A fraction of the total pool of licensed origins are actually fired during each round of 
replication, with as many as 90% of licensed origins remaining dormant (Blow and 
Ge, 2008). Therefore the marked reduction in ORC1 protein levels in these cells 
may not confer any major growth abnormalities. However, dormant origins may be 
a) 
WT    P1    WT   P1   WT    P1 
  0      0     10    10    25   25       MG132 (µM) 
ORC2 
ORC1 - N 
ORC2 
ORC1 - C 
ORC1 - N 
KAP1 
  0      0     10     10    25    25   MG132 (µM) 
WT    P1    WT    P1   WT   P1 
b) 
ORC1 
Loading 
 WT    P1    F     M WT   P1     F     M  
Soluble             Insoluble 
c) 
Figure 5.3  ORC1 expression and pre-RC complex assembly in ORC1 deficient 
cell lines 
WT and Patient cells were pre-treated with increasing levels of MG132 
protease inhibitor and separated into soluble (a) or insoluble fractions 
containing chromatin bound proteins (b). Extracts were resolved on 8% 
SDS-PAGE and transferred onto nitrocellulose membrane. Membranes were 
then probed with ORC1 (ORC1-N detects epitope at N terminus, ORC1-C 
detects epitope at C terminus) and ORC2 antibodies. ORC1-N was used for 
all subsequent blots. ORC2 served as a loading control for the soluble 
fraction. Heterozygous parental (mother M, father F) control cell extracts (c) 
also showed reduced ORC1 protein expression.  
Soluble extract 
Chromatin extract 
WT   ATR   P4 WT   ATR   P4 
Soluble          Insoluble 
ORC1 
ORC2 
HDAC1 
e) 
C1          C2 
WT    ATR    P1 WT    ATR    P1 
ORC1 
ORC2 
Mcm2 
Histone H3 
HP1 
d) 
Figure 5.3 (cont) ORC1 expression and pre-RC complex assembly in ORC1 
deficient cell lines 
(d) WT and ORC1-P1 extracts were subjected to a two step micrococcal 
nuclease (Mnase) extraction procedure to obtain chromatin enriched fractions 
of increasing Mnase resistance (C1 and C2). These fractions were then 
resolved and immunoblotted for ORC and pre-replication complex 
components. (e) Cell extracts from ORC1- P4 fibroblasts were examined as in 
(a,b). 
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utilised in S phase in response to replication fork stalling or slowing (Woodward et 
al., 2006). Therefore we addressed whether the reduced licensing capacity 
observed in the ORC1-P1 cells, would affect the rate at which the cells progress 
through S phase. In order to address this question, the time taken for WT and 
ORC1-P1 cells to progress through S phase was examined. Cells were pulse-labelled 
for 30-minutes with BrdU to label S phase cells and then samples were taken over 
a six hour time period, in the presence of Colcemid to block cells in mitosis. 
Samples were then processed for Facs analysis using FITC-conjugated BrdU 
antibodies with propidium iodide staining. The rate of loss of BrdU positive early S 
phase cells was measured as an indicator of S phase progression (Figure 5.4b). 
ORC1-P1 cells were shown to progress through S phase more slowly than the WT 
control cell line (Figure 5.4a and b), although gross cell doubling times for each cell 
line were normal (data not shown). Further work was then undertaken in our 
laboratory, using sucrose gradient sedimentation to monitor the size of replication 
intermediates (T. Stiff). This work demonstrated that following 60 minutes of 
growth in medium containing labelled thymidine, the DNA from ORC1-P1 cells did 
not increase in size to the same degree as DNA from WT control cells (Figure 5.5).  
These results indicate that the rate of replication in ORC-P1 cells appears to be 
slower than in WT cells. This could be due to the presence of multiple origins but 
with a reduced rate of replication fork progression from those origins, or that there 
is reduced origin availability. The reduced ability to form pre-replication complexes 
on chromatin (Section 5.2.3), along with reduced capability to activate those 
origins (this section) is consistent with reduced origin availability.  
 
5.2.5 The replication forks in ORC1-P1 cells are inherently less 
stable than those in WT cells 
 
In order to gain further insight into the replication dynamics of ORC1-P1 cells, 
replication structures from WT and ORC1-P1 cells were directly analysed using 
techniques for the spreading of DNA fibres. Cells were double labelled first with IdU 
and then with CldU to enable visualisation of ongoing forks. DNA fibre spreads were 
prepared according to established protocols (Maya-Mendoza et al., 2007).  
Replication structures were scored according to the classification by Maya-Mendoza 
et al, 2007, where 1 = elongating fork, 2 = fork growing from one origin, 3 = 
terminal fusion, 4 = isolated and 5 = interspersed. 100 fibres were analysed in 
preliminary experiments. In WT cells, 75% of structures observed were elongating 
forks, consistent with ongoing replication. 10% of structures contained two forks 
growing from the same origin and 5% of structures were terminal fusions indicating 
Figure 5.4  S phase progression is compromised in ORC1-P1 cells. 
a)  WT and ORC1-P1 patient cell lines were pulse-labelled with BrdU for 30 
minutes. Cells were prevented from exiting mitosis by the addition of 
0.2µg/mL Colcemid. Samples were collected for BrdU Facs analysis at 2 
hr time intervals.  
b)  The rate of loss of early S phase cells (from R3 compartment) represents 
S phase progression. The graph represents the mean of three 
independent experiments. Error bars represent the standard deviation. 
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Figure 5.5 ORC1-P1 DNA fragments are smaller than WT fragments 
WT or ORC1-P1 LBLs were labeled with [3H]TdR for 1 h and subjected to 
sucrose-gradient sedimentation following fragmentation and concurrent lysis. 
Newly fired origins sediment within fractions 25–30, precluding an estimation 
of new origin firing. DNA from WT LBLs increases in size more rapidly 
compared to ORC1-P1 DNA. Plot shows a representative profile from three 
experiments. 
Figure and legend taken from Bicknell et al, Nature Genetics 2011. 
Experiment performed by T Stiff. 
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As further confirmation, we used an immunofluorescence 
approach to examine S-phase progression in ORC1-P4 hTERT 
fibroblasts. We used BrdU pulse labeling and pan-nuclear ?H2AX 
 immunostaining to distinguish cells that are actively replicating 
from those that have progressed through S phase (see Fig. 3e 
 legend for details). This approach showed that ORC1-P4 hTERT 
fibroblasts also progress slowly through S phase (Fig. 3e). For all 
these approaches, transfection with exogenous DNA slowed S-phase 
progression, precluding examination of complementation by ORC1 
complementary DNA expression. In summary, these combined 
approaches provide strong evidence that ORC1 deficiency impairs 
the rate of S-phase progression, a previously unknown phenotype 
conferred by ORC1 deficiency.
Pre-RC complex assembly starts upon G1-phase entry, and a 
‘licensing checkpoint’ acts to preclude S-phase entry until a critical 
level of licensed origins assemble17,18. Therefore, we examined whether 
ORC1 deficiency prolongs the G1 phase. We synchronized primary 
fibroblasts in G0 by serum starvation, and we promoted G1 phase entry 
by serum addition. We added BrdU after serum addition to monitor 
S-phase entry by immunofluorescence. ORC1-P4 fibroblasts showed 
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precluding an estimation of new origin firing. DNA from WT LBLs increases in size more rapidly compared to ORC1-P1 DNA. Plots show a representative 
profile from three experiments. (d) A diagram showing how smaller replication intermediates arise when origin firing is limited. Slow fork progression 
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the fusion of two forks and thus termination during the labelling period. Very few 
isolated forks were observed in the WT cell fibre preparations (Figure 5.6). In 
contrast, preparations from the ORC1-P1 cells contained fewer elongating forks 
(55%) and a higher proportion of isolated and interspersed (closely spaced active 
origins) structures than WT cells. These preliminary findings raise the possibility 
that forks frequently stall and occasionally collapse during the labelling period 
(Maya-Mendoza et al., 2007) suggesting that the replication forks in ORC1-P1 cells 
could be less stable than those in WT cells. An alternative explanation for this result 
could be that fewer origins are fired within the labelling period in the ORC1-P1 cells, 
resulting in detection of fewer elongating forks. This aspect of replication dynamics 
in ORC1-P1 cells is interesting but requires further investigation in order to draw 
firm conclusions. 
 
5.2.6 Assessment of the ATR-dependent DNA damage response in 
ORC1-P1 cells 
 
In order to determine if the observed reduction in ORC1 protein in these cells has 
any impact on the ATR-dependent DNA damage response, as we have observed 
with other SS cell lines (Alderton et al., 2004), ORC1-P1 cells were assessed for the 
response to damage induced by UV or HU using several assays. The 
phosphorylation of H2AX after exposure to HU is ATR dependent (Ward and Chen, 
2001). The formation of 53BP1 foci at sites of replication stress is dependent on 
both Chk1 and ATR (Sengupta et al., 2004, Tripathi et al., 2008). ATR-Seckel cells 
have previously been shown to exhibit reduced H2AX phosphorylation and reduced 
53BP1 foci formation following treatment with hydroxyurea (Alderton et al., 2006). 
H2AX phosphorylation, Chk1 phosphorylation and 53BP1 foci formation responses 
were all normal in the ORC1-P1 cells, demonstrating that both ATR and Chk1 
kinases are activated appropriately in this cell line (Figure 5.7 b,c,d). ORC-P1 cells 
display supernumary mitotic centrosomes, to a similar level to the ATR-S cells, 
(Figure 5.7a), possibly reflecting the established role for ORC1 in the prevention of 
centrosome reduplication (Hemerly et al., 2009).    
 
 
5.2.7 ORC1-P1 cells fail to activate the ATR-dependent G2/M 
checkpoint 
 
ATR-Seckel cells have previously been shown to display a defective G2/M 
checkpoint response both 24 hours (Alderton et al., 2004) and 2 hours (Stiff et al., 
2008) post UV irradiation. In order to determine if the reduction in ORC1 protein 
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Figure 5.6 The replication forks in ORC1-P1 cells are inherently less stable 
than those in WT cells  
WT and ORC1-P1 LBL cells were labelled with IdU and then CldU for 20 min 
periods. DNA was then isolated from the cultures and spreads prepared as in 
Maya-Mendoza et al, 2007. Spreads were immunostained using BrdU 
antibodies and images captured using Deltavision microscope and Softworx. 
Replication structures were examined according to classification by Maya-
Mendoza et al, 2007. 100 fibres were scored for each cell line. 
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Figure 5.7 The ATR-dependent DNA damage response in ORC1-P1 cells 
a)  ORC1-P1 cells display supernumary mitotic centrosomes. Cells were 
treated with nocodazole for 24hrs to increase the number of mitotic cells. 
Centrosomes were then examined by immunofluorescence using antibodies to 
!-tubulin. The number of cells containing more than two centrosomes was 
assessed. b) H2AX phosphorylation is normal in ORC1-P1 cells. WT, ATR-S and 
ORC1-P1 cell lines were treated with 5mM Hydroxyurea and incubated at 37°C 
for 2hr. Phosphorylation of H2AX on ser139 was detected using 
immunofluoresence with specific antibodies. The percentage of cells staining 
positively for H2AX phosphorylation was determined for each cell line. c) 
53BP1 foci formation in response to replication stress is normal in ORC1-P1 
cells. WT, ATR-S and ORC1-P1 cell lines were exposed to 5mM hydroxyurea for 
2hr. 53BP1 foci were examined using immunofluoresence with a specific 
antibody. The percentage of cells with more than 5 foci was determined for 
each cell line. Each graph represents the mean of three independent 
experiments. Error bars represent the standard deviation. 
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Figure 5.7 The ATR-dependent DNA damage response in ORC1-P1 cells 
(cont) 
d) Chk1 is phosphorylated normally in ORC1-P1 cells. WT, ATR-S and ORC1-
P1 cells were treated with increasing doses of HU or UV. Chk1 
phosphorylation assessed by immunoblotting with specific antibodies. Total 
Chk1 levels are used as a loading control.  
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levels observed resulted in similar checkpoint defects, ORC1-P1 cells were 
examined for their ability to activate a G2/M checkpoint arrest, 24 hours after 
irradiation with UV. The patient cell line examined failed to arrest effectively after 
exposure to UV, similar to the response seen in ATR-Seckel patient cell lines and in 
contrast to wild-type cell lines (Figure 5.8). ORC1-P1 cells are therefore 
compromised in their ability to activate an ATR-dependent checkpoint in response 
to UV damage. 
 
 
5.2.8 The G2/M checkpoint defect in ORC1-P1 cells can be 
complemented by transfection with WT ORC1 cDNA 
 
To confirm that the reduced expression of ORC1 in ORC1-P1 patient cells causes an 
ATR-dependent G2/M checkpoint defect, wild type control, ATR-S and ORC1-P1 
cells were transfected with either empty vector, WT ATR or WT ORC1 cDNA 
plasmids and examined for the ability to activate an ATR-dependent G2/M 
checkpoint arrest, 24 hours post UV irradiation. Transfection with WT ATR rescued 
the G2/M checkpoint defect in ATR-S cells but not in ORC1-P1 cells. Transfection 
with WT ORC1 rescued the G2/M checkpoint defect in ORC1-P1 cells but not in ATR-
S cells. Transfection of the empty vector did not rescue the G2/M checkpoint defect 
in ORC1-P1 cells (Figure 5.9). These results demonstrate that the reduced 
expression of ORC1 in the patient cell line contributes to the checkpoint defect 
observed. 
 
 
5.2.9 Depletion of ORC1 impairs ATR-dependent G2/M checkpoint 
arrest 
 
In order to provide further confirmation that loss of ORC1 results in an ATR-
dependent G2/M checkpoint defect, MG63 osteosarcoma weed cells were treated 
with control or ORC1 targeting siRNA oligonucleotides for 72hrs in order to deplete 
ORC1 protein levels. Residual protein was still detectable at this time-point 
although protein levels were reduced dramatically (Figure 5.10b). Cells were then 
exposed to 5J UV or 3Gy ionising radiation and examined for G2/M arrest 2hrs post 
irradiation. Untransfected, Mock and Control siRNA treated cells all arrested after 
exposure to UV or IR, as expected. ORC siRNA treated cells arrested normally after 
IR exposure but failed to arrest efficiently after exposure to UV irradiation (Figure 
5.10a). This recapitulates the result observed in the patient cell line and confirms 
the requirement of ORC1 for ATR-dependent G2/M checkpoint activation. 
Figure 5.8 ORC1-P1 cells fail to efficiently activate the ATR-dependent G2/M 
checkpoint 
WT, ATR-S, unaffected heterozygous relative (Mother, Father) and ORC1-P1 
cell lines were examined for G2/M checkpoint arrest, 24hrs after treatment 
with 5J/m2  UV irradiation and in the presence of 1.5µM nocodazole. A 
decrease in the number of mitotic cells was taken as indicative of a G2/M 
arrest.  
Graph represents the mean of three experiments. Error bars represent the 
standard deviation. 
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Figure 5.9  Transfection with WT ORC1 can complement the G2/M checkpoint 
arrest defect in ORC1-P1 cells 
WT, ATR-S and ORC1-P1 cells were transfected with empty vector (pCGT), 
WT ATR or WT ORC1 DNA plasmids and examined for ATR-dependent 
checkpoint arrest, 24hrs after exposure to 5Jm2 UV and in the presence of 
1.5µM Nocodazole. A decrease in the mitotic index is indicative of G2/M 
checkpoint arrest.  
The graph represents the mean of three independent experiments. Error bars 
represent the standard deviation. 
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Figure 5.10  RNAi Depletion of ORC1 in MG63 osteosarcoma weed cells 
impairs ATR-dependent G2/M arrest 
a)  MG63 osteosarcoma cells were untransfected (Unt), mock transfected 
(Mock) or transfected with control (Cont) or ORC1 siRNA oligonucleotides for 
72hrs and cells were then examined for G2/M arrest 2hrs after exposure to 
5J/m2 UV or 3 Gy IR. A decrease in the number of mitotic cells was taken as 
indicative of a G2/M arrest. Graph represents the mean of three independent 
experiments. Error bars represent the standard deviation. 
b) Western blot confirming ORC1 depletion. A non-specific band was used as 
a loading control.  
ORC1 
Non-specific 
loading 
Unt  Mock  Cont  ORC1 
a) 
b) 
0.00 
1.00 
2.00 
3.00 
4.00 
5.00 
6.00 
7.00 
8.00 
Untransfected Mock 
transfected 
Control RNA ORC1 
M
it
os
is
 (
%
) 
siRNA treatment 
Unt 
+ UV 
+ IR 
! 72!
In conclusion, in this chapter I have shown that the mutations identified in ORC1L 
patients result in reduced levels of ORC1 protein and reduced localisation of ORC1 
and other preRC components to the chromatin. This leads to defects in S phase 
progression, possibly due to reduced origin availability and compromised replication 
fork stability. ATR-dependent G2/M checkpoint activation is also defective and cells 
harbour supernumerary mitotic centrosomes. The G2/M checkpoint defect can be 
corrected by expression of WT ORC1 in patient cells and recapitulated by depletion 
of ORC1 in weed cells, demonstrating that ORC1 is required for ATR-dependent 
G2/M checkpoint activation.   
 
5.3 DISCUSSION 
 
In this chapter I have described the functional characterisation of a cell line with 
mutations in ORC1L and novel defects in replication origin licensing. This is the first 
time that mutations in a preRC component have been implicated in human disease.  
 
At the same time as the data presented in this chapter was published, two other 
reports of preRC mutations were reported. Further mutations in ORC1, ORC4, 
ORC6, CDT1 and CDC6 were reported in patients presenting with Meier-Gorlin 
syndrome (MGS) (Bicknell et al., 2011a) and another group reported mutations in 
ORC4 in MGS (Guernsey et al., 2011). MGS is a microcephalic primordial dwarfism 
disorder, similar to SS, and has been discussed in the introduction section of this 
thesis. These patients present with microcephaly, short stature, absent patellae and 
small external ears.  
 
The data presented in this chapter implicates impaired origin licensing as a possible 
cause of microcephalic dwarfism. A reduction in origin licensing, as evidenced by 
reduced levels of preRC proteins bound to the chromatin and the presence of 
smaller replication intermediates (Figure 5.11), has an impact on S-phase 
progression. Entry into S-phase was also found to be delayed in ORC1 deficient 
cells (Bicknell et al., 2011b) suggesting that these cells require a longer time in G1 
phase in order to assemble sufficient preRC’s to enter into S-phase. 
 
How does reduced origin licensing impact on cell cycle kinetics? If fewer origins are 
licensed due to limiting ORC1 levels, the time taken for cells to build up enough 
licensed origins to enter S phase will be increased. The ‘licensing checkpoint’ has 
been shown to prevent cells from entering S phase until they have sufficient 
numbers of licensed origins (Shreeram et al., 2002, Blow and Gillespie, 2008). 
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Therefore the G1 phase in ORC1 cells is prolonged while origin licensing proceeds to 
the required level for S phase entry. It has been demonstrated that cells entering S 
phase with too few licensed origins synthesize their DNA at a reduced rate and 
accumulate DNA damage (Nevis et al., 2009). 
 
S phase progression could slow as there are less origins fired in any one stretch of 
DNA. Thus, forks have to travel further to complete replication, potentially making 
them less stable and more prone to stalling (Pruitt et al., 2007, Shima et al., 
2007). If there are reduced licensed origins available, the firing of dormant origins 
may also be compromised with a failure to complete S phase in a timely manner. 
Conversely, more dormant origins may be fired than in a WT scenario due to the 
longer distance travelled by each fork. Dormant origins may be passively replicated 
(and inactivated) before they have a chance to fire. If fork progression is slowed, 
the dormant origins are more likely to fire as it takes longer for them to be 
inactivated (Blow and Ge, 2009). DNA fibre analysis would suggest that possibly 
more origins are fired within an ‘active replication cluster’ in ORC cells than WT 
cells, although this aspect requires further study. Indeed Chk1 depleted cells have 
been reported to show slow fork progression coupled with increased origin firing 
(Seiler et al., 2007).  
 
Another possibility is that the fork speed in ORC1 cells is reduced due to the 
reduction of components such as the MCM helicase bound to the chromatin. MCM 
moves along with the replication fork, unwinding the DNA ahead of the polymerase. 
Could reduced levels of MCM helicase lead to a slowing of the replication fork? This 
question could be addressed by analysis of fork speed from combed DNA fibres.  
 
Although the changes in cell cycle kinetics described above do not seem to affect 
growth of cells in culture (data not shown), they could be important in 
development. In early neurogenesis, total cell cycle duration can be as short as 8 
hrs with periods of rapid replication (Takahashi et al., 1995). Increases in length of 
G1 phase in neuronal progenitor cells have been implicated in the switch from 
symmetric to asymmetric cell division, potentially decreasing the total number of 
neurons produced (Arai et al., 2011). These authors also found that S phase 
duration was an important factor in the ability of progenitor cells to either continue 
to proliferate or to differentiate.  
 
A perhaps surprising phenotype conferred by mutation in ORC1 is the loss of the 
ATR-dependent G2/M checkpoint. This phenotype is common to all SS cell lines 
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tested in our laboratory but why should a mutation in a pre-replication complex 
component result in a checkpoint defect? ORC1 has been shown to be required for 
control of centrosome numbers and to be localised to the centrosome (Hemerly et 
al., 2009). We have previously identified mutations in centrosome components, 
such as PCNT, in SS patients and further mutations have been identified in CEP152 
(Kalay et al., 2011) and CENPJ (Al-Dosari et al., 2010) in SS patients and in 
Primary Microcephaly patients.  The centrosome is now regarded as an important 
organelle involved in cell cycle control (Doxsey et al., 2005). It is possible that 
ORC1 that is localised at the centrosome plays some role in G2/M checkpoint 
regulation.  
 
CDC6, another important preRC component interacts with ORC1 and is proposed to 
act as a monitor to ensure that replication is complete before cells enter mitosis 
(Lau et al., 2006). Overexpression of CDC6 in G2 phase human cells prevents entry 
into mitosis but this block can be overcome by the use of a Chk1 inhibitor. The 
ability of CDC6 to block mitotic entry may be regulated by the phosphorylation of 
CDC6 at serine74 (Clay-Farrace et al., 2003). These authors postulated that when 
CDC6 is not inactivated, Chk1 activation occurs and cells are not able to enter 
mitosis. It is possible that the function of CDC6 as a mitotic inhibitor requires its 
localisation at the chromatin or the centrosome through an interaction with ORC1. 
 
CDC6 also interacts with ATR in a manner that is stimulated by Cdk 
phosphorylation (Yoshida et al., 2010). These authors demonstrated that CDC6 is 
required for an ATR-dependent replication checkpoint after exposure to low doses 
of HU, representing low levels of replication stress. However they found no 
requirement for CDC6 after higher HU doses or after treatment with UV. CDC6 is, 
however, polyubiquitinated by the ubiquitin ligase Huwe1 upon exposure to UV and 
is subsequently degraded (Hall et al., 2007).  
 
In this chapter I have demonstrated that ORC1 deficiency leads to reduced origin 
licensing and a slowing of S-phase progression. I have presented data that ORC1 
deficiency results in a defective UV-induced ATR-dependent G2/M checkpoint 
response in these cells. Supernumerary mitotic centrosomes are also observed in 
these cells, similar to other SS cell lines examined. Which of these cellular 
phenotypes correlate with the clinical features of the patients? The later two 
phenotypes are common to other microcephaly disorders such as Primary 
Microcephaly, therefore, in the next chapter I will attempt to examine the molecular 
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basis of the defective G2/M checkpoint response in cell lines derived from patients 
with MPD disorders.  
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CHAPTER SIX 
 
RESULTS IV: Dissecting the molecular basis of the 
defective ATR-dependent G2/M checkpoint response 
in various MPD patient derived cell lines: Roles of 
Aurora A kinase and Polo-like kinase 1 
 
6.1 INTRODUCTION 
 
The cell lines that I have examined in this thesis have been shown to harbour 
mutations in proteins with diverse functions such as structural centrosomal proteins 
(PCNT), PreRC proteins (ORC1) and DNA damage response proteins (ATR-ATRIP). 
Each of the cell lines are derived from patients with MPD, although the precise 
clinical description of the patients varies from MGS to MOPDII to SS. All of these 
patients display microcephaly and growth retardation to varying degrees. One of 
the cellular phenotypes that all of these cell lines have in common is a defective 
ATR-dependent G2/M checkpoint response.  
 
Control of mitotic entry is ultimately governed by levels and activity of the Cyclin 
dependent kinase, Cdk1 in complex with cyclin B. When DNA is damaged and 
mitotic entry must be delayed, the Chk1/Chk2 kinases have a well-established role 
in activating a G2/M checkpoint response, via their activation through ATM/ATR. 
This is achieved through the inhibition of the Cdc25 family of phosphatases, which 
are then unable to activate Cdk1. A further important mechanism existing in cells is 
regulation of the Aurora A kinase (AurA) and polo-like kinase 1 (PLK1). These 
kinases also play an important role in the control of mitotic entry. They are 
considered important for the ‘commitment’ step for entry into mitosis and regulate 
cyclinB-Cdk1 activation.  
 
6.1.1 Aurora A Kinase (AurA) 
 
AurA is a serine/threonine mitotic kinase (Figure 6.1) and is often overexpressed in 
tumours (Zhou et al., 1998, Yang et al., 2007, Otto et al., 2009). It is localised to 
the centrosome during interphase, via interactions with centrosomin (CDK5RAP2) 
(Terada et al., 2003) and CEP192 (Gomez-Ferreria et al., 2007). It is also localised 
PLK1 
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Figure 6.1 Protein schematic showing conserved domains 
a)  Polo-like kinase 1 (PLK1) 
b)  Aurora A Kinase (AurA) 
T210 
T288 
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at the spindle during mitosis via an interaction with Targeting Protein for Xenopus 
kinesin-like protein 2 (TPX2) (Kufer et al., 2002). The localisation of AurA to the 
centrosome is promoted by PLK1 (van de Weerdt et al., 2008). Depletion of CEP192 
leads to a mis-localisation of AurA at the centrosomes of mitotic cells (Gomez-
Ferreria et al., 2007). Once located at the centrosome, AurA undergoes 
dimerisation and becomes activated, as evidenced by T288 autophosphorylation. 
CEP192 is not essential for this dimerisation process (Joukov et al., 2010). 
 
The full activation of AurA is complex, involving many cofactor proteins and 
activation steps. Phosphorylation of the T loop of AurA at threonine 288 (T288) 
results in a marked increase in kinase activity (Walter et al., 2000). In Xenopus 
extracts, TPX2 stimulates AurA autophosphorylation at T295 (equivalent to T288 in 
humans) (Eyers et al., 2003). In humans, the binding of TPX2 to AurA induces a 
conformational change in AurA and the T loop containing T288 becomes 
inaccessible to the PP1 phosphatase (Bayliss et al., 2003), which dephosphorylates 
this site during interphase to inhibit AurA (Eyers et al., 2003). The binding of TPX2 
confers a protective effect to AurA, preventing its degradation and enabling the 
accumulation of AurA levels during G2 phase. However, the earliest centrosomal 
pool of AurA, detected at this location in interphase, does not require this TPX2-
dependent stabilisation (Giubettini et al., 2011). TPX2 binding may therefore be 
more important for localizing AurA to the spindle, rather than the centrosome, to 
perform its role in spindle formation (Kufer et al., 2002). 
 
In human cells, Ajuba interacts with AurA at the centrosome during G2 and mitosis, 
promotes the phosphorylation of AurA at T288 and is required for the activation of 
AurA at the centrosomes. Active AurA can first be detected in late G2 phase at the 
centrosomes, before full activation in early mitosis and appears to be required for 
the initial recruitment of cyclinB-Cdk1 to the centrosome (Hirota et al., 2003). This 
initial activation of AurA at the centrosome is Cdk1 independent. In Drosophila 
neuroblasts Ajuba was shown to be important in maintaining active AurA at the 
centrosome but was not required for the activation of AurA (Sabino et al., 2011). 
 
In contrast to this initial activation of AurA in G2, full mitotic activation of AurA is 
Cdk1 dependent with positive feedback loops of Cdk1, AurA and PLK1 leading to 
swift co-activation of these kinases (Figure 6.2) (Van Horn et al., 2010). However, 
several studies have indicated that AurA and PLK1 are not essential for mitotic 
entry under normal cell cycle conditions, although they can accelerate entry into 
mitosis (van Vugt et al., 2004). These kinases only become essential for mitotic 
entry following recovery from DNA damage-induced arrest (van Vugt et al., 2004, 
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Figure 6.2 PLK1 and AurA function during mitotic entry 
Green phosphates (P) are activating, red are inhibitory and yellow prime the 
protein for degradation. In late G2 AurA and PLK1 are recruited to the 
centrosome. PLK1 is recruited by cenexin1 and promotes the recruitment of 
AurA. AurA binds to CDK5RAP2. Cep192 and Ajuba are also important to 
localise AurA to the centrosome. AurA once located at the centrosome 
undergoes dimerisation and can be activated by autophosphorylation. AurA 
activity is enhanced by BORA. AurA in conjunction with BORA activates PLK1 in 
G2 but it is unclear whether this occurs in the nucleus, on centrosomes or in 
the cytoplasm. Active PLK1 can phosphorylate WEE1, which negatively 
regulates CDK1-CyclinB complexes.  
Figure and legend adapted from Lens at al, 2010. Nature Reviews Cancer 
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Mac!rek et al., 2008). Furthermore, overexpression of AurA overrides the G2/M 
damage-induced checkpoint (Marumoto et al., 2002), whilst depletion of AurA by 
siRNA treatment leads to a block to mitotic entry in some studies (Hirota et al., 
2003) or a delay to mitotic entry in others (Marumoto et al., 2002, Marumoto et al., 
2003).  
 
A further interaction partner of AurA in human cells is Bora. Bora is able to bind to 
AurA and activate the kinase in vitro (Hutterer et al., 2006).The interaction 
between Bora and AurA is essential for AurA to phosphorylate its target PLK1. 
Following phosphorylation of Bora on serine 252 by Cdk1 (Chan et al., 2008), Bora 
binds to PLK1 in G2 and increases the accessibility of the T210 site for 
phosphorylation by AurA (Seki et al., 2008). PLK1 in turn regulates AurA levels by 
phosphorylation of a phosphodegron site in Bora. This leads to degradation of Bora 
by the SCF"-TrCP ubiquitin ligase (Chan et al., 2008), resulting in a reduction in 
levels of active AurA.  
 
AurA can also be activated in vitro by Protein Kinase A (PKA), which phosphorylates 
at least three sites including T288 (Eyers and Maller, 2003). Dephosphorylation of 
T288 by Protein phosphatase 1 (PP1) or Protein phosphatase 2 (PP2) is also known 
to occur, inhibiting the kinase activity of AurA during interphase (Walter et al., 
2000, Katayama et al., 2001). 
 
Interestingly, in terms of SS cell lines and the defective ATR-dependent G2/M 
checkpoint response observed, AurA kinase activity is inhibited following DNA 
damage. This occurs in a manner dependent on ATR/ATM signaling through the 
Chk1 kinase (Krystyniak et al., 2006). No direct interaction between Chk1 and AurA 
has been detected, suggesting that further proteins could be involved in this 
signaling pathway. AurA is also known to phosphorylate CDC25B on serine 353, an 
event that occurs at the centrosome. This phosphorylation event is also inhibited 
after DNA damage (Cazales et al., 2005). 
 
AurA also binds to BRCA1 and phosphorylates this protein at serine 308. BRCA1 is 
present at the centrosomes during the G2/M transition and has been postulated to 
play a role in G2/M progression (Ouchi et al., 2004). 
 
Just before mitotic entry, centrosomes increase in both size and microtubule 
nucleating capability, in a process termed centrosome maturation (Carmena et al., 
2009). AurA contributes to this process by phosphorylation and recruitment of 
pericentriolar material proteins such as Transforming acidic coiled-coil protein 
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(TACC) (Barros et al., 2005), Centrosomin (CDK5RAP2) (Hannak et al., 2001), 
Large tumor suppressor homolog 2 (LATS2) (Toji et al., 2004) and Nuclear 
distribution element-like 1 (NDEL1) (Mori et al., 2007). PLK1 is also required for the 
initiation of centrosome maturation and was recently shown to phosphorylate PCNT 
at the onset of mitosis to facilitate this process (Lee and Rhee, 2011). PLK1 
inhibition has also been demonstrated to lead to a reduction in the recruitment of 
CEP192 and PCNT to the centrosome in mitotic cells although this mechanism does 
not appear to be important in interphase cells (Haren et al., 2009). !
AurA is also localized at the basal body of the primary cilia. It is activated here by 
human enhancer of filamentation 1!"HEF1), resulting in the phosphorylation of 
ciliary Histone Deacetylase 6 (HDAC6) (Pugacheva et al., 2007). Ciliary resorption 
is then induced, a process that has been postulated to be important for cell cycle 
re-entry (Kim and Tsiokas, 2011). In mammalian cells, Ajuba has also been shown 
to localize to the basal body and is required for ciliogenesis (Nagai et al., 2010).  
 
AurA is essential for embryonic development as AurA-/- mice are embryonic lethal 
and early embryos from these mice do not survive beyond the sixteen cell stage of 
development (Lu et al., 2008b). Fibroblasts from heterozygous AurA+/- mice 
showed higher levels of aneuploidy and heterozygous mice have an increased 
incidence of tumour formation compared to WT mice. 
 
6.1.2 Polo-like kinase 1 (PLK1) 
 
PLK1 is a member of the Polo-like kinase family of serine/threonine kinases (Figure 
6.1). There are five mammalian PLKs: PLK1, PLK2, PLK3, PLK4 and the recently 
identified PLK5. They possess a highly conserved N-terminal kinase domain and a 
C-terminal polo-box domain, which is more divergent (Kishi et al., 2009). PLK1 
functions in multiple cellular processes including mitotic entry, centrosome 
maturation, spindle formation, chromosome segregation, cytokinesis and mitotic 
exit (Lens et al., 2010).  
 
PLK1 has also recently been demonstrated to participate in the regulation of DNA 
replication as depletion of PLK1 can disrupt pre-RC formation and reduce DNA 
synthesis (Yim and Erikson, 2009). PLK1 interacts with pre-RC proteins such as 
MCM7 (Tsvetkov and Stern, 2005a) and ORC2 (Song et al., 2011). An interaction of 
PLK1 with Timeless was also observed, predominately in G2/M phase cells and a 
function for this complex in the coordination of S phase and mitotic events was 
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proposed (Dheekollu et al., 2011). In Xenopus extracts, the recruitment of Plx1 to 
the chromatin was shown to be dependent on the phosphorylation of MCM2 by ATR 
and important for the prevention of replication associated DNA breakage (Trenz et 
al., 2008). 
 
PLK1, like AurA, is required for embryonic development as PLK1-/- mice are 
embryonic lethal and early embryos from these mice do not survive beyond the 
eight cell stage of development (Lu et al., 2008a). In this study, heterozygous 
PLK1+/- mice also went on to develop tumours, at an incidence that was three-fold 
higher than WT counterparts. 
 
PLK1 is located at the centrosome in interphase and early prophase via an 
interaction between the polo-box domain of PLK1 and centrosomal proteins such as 
cenexin1 (Soung et al., 2006). It is highly dynamic at mitotic centrosomes and 
complete removal of the kinase domain causes the protein to stably associate with 
the centrosome, suggesting that the release of PLK1 from the centrosome is 
facilitated by its kinase activity (Kishi et al., 2009). Later in mitosis PLK1 becomes 
located at the midbody, spindle and kinetochores. Thus the kinase-dependent 
release from the centrosomes may be important for the relocation of PLK1 to these 
structures in late mitosis. Additionally, PLK1 anchored at the centrosome prevents 
proper mitotic progression, inducing a G2 delay (Kishi et al., 2009).  
 
PLK1 is activated several hours before the onset of mitosis by phosphorylation of 
threonine 210 in the T loop of the kinase. This phosphorylation is performed by 
AurA in G2, in concert with Bora (Seki et al., 2008), and active PLK1 is present on 
the centrosomes in G2. It is not known if the AurA-dependent activation of PLK1 
occurs at this location or in the nucleus. Depletion of AurA, however, does reduce 
the phosphorylation at T210 of centrosomally located PLK1 (Mac!rek et al., 2008).  
 
Cdk1 dependent phosphorylation of many target proteins such as WEE1, Myt1 and 
Cdc25c creates a ‘docking site’ for PLK1 (Elia et al., 2003a, Elia et al., 2003b), 
allowing the targeting of PLK1 to many Cdk1 substrates. PLK1 phosphorylates 
Cdc25C at serine 198, promoting its nuclear translocation (Roshak et al., 2000, 
Toyoshima-Morimoto et al., 2002), phosphorylates Myt1 and inhibits its kinase 
activity (Nakajima et al., 2003, Inoue and Sagata, 2005) and phosphorylates WEE1 
resulting in its ubiquitination and degradation via the SCF"-TrCP complex (Watanabe 
et al., 2004). PLK1 also regulates Cdc25B activity by promoting its nuclear 
localization (Lobjois et al., 2009). CyclinB1 is phosphorylated on serine 147 by 
PLK1, promoting its accumulation in the nucleus (Toyoshima-Morimoto et al., 
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2001). PLK1 therefore activates or inhibits many targets involved in cell cycle 
control in order to facilitate mitotic entry. 
 
Similarly to AurA, the activation of PLK1 is also inhibited after DNA damage (Smits 
et al., 2000) in a manner dependent on ATM or ATR (van Vugt et al., 2001). 
Further studies showed that the phosphorylation of PLK1 at S137 and T210 are 
inhibited in response to DNA damage, in a manner dependent on ATM/ATR and 
Chk1/Chk2 (Tsvetkov and Stern, 2005b). PLK1 kinase activity is also inhibited in an 
ATR-dependent manner after topoisomerase II inhibition (Deming et al., 2002). The 
overexpression of an activated PLK1 T210D phospho-mimetic mutant causes 
abrogation of the G2/M checkpoint and cells are able to enter and progress through 
mitosis (Smits et al., 2000). PLK1 is degraded by the APC/CCdh1 after damage, 
mediated by the Cdh1 binding site on PLK1. This degradation is proposed to be 
critical for the initiation and maintenance of the G2/M checkpoint and is suggested 
to be necessary for the inhibition of Cdk1 after damage (Bassermann et al., 2008).  
 
The role of PLK1 in mitotic exit is proposed to be via its regulation of CDC6. The 
phosphorylation of CDC6 on T37 by PLK1 results in an inhibition of CDK1 and the 
activation of Separase, promoting chromosome segregation (Yim and Erikson, 
2010). 
 
53BP1, a checkpoint mediator protein involved in the G2/M checkpoint response to 
ionizing radiation, has also been shown to interact with PLK1. It was speculated to 
act as a scaffold to facilitate an interaction between PLK1 and Chk2. Direct 
phosphorylation of Chk2 by PLK1 results in a down regulation of Chk2 activity and 
allows release from the checkpoint (van Vugt et al., 2010). 
 
PLK1 also directly activates Forkhead Box M1 (FoxM1), an enhancer of 
transcription, which then stimulates the transcription of many genes involved in 
mitotic entry such as cyclinB1, PLK1 and the Cdc25 phosphatases (Fu et al., 2008). 
 
It has recently been demonstrated in C. Elegans and Drosophila that PLK1, Bora 
and AurA play a role in asymmetric cell division through acting on PAR and NUMB 
proteins (Budirahardja and Gönczy, 2008, Wirtz-Peitz et al., 2008, Khazaei and 
Püschel, 2009, Noatynska et al., 2010). This could highlight a role for these 
proteins in the maintenance of stem cell populations and brain development.  
 
Due to the above documented links between AurA and PLK1 with the DNA damage 
response, the centrosomal location of these proteins and their possible role in 
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asymmetric cell division, I undertook an examination of the regulation of these 
proteins after damage in a subset of MPD cell lines. G2/M checkpoint defects in 
response to UV irradiation are a consistently observed phenotype in all MPD cell 
lines that I have examined. These cell lines carry mutations in diverse proteins such 
as ATR, ATRIP, PCNT and ORC1. A common feature of all of these proteins is their 
localization at the centrosome. We have also observed G2/M checkpoint defects in 
cell lines with mutations in other centrosomal proteins such as MCPH1 (Alderton et 
al., 2006) and ASPM (data not shown). The ATR-dependent Chk1 phosphorylation 
in these cell lines is not consistently defective, although the defect may lie 
downstream of global Chk1 phosphorylation, such as in PCNT mutated cells, where 
Chk1 is not effectively localized at the centrosome (Chapter Three). The aim of this 
chapter was to examine a panel of MPD cell lines and attempt to dissect the 
molecular basis underlying the ATR-dependent G2/M checkpoint defect observed.  
 
6.2 RESULTS 
 
6.2.1 Meier-Gorlin syndrome cells fail to activate the ATR-dependent 
G2/M checkpoint 
 
ATR-Seckel cells have previously been shown to display a defective G2/M 
checkpoint response both 24 hours (Alderton et al., 2004) and 2 hours (Stiff et al., 
2008) post UV irradiation. ORC1-MPD (Chapter Five) and PCNT mutated cells 
(Griffith et al., 2008) have also been shown to display a defective G2/M checkpoint 
response to UV exposure. Due to the unexpected finding that ORC1 may be 
required for efficient ATR-dependent G2/M checkpoint arrest, LBL cells from 
patients with MGS with further mutations in preRC components (Table 8) were 
assessed for the ability to arrest at the G2/M checkpoint 24 hr after exposure to UV 
irradiation. LBL’s with mutations in CDC6, CDT1, ORC4 and ORC6 all failed to arrest 
at the G2/M checkpoint following UV exposure, similar to the ATR-S line and in 
contrast to the WT cell line (Figure 6.3). This result suggests that all of the preRC 
components examined are required for an efficient ATR-dependent G2/M checkpoint 
response. 
 
6.2.2 Phosphorylation of Chk1 after UV exposure is defective in 
Cdc6-MGS patient cell lines 
 
Cdc6 interacts with ATR (Chung and Bunz, 2010, Yoshida et al., 2010) and is able 
to arrest cells in G2 in a Chk1 dependent manner (Clay-Farrace et al., 2003). In 
! 
Table 8 PreRC mutations in MGS patients 
!
Gene Amino Acid 
Alterations 
Current  
Height (SD) 
Current 
OFC (SD) 
Microtia Absent/small 
   Patellae 
ORC1 R105Q + 
V667fsX24 
-9.6 -9.8 + + 
ORC4 Y174C -4.2 -2.1 + - 
ORC6 F86X + Y232S -3.3 -1.6 + + 
CDT1 R462Q + 
Y520X 
-1.6 +1.7 + + 
CDC6 T323R -4.1 -3.3 + + 
Figure 6.3 Meier-Gorlin Syndrome cells display a defective UV-induced G2/M 
checkpoint. 
     WT, ATR-S and Meier-Gorlin Syndrome cell lines with mutations in pre-
replication complex components were examined for G2/M checkpoint 
arrest 24hrs after treatment with 5J/m2 UV irradiation and in the 
presence of 1.5µM Nocodazole. A decrease in the number of mitotic cells 
was taken as indicative of a G2/M arrest.  
The graph represents the mean of three independent experiments. The error 
bars represent the standard deviation. 
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Figure 6.4 Chk1 phosphorylation after UV exposure is defective in the Cdc6 
MGS cell line 
WT, ATR-S and Cdc6-MGS LBL patient cell lines were treated with 5 or 10 J-
m2 UV and cell pellets harvested 1hr later.  Whole cell extracts were then 
resolved on a 8% SDS-PAGE and transferred onto a PVDF membrane. 
Membranes were then probed with an anti-phospho Chk1 (ser317) antibody. 
Total Chk1 levels were used as a loading control.  
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order to determine at which point in the ATR signaling pathway Cdc6 could be 
functioning, the phosphorylation of Chk1 after UV irradiation was examined. Cdc6-
MGS patient LBL’s were assessed for their ability to phosphorylate Chk1 at ser317 
after exposure to UV irradiation using western blotting. After both 5J and 10J of UV 
irradiation, Chk1 phosphorylation in the Cdc6 cell line was found to be reduced 
compared to the WT response and similar to the ATR-S line (Figure 6.4). This result 
suggests that Cdc6 is required for the efficient ATR-dependent phosphorylation of 
Chk1. 
 
6.2.3 Inhibition of PLK1 can rescue the ATR-dependent G2/M 
checkpoint defect in several MPD cell lines 
 
Several MPD cell lines that have already been characterized in this thesis were 
chosen for further study. Why should lines with mutations in proteins of diverse 
function such as centrosomal proteins and pre-replication complex proteins all 
result in G2/M checkpoint defects? As described in the introduction to this chapter, 
PLK1 is inhibited after damage in a manner dependent on ATR/ATM (van Vugt et 
al., 2001). We therefore considered the possibility that as PLK1 must be inhibited in 
order to prevent mitotic entry following DNA damage, ATR-dependent PLK1 
inhibition may not occur efficiently in these MPD cell lines. In order to test this 
hypothesis, cell lines with ATR-dependent G2/M checkpoint defects were treated 
with PLK1 inhibitor BI2536 for 15 minutes prior to UV treatment and maintained for 
two hours post UV exposure. Cultures were also treated with Colcemid in order to 
block cells at metaphase, thus eliminating the influence of the checkpoint exit 
function of PLK1 on the data. Cells were then examined for the ability to arrest at 
the G2/M checkpoint by analysis of mitotic index. Treatment with the PLK1 inhibitor 
rescued the ATR-dependent G2/M checkpoint defect observed in all cell lines tested, 
ATR-S, PCNT-S, ORC1-P1 and CDC6 (Figure 6.5a). The PLK1 inhibitor failed to 
rescue the G2/M checkpoint defect observed in ATM deficient LBL cells following 
exposure to IR, indicating a role for PLK1 in the ATR-dependent checkpoint pathway 
specifically (Figure 6.5b). The number of mitotic cells with monopolar spindles 
increased after PLK1 inhibition from 3.4% to 94.8% (data not shown), indicating 
that PLK1 was effectively inhibited under these experimental conditions.  
 
 
 
 
Figure 6.5  PLK1 inhibition rescues the UV induced G2/M checkpoint defect 
observed in Seckel Syndrome and Meier-Gorlin Syndrome cell lines but fails to 
rescue the IR-induced G2/M checkpoint defect observed in an ATM deficient 
cell line. 
a)  WT, ATR-S, ORC1-P1-S, PCNT-S and Meier-Gorlin Syndrome Cdc6 LBL cell 
lines were examined for G2/M checkpoint arrest, 2hrs after treatment with 
5J/m2 UV irradiation and in the presence of 0.2µg/mL Colcemid.   PLK1 
inhibitor BI2536 (PLK1i) 100nM was added to indicated cultures 15 min 
prior to UV exposure and maintained for 2hrs prior to harvest. A decrease 
in the number of mitotic cells was taken as indicative of a G2/M arrest.  
b)  WT and ATM deficient LBL’s were examined for G2/M checkpoint arrest 
2hrs after treatment with 3Gy Ionising Radiation and in the presence of 
0.2µg/mL Colcemid. PLK1 inhibitor BI2536 (PLK1i) 100nM was added to 
the indicated cultures 15 min prior to IR exposure and maintained for 2hrs 
prior to harvest. A decrease in the number of mitotic cells was taken as 
indicative of a G2/M arrest. 
Each graph represents the mean of three independent experiments. The 
error bars represent the standard deviation. 
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6.2.4 Inhibition of AurA can rescue the ATR-dependent G2/M 
checkpoint defect in several MPD cell lines 
 
AurA, the upstream kinase that phosphorylates PLK1, is also inhibited following 
DNA damage, in a manner dependent on ATR/ATM and Chk1 (Krystyniak et al., 
2006). In order to determine whether the inhibition of AurA after DNA damage is 
similarly inefficient in the MPD cell lines examined, the Aurora kinase inhibitor 
MLN8237 was added to cell cultures prior to UV treatment and maintained for two 
hours post treatment. Cells were examined for the ability to arrest at the G2/M 
checkpoint by analysis of mitotic index. Again, treatment with the AurA inhibitor 
rescued the ATR-dependent G2/M checkpoint defect observed in all cell lines tested, 
ATR-S, PCNT-S, ORC1-P1 and CDC6 (Figure 6.6a). The AurA inhibitor failed to 
rescue the G2/M checkpoint defect observed in ATM deficient LBL cells following 
exposure to IR, indicating that AurA also plays a role in the ATR-dependent 
checkpoint pathway specifically (Figure 6.6b). The number of mitotic cells with 
monopolar spindles in AurA inhibited cultures increased from 2% to 19.2% (data 
not shown), indicating that AurA was effectively inhibited under these experimental 
conditions.  
 
6.2.5 Phosphorylated PLK1 T210 levels are not appropriately 
downregulated following UV exposure in ORC1-P1 MPD patient cell 
lines 
 
Phosphorylation of the PLK1 T210 site is inhibited after DNA damage (Tsvetkov and 
Stern, 2005b) in a manner dependent on ATR/ATM and Chk1/Chk2. In order to 
determine how PLK1 T210 phosphorylation is regulated in MPD LBL’s, WT and 
ORC1-P1 cells were treated with 30Jm-2 UV and then cells harvested 30 minutes or 
2 hours later. Extracts were prepared and levels of PLK1 phosphorylated at 
threonine 210 were examined by western blotting. In WT cells, inhibition of this 
phosphorylation could be clearly seen 30 minutes after UV exposure and levels of 
phosphorylation were still diminished at 2 hours post UV exposure (Figure 6.7). In 
ORC1-P1 cells, some inhibition was observed but levels of phosphorylated T210 
PLK1 remained at higher levels than that seen in the WT at both 30 minutes and 2 
hours post UV exposure. This raises the possibility that in ORC1-P1 cells, there is a 
failure to inhibit the phosphorylation of PLK1 at threonine 210 after DNA damage 
caused by UV irradiation. This suggests that PLK1 activity remains high, 
contributing to an inability to activate the G2/M checkpoint and allowing cells to 
enter mitosis even in the presence of DNA damage. 
a) 
Figure 6.6  Aurora A Kinase inhibition rescues the UV induced G2/M 
checkpoint defect observed in Seckel Syndrome and Meier-Gorlin Syndrome 
cell lines but fails to rescue the IR-induced G2/M checkpoint defect observed 
in an ATM deficient cell line. 
a)  WT, ATR-S, ORC1-P1, PCNT and Meier-Gorlin Syndrome Cdc6 LBL’s were 
examined for G2/M checkpoint arrest, 2hrs after treatment with 5J/m2 UV 
irradiation and in the presence of 0.2µg/mL Colcemid. Aurora A Kinase 
inhibitor MLN8237 (AAi) 250nM was added to indicated cultures 15 min 
prior to UV exposure and maintained for 2hrs prior to harvest. A decrease 
in the number of mitotic cells was taken as indicative of a G2/M arrest.  
b)  WT and ATM deficient LBL’s were examined for G2/M checkpoint arrest 
2hrs after treatment with 3Gy ionising radiation and in the presence of 
0.2µg/mL Colcemid. Aurora A Kinase inhibitor MLN8237 (AAi) 250nM was 
added to the indicated cultures 15 min prior to IR exposure and 
maintained for 2hrs prior to harvest. A decrease in the number of mitotic 
cells was taken as indicative of a G2/M arrest. 
Each graph represents the mean of three independent experiments. The 
error bars represent the standard deviation. 
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Figure 6.7  Phosphorylated PLK1 T210 levels are not appropriately 
downregulated following UV exposure in an ORC1-P1 MPD cell line 
a) WT and ORC1-P1 MPD patient LBL’s were treated with 30 Jm2 UV 
and cell pellets harvested 30 min and 2 hr later.  Whole cell extracts were 
then resolved on a 8% SDS-PAGE and transferred onto a PVDF membrane. 
Membranes were then probed with an anti-phospho PLK1 (Thr210) antibody. 
Total PLK1 levels were also examined. ! tubulin was used as a loading 
control.  
b) Protein levels of phospho PLK1 (Thr210) were quantified from two 
independent immunoblotting experiments. Protein levels of total PLK1 were 
quantified from one immunoblotting experiment.  The graph shows the 
phospho PLK1 (T210) protein levels relative to total PLK1 protein levels.  
Error bars represent the standard deviation. 
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6.2.6 Phosphorylated Aurora A T288 levels at the centrosome are 
not appropriately regulated following UV exposure in MPD cell lines. 
 
In order to confirm and extend the finding that PLK1 T210 phosphorylation is not 
appropriately inhibited following damage in ORC-P1 MPD cells, an examination of 
the regulation of AurA phosphorylation at the centrosome was undertaken. Cells 
were treated with 30Jm-2 UV irradiation and slides prepared 30 min later. Slides 
were stained using techniques to visualize centrosomes, using !-tubulin as a 
centrosomal marker and co-staining with an antibody towards AurA phosphorylated 
at threonine 288, or an antibody for Total AurA. The T288 site is an 
autophosphorylation site on AurA and indicates that the kinase is activated (Walter 
et al., 2000). AurA was found to be present only at those cells containing two 
centrosomes, and highly expressed in mitotic cells. As the role of AurA in G2/M 
checkpoint regulation was of interest, mitotic cells were excluded from further 
analysis. Z series of 0.2µM stack images were acquired using softWorX software on 
a Deltavision microscope.  Images were then imported into ImageJ software and a 
standard region of interest for the centrosomes defined. A Z-projection of the stack 
images was performed and a summed intensity measured at each centrosome in at 
least 20 cells per experiment. An intensity measurement was taken within each 
cell, outside the centrosome, and subtracted as background. In WT cells UV 
treatment resulted in a reduction in signal intensity of AurA phosphorylated on 
T288, but not of total AurA protein at the centrosome. The intensity of 
phosphorylated AurA signal decreased by approximately 50% in three independent 
experiments (Figure 6.8) and this reduction was statistically significant (Figure 
6.9). In contrast, the phosphorylation of AurA at T288 did not decrease after 
treatment with UV irradiation in any of the MPD cell lines examined. In the ATR-S 
line there was a small, statistically significant, increase in total AurA at the 
centrosome following exposure to UV irradiation. The reason for this is unclear, 
however, the levels of phosphorylated T288 AurA at the centrosome remain 
unchanged in the ATR-S line after damage. Overall, this result indicates that there 
is a failure to inhibit the phosphorylation of AurA at T288 after DNA damage in MPD 
patient cell lines, suggesting that this kinase remains active in these cells. This 
could again contribute to the failure of these cells to activate a G2/M checkpoint in 
response to DNA damage. 
 
 
 
a) 
Figure 6.8a Phosphorylation of Aurora A at the centrosome is not 
appropriately regulated following exposure to UV in Seckel syndrome cells  
WT, ATR-S, PCNT and ORC1 LBL cell  lines were untreated (UNT) or treated 
with 30 J/m2  UV and slides prepared after 30 min. Slides were stained using 
techniques to identify the centrosomal pool of phosphorylated Aurora A (red). 
Centrosomes were identified by co-staining with a !-tubulin marker (green). 
Aurora A signal was only detected in cells possessing two centrosomes. 
Deconvolved images from Deltavision stacks. 
Figure 6.8b Phosphorylation of Aurora A at the centrosome is not 
appropriately regulated following exposure to UV in Seckel syndrome cells  
The level of phosphorylated Aurora A at the centrosome was quantified in 20 
cells in three independent experiments. The level of total Aurora A at the 
centrosome was also quantified in 20 cells in three independent experiments. 
Mitotic cells were not included in this analysis. The graph represents the 
normalised mean intensity of phospho AurA relative to total AurA signal. Error 
bars represent the standard deviation. 
b) 
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Figure 6.9 Box plots of AurA intensity at the centrosome 
a)  Box plot of quantification of phosphorylated AurA T288 intensity at the 
centrosome as shown in figure 6.8. Data shown from three independent 
experiments. 
b)  Box plot of quantification of total AurA at the centrosome as shown in 
figure 6.8. Data shown from three independent experiments.  
Statistics performed were Shapiro-Wilk normality test followed by 
Mann-Whitney Rank Sum test. Statistically significant differences are  
indicated by *. ns = not statistically significant 
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6.2.7 Depletion of CEP192 results in an ATR-dependent G2/M 
checkpoint defect 
 
CEP192 interacts with AurA and localizes it to the centrosome (Gomez-Ferreria et 
al., 2007). CEP192 also interacts with PCNT and these proteins are partially co-
dependent on each other for localization to the centrosome (Gomez-Ferreria et al., 
2007). In order to determine whether CEP192 is also required for ATR-dependent 
G2/M checkpoint responses, CEP192 was depleted in HeLa cells for 72hrs and the 
G2/M checkpoint response to UV and IR examined. Western blotting to confirm 
depletion levels was not possible due to unavailability of commercial antibodies at 
the time of experimentation. However, in CEP192 siRNA treated samples, cells 
failed to arrest efficiently after UV treatment but arrested proficiently after 
exposure to IR (Figure 6.10), although not to the same extent as untransfected 
cells. This indicates that CEP192 may be involved in the ATR-dependent damage 
response to UV but is not required for the damage response to IR.  
 
In conclusion, in this chapter I have shown that further MGS lines with mutations in 
preRC components display a defective ATR-dependent UV-induced G2/M checkpoint 
response, similarly to all MPD line that I have examined in this thesis. I have 
investigated the molecular basis underlying the G2/M checkpoint defect and have 
shown that the phosphorylation of AurA kinase and PLK1 at the centrosome is mis-
regulated after UV exposure in all MPD lines examined.  
 
6.3 DISCUSSION 
 
The results presented in this chapter reveal an interesting impact of AurA and PLK1 
in the ATR-dependent damage response. Published data suggests that PLK1 can 
regulate mitotic entry via phosphorylation of CDC25C (Roshak et al., 2000, 
Toyoshima-Morimoto et al., 2002) and CDC25B (Lobjois et al., 2009), promoting 
the nuclear translocation of these proteins. It has been proposed that PLK1 and 
CDC25B are required for recovery from a G2 arrest following DNA damage but are 
dispensable for mitotic entry in unperturbed cell cycles (Van vugt et al., 2004). 
Further, PLK1 activity, via AurA regulation, is down regulated in an ATR-dependent 
manner after damage (Tsvetkov and Stern, 2005b).  
My results confirm and extend these findings with the observations that: 
 
1. AurA phosphorylation is not efficiently down regulated at the centrosome in 
MPD patient derived cell lines deficient in ATR, PCNT or ORC1. 
Figure 6.10 Depletion of Cep192 results in an ATR-dependent G2/M checkpoint 
defect 
Cep192 was depleted in Hela cells for 72hrs and then cells were examined for 
G2/M arrest 2hrs after exposure to 5J/m2 UV or 3 Gy IR. A decrease in the 
number of mitotic cells was taken as indicative of a G2/M arrest.  
Graph represents the mean of three independent experiments. Error bars 
represent the standard deviation. 
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2. In these cell lines, ATR-dependent UV induced checkpoint induction is 
compromised, however, inhibition of AurA or PLK1 can re-establish the 
checkpoint arrest 
 
The phosphorylation of both AurA and PLK1 at the centrosome is clearly mis-
regulated following exposure to UV radiation in a panel of MPD lines. Results 
presented in this chapter suggest that ATR-dependent inhibition of AurA, and 
consequently PLK1, is required in order to proficiently activate the G2/M checkpoint 
response after UV exposure. The process requires the centrosome as defects in 
centrosome proteins, such as in the PCNT deficient line, result in an inability for this 
ATR-dependent regulation to occur. In ATR deficient cells, where the 
phosphorylation of Chk1 after UV exposure is not efficient, Cdc25 is therefore not 
efficiently inhibited by direct phosphorylation by Chk1 (Alderton et al., 2006), 
although residual protein present in the patient cells makes interpretation of the 
level of residual activity difficult. However, inhibition of PLK1 in this context can still 
result in checkpoint activation, suggesting that the inhibition of PLK1 after damage 
is a critical step in establishing the checkpoint. In undamaged cells, treatment with 
AurA or PLK1 inhibitors did not significantly affect mitotic entry, suggesting that 
these proteins are indeed dispensable for mitotic entry in the absence of damage. 
After damage, mitotic entry becomes dependent on PLK1, suggesting that the 
regulation of mitotic entry in this context is different.  
 
A model for regulation of AurA and PLK1 after UV irradiation is presented in Figure 
6.11. There are two possible interpretations for the role of AurA and PLK1 in G2/M 
checkpoint control. The first model is that Chk1, activated by ATR, can control 
Cdc25 regulation both by direct phosphorylation and also indirectly via the 
inhibition of PLK1. The second model is that ATR regulates PLK1 via an, as yet 
undefined, Chk1-independent mechanism. Data from our laboratory (T. Stiff, 
personal communication) suggests that Chk1 inhibition combined with PLK1 
inhibition nevertheless results in checkpoint arrest, suggesting that the first model 
is correct. 
 
AurA is required for the initial localization of Cdk1-CyclinB to the centrosome. As 
AurA is inappropriately active at the centrosome in MPD lines it is possible that 
Cdk1-CyclinB is also inappropriately located at the centrosome. Premature 
Chromosome Condensation (PCC’s) is a hallmark of cells that enter mitosis 
prematurely, possibly due to increased Cdk1-CyclinB activity (Alderton et al., 
2006). I have not observed PCC’s in the cell lines examined here, although it is a 
UV 
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MITOTIC ENTRY 
Figure 6.11 AurA and PLK1 in the ATR-dependent damage response at the 
centrosome 
Upon UV exposure, ATR becomes activated and phosphorylates Chk1 at the 
centrosome, possibly in concert with Cdc6. Active Chk1 inhibits the Cdc25s 
which are then unable to activate Cdk1-CyclinB, inhibiting mitotic entry. In 
parallel, ATR inhibits the phosphorylation of Aurora A and PLK1 at the 
centrosome, either via a mechanism involving Chk1 or potentially via 
regulation of CEP192. Inhibition of PLK1 prevents the activation of Cdc25B 
and C and further inhibits Cdk1-CyclinB1 activation and mitotic entry.  
Centrosome 
Cdc6 
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feature of some microcephalic cell lines such as Primary Microcephaly patients with 
mutations in MCPH1 (Alderton et al., 2006).  
 
A minimal level of AurA activity is sufficient for cells to enter mitosis (Hirota et al., 
2003), therefore even a small amount of mis-regulation after damage could 
account for the loss of the G2/M checkpoint. In many of these lines, Chk1 is either 
not phosphorylated efficiently after damage (ATR-S) or is not localized at the 
centrosome sufficiently (PCNT mutated), resulting in inappropriate Cdc25 
activation. If AurA/PLK1 are also inappropriately activating the Cdc25s, the levels of 
active Cdk1-CyclinB will be high and cells will enter mitosis. If Chk1 at the 
centrosome is involved in regulation of AurA phosphorylation, it is possible that 
reduced Chk1 at the centrosome in the PCNT line results in an inability to inhibit 
AurA at centrosome. Chk1 could also regulate the function of CEP192 at the 
centrosome after DNA damage, resulting in reduced localization of AurA at 
centrosomes. It is possible that an important function of the G2/M checkpoint 
response is also to inhibit centrosome maturation, ensuring that the centrosome 
cycle and nuclear cell cycle remain coupled. 
 
Further work to confirm and extend the findings presented here could include the 
use of AurA inhibitors to determine if the excess signal detected at the centrosome 
after UV exposure in MPD lines could be reduced. Chk1 inhibitor treatment of the 
WT cell line could determine if the UV-induced inhibition of AurA at the centrosome 
is Chk1 dependent. Immunoprecipitation experiments could address the possibility 
that ATR or Chk1 interacts with CEP192 and/or AurA. Does ATR or Chk1 
phosphorylate CEP192 and inhibit it after damage, contributing to the inhibition of 
AurA activity at the centrosome?  
 
PLK1 also phoshorylates ORC2 following exposure to UV radiation. Increased 
replication stress in the ORC1 cell line could lead to an increase in PLK1 
phosphorylation on T210 in order for PLK1 to then phosphorylate ORC2. Slow S 
phase progression has been detected when PLK1 is inhibited or depleted, but PLK1 
is not required for DNA replication unless cells encounter replication stress (Song et 
al., 2011).  
 
The question still remains: how are ORC1 and Cdc6, pre-replication complex 
components, involved in G2/M checkpoint regulation after UV exposure? ORC1 has 
a role outside of replication, at the centrosome and is involved in the control of 
centriole duplication (Hemerly et al., 2009). However, there is no evidence as yet 
for centrosomal localization of Cdc6. Is Cdc6 localised to the centrosome via its 
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interaction with ORC1? It is possible that the centrosomally located pools of these 
proteins are important in contributing to checkpoint control. 
 
Cdc6 is phosphorylated by Cdks during the cell cycle, resulting in its nuclear export 
(Petersen et al., 1999). A phosphorylation site mutant Cdc6 S74A is not able to 
arrest cells in G2 (Clay-Farrace et al., 2003). Cdc6 null yeast cells still enter mitosis 
even without fully completing replication of the DNA (Piatti et al., 1995). Cdc6 is 
therefore postulated to play a role in a checkpoint that couples completion of DNA 
replication and entry into mitosis. In human cells, depletion of Cdc6 causes cells to 
enter mitosis without activating the ATR-dependent checkpoint and also results in 
increased apoptosis (Lau et al., 2006). In Xenopus, Cdc6 is required for the 
activation of Chk1 following replication fork stalling induced by aphidicolin 
(Oehlmann et al., 2004). I have also observed an ATR-dependent G2/M checkpoint 
defect in Cdc6 depleted Hela cells (data not shown). Only one experiment was 
conducted and the result needs confirming, however this recapitulates the 
phenotype observed in the Cdc6 mutated MGS cell line.  
 
Chromatin bound Cdc6 interacts with MCM7 (Kneissl et al., 2003, Shin et al., 
2003). MCM7 interacts with ATRIP and depletion of Mcm7 results in defective Chk1 
phosphorylation (Cortez et al., 2004). It is possible therefore that Cdc6 is involved 
in the upstream steps of checkpoint activation. My results also suggest that Cdc6 is 
somehow required for the phosphorylation of Chk1 after UV exposure.  This aspect 
of ATR-dependent signalling requires further investigation.  
 
In this chapter I have explored the molecular basis underlying the ATR-dependent 
G2/M checkpoint defect in a panel of MPD lines. I have shown that the 
phosphorylation of AurA and PLK1 at the centrosome is not inhibited in MPD lines 
after exposure to UV, to the same extent that it is inhibited in WT lines. These 
results highlight an important role for AurA and PLK1 at the centrosome in the ATR-
dependent DNA damage response. 
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CHAPTER SEVEN 
 
 
7.1 DISCUSSION 
 
 
In this thesis I have examined multiple genetically uncharacterised cell lines from 
patients with MPD disorders for ATR-dependent DNA damage response signalling 
and have contributed to the identification of the underlying genetic defects. I have 
further shown that the mutations identified in PCNT, ATRIP and ORC1L result in 
defects in ATR-dependent DNA damage response signalling. I have explored the 
molecular basis of the defective ATR-dependent G2/M checkpoint response 
exhibited by various MPD patient derived cell lines and highlight an important role 
for AurA and PLK1 at the centrosome in the ATR-dependent DNA damage response. 
 
7.1.1 PCNT mutation and defects in ATR-dependent G2/M checkpoint 
activation 
 
I have shown that a subset of patients with MPD harbour mutations in PCNT with 
accompanying defects in ATR-dependent DNA damage responses. Prior to this work, 
mutations in centrosomal proteins had already been indentified in Primary 
Microcephaly patients (Bond et al., 2005, Gul et al., 2006), however the results 
presented in this thesis provide further evidence of a link between mutations in 
proteins that localise to this organelle and the incidence of MPD. This work also 
provides the first evidence that mutations in a structural centrosomal protein can 
impact on the ATR-dependent DNA damage response. Further centrosomal protein 
mutations have since been identified in MPD and Primary Microcephaly patients, 
such as CENPJ (Al-Dosari et al., 2010) and CEP152 (Kalay et al., 2011). Could 
centrosome defects therefore be the sole cause of these patients’ clinical features? 
All SS lines studied to date possess supernumerary mitotic centrosomes, indicating 
that problems in centrosome duplication or segregation occur in the patient cells. It 
is likely that these cells either die in a ‘mitotic catastrophe’ event or continue 
cycling and become aneuploid or polyploid. In developmental terms, if the cells die 
in sufficient numbers during brain development then this could deplete the stem 
cell population number, resulting in an overall reduction in brain volume, hence 
resulting in microcephaly. A similar effect on overall cellular proliferation could 
result in the overall growth retardation observed in these patients both pre- and 
post-natally. We have also conducted G2/M checkpoint analysis on patient cell lines 
with mutations in other centrosomal associated proteins such as CENPJ and ASPM. 
All cell lines examined show a defective ATR-dependent G2/M checkpoint response, 
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raising the possibility that events at the centrosome are indeed required to co-
ordinate this signalling event. These results extend the findings of Jackman et al., 
2003, who showed that the first detectable active Cdk1-CyclinB is localised at the 
centrosome and proposed that pathways for the negative and positive regulation of 
mitotic entry may be located at the centrosome.   
 
How does the absence of PCNT result in an inability to down regulate AurA/PLK1 
activity? PCNT has been shown to interact with Chk1 and tether it at the 
centrosome (Tibelius et al., 2009). Chk1 levels at the centrosome are reduced in 
these cells, resulting in reduced inhibitory phosphorylation of Cdc25B. This coupled 
with the mis-regulation of AurA phosphorylation at the centrosome that I have 
observed could result in an inability to inhibit PLK1 after damage. This could result 
in inappropriate activation of Cdc25 and therefore an inability to effectively inhibit 
Cdk1-CyclinB1 complexes and lead to inappropriate mitotic entry. Indeed, reduced 
Chk1 activity at the centrosome has been demonstrated to result in G2/M 
checkpoint defects (Löffler et al., 2007). A direct interaction between Chk1 and 
AurA has not been shown, although if Chk1 does negatively regulate AurA kinase 
activity, this could be compromised by the reduced levels of Chk1 at the 
centrosome in these cells. After exposure to ionising radiation, Cdc25 activation is 
also inhibited, either by Chk2 or Chk1, to activate the G2/M checkpoint. However, I 
have not observed defects in checkpoint activation after exposure to IR in patient 
cell lines, suggesting that the centrosome is not required for checkpoint activation 
in this context. These results suggest that the regulation of PLK1 could be the step 
in checkpoint control that occurs at the centrosome and that this is critical for 
checkpoint activation following exposure to UV but not IR.  
 
It is possible that the UV-induced checkpoint arrest is not as efficient as that 
induced after IR exposure, as I have observed that a substantial number of control 
cells still enter mitosis after UV exposure, compared to a negligible number of cells 
after IR. This could suggest that either the activation of ATR, or the ability of ATR 
to inhibit Cdc25 after UV exposure is not efficient. In this context, the concomitant 
down regulation of PLK1 becomes critical to activate the checkpoint. After IR, it is 
possible that the down regulation of PLK1 is not critical as the Cdc25s are inhibited 
more efficiently. 
 
Both AurA and PCNT also interact with CEP192, therefore it could be expected that 
a reduced level of PCNT at the centrosome would result in reduced amounts of 
CEP192 and therefore a reduction in AurA levels at the centrosome would be 
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observed. I have not observed this in the patient cells, although the residual 
protein present may account for this. It is possible that ATR also regulates CEP192 
after damage, by inhibiting the localisation of AurA to the centrosome. ATR 
phosphorylates CEP63 after chromosome breakage, resulting in the inhibition of 
spindle assembly (Smith et al., 2009), demonstrating the existence of important 
links between control of the centrosome control and control of the nuclear cell cycle 
by the DNA damage response.  
 
The centrosome is also important for the correct orientation of the spindle during 
neurogenesis, influencing the decision between asymmetric and symmetric cell 
division (Higginbotham and Gleeson, 2007). Defects in spindle orientation were 
observed in PCNT-MOPDII patients (Rauch et al., 2008), and PCNT depletion leads 
to loss of astral microtubules (Zimmerman et al., 2004). It is possible that spindle 
orientation defects in PCNT mutated cells could cause a shift from symmetric 
division to asymmetric division, resulting in an overall decrease in the progenitor 
stem cell population (Cox et al., 2006). 
 
7.1.2 ORC1 mutation and defects in ATR-dependent signalling 
 
The identification of mutations in ORC1 in further MPD patients in this thesis has 
provided evidence for an important link between replication origin licensing and 
ATR-dependent signalling. This has also opened up a new avenue for the 
identification of further genetic defects in other replication-associated proteins. 
Indeed, further mutations in preRC components, such as CDC6, CDT1 and further 
ORC members were also uncovered in patients with MGS (Bicknell et al., 2011a). 
Defects in origin licensing and S-phase progression were observed in an ORC1 
deficient patient cell line. One model, which was suggested in our publication of this 
work is that ORC1 deficiency could be important during development when cell 
cycle phase and replication rate is rapid. During development, the cell cycle phases 
are shorter than for mammalian cells in culture (Takahashi et al., 1995). Therefore 
the defect in origin licensing, observed in the patient cells, may become rate-
limiting in the context of the shorter cell cycle. This phenotype, coupled with an 
increased time taken to complete S phase due to the observed defect in S-phase 
progression, could result in a slowing of overall cellular proliferation. This could 
therefore reduce the overall cell number, leading to a reduction in overall brain and 
body size (Klingseisen et al., 2011). The rescue of growth retardation in ORC1 
zebrafish by the introduction of WT ORC1 but not by an ORC1 that cannot 
efficiently bind to origins (Kuo et al., 2012) suggests that origin licensing is indeed 
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important during development and perturbation of cell-cycle progression in this 
context could cause the clinical features observed in MGS.  
 
The above model demonstrating an impact of reduced origin licensing capability in 
the patient cell line reflects the canonical function of ORC1 in the regulation of 
replication. However my results provide potential alternative or additional impacts 
of deficiency in ORC1. 
 
A surprising phenotype conferred by ORC1 deficiency is the defect observed in the 
ATR-dependent G2/M checkpoint response. ORC1 is known to play a role in the 
prevention of centrosome duplication at the centrosome (Hemerly et al., 2009), 
and it is postulated that the centrosome acts as a scaffold for the coordination of 
centrosome and nuclear cycle events (Doxsey et al., 2005). Therefore the absence 
of ORC1 may cause centrosome duplication as well as a loss of G2/M checkpoint 
control if these two events are somehow related or regulated by the same 
machinery. The completion of replication before the decision to undergo mitosis is 
undertaken may also be co-ordinated by the centrosome. CDC6 has been 
postulated to be involved in this regulation (Clay-Farrace et al., 2003). However, a 
centrosomal location for this protein has not been established. It does however 
interact with ORC1 (Saha et al., 1998) raising the possibility that a centrosome link 
to CDC6 exists. If centrosome defects in the ORC1 patients also cause spindle mis-
orientation, a premature switch from symmetric to asymmetric cell division could 
also result in a decrease in the progenitor stem cell population, leading to 
microcephaly (Cox et al., 2006). 
 
In the ORC1 deficient cell line Chk1 appears to be phosphorylated normally, yet 
AurA and PLK1 remain inappropriately activated after damage. It is possible that if 
Chk1 regulates AurA/PLK1 activity, then the defect lies downstream of Chk1 
phosphorylation in this pathway.  
 
Unpublished data from our laboratory has shown that mutations in ORC1, and other 
preRC proteins, also lead to defects in cilia function. We consider that this could be 
due to impairments in centrosome biology, raising the possiblility that a further 
non-canonical function of ORC1 might have a clinical impact in the patients and be 
a further cause of microcephaly.  
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7.1.3 Basis underlying MPD 
 
Overall, which of the cellular phenotypes observed could be causal in the clinical 
features observed in MPD patients with mutations in ATR, ATRIP, PCNT and ORC1? 
There are a number of possible explanations, which I will now address: 
 
1. Replication stress during development, leading to increased levels of 
apoptosis has been shown in the ATRs/s mouse (Murga et al., 2009) and ATR 
mutations in the patient cells also likely result in problems in progression 
though replication, as evidenced by a decrease in the stability of replication 
forks (Alderton et al., 2006). Defects in replication dynamics are also 
observed in the ORC1 patient lines. These cells however, also display 
supernumerary mitotic centrosomes and G2/M checkpoint defects making it 
somewhat difficult to ascribe the clinical features purely to replication stress 
alone. High levels of apoptosis due to replication stress during development 
could lead to depletion of progenitor cell populations. 
2. Mutations in centrosome proteins are increasingly observed in various MPD 
patients (Al-Dosari et al., 2010, Bond et al., 2005, Gul et al., 2006, (Kalay 
et al., 2011) providing a compelling link between defects at this organelle 
and these disorders. Defects in centrosome biology could result in an 
inappropriate switch from symmetric to asymmetric cell division, leading to 
depleted progenitor cell populations and resulting in microcephaly and 
growth retardation (Cox et al.,2006). 
3. The link between the centrosome and the primary cilia is also interesting in 
terms of the skeletal defects commonly observed both in MPD disorders and 
ciliopathies (Duldulao et al., 2010), for instance fifth finger clinodactyly is a 
clinical feature common to both sets of disorders. Defects in both cilia 
formation and function have been observed in many MPD cell lines in our 
laboratory (T.Stiff, personal communication) suggesting this could also be 
an important phenotype contributing to the clinical features observed. 
However, as the cilia are formed from the centrosome it is not trivial to 
distinguish if centrosome defects are causal of cilia defects or vice versa. 
 
In addition, as described above, the G2/M checkpoint defect is also a common 
phenotype observed in most MPD lines examined to date. Do centrosomal 
mutations always confer ATR-dependent G2/M checkpoint defects? The two 
phenotypes do seem to correlate in all the MPD patients examined to date, 
indicative of some connection. It is possible that for all the MPD cell lines examined 
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in this thesis, a small amount of mis-regulation of Cdk1-CyclinB1 activity, even in 
unperturbed cell cycles, results in a ‘edging towards’ mitotic entry rather than not. 
In terms of the bistability hysteresis model (Lindqvist et al., 2009), detailed in the 
introduction to this thesis, the level of Cdk1-CyclinB1 that is in an active state could 
be consistently higher in these cells, due to aberrant CDC25 regulation, and 
therefore the tendency is for cells to enter mitosis rather than not enter. After DNA 
damage, this becomes more evident as checkpoints are not activated efficiently. 
 
It is likely that the clinical features observed in the patients are due to a 
combination of all of the cellular phenotypes described above, resulting in overall 
impaired cell cycle progression during development. To what degree each separate 
phenotype contributes to the clinical features observed is not clear, and indeed the 
explanation may be different in each of the different patients. Further studies could 
provide insight into the overall mechanisms regulating growth during development.  
 
7.1.4 MPD patient classification 
 
An interesting problem highlighted in this work has been the clinical classification of 
patients. Some PCNT-mutated patients were originally classified as SS and then re-
classified to MOPDII (Willems et al., 2010). Patients with ORC1 mutation were 
included in our mapping studies as SS but are now regarded as MGS with further 
mutations in preRC components identified in this disorder (Bicknell et al., 2011a). 
The identification of further ATR/ATRIP Seckel patients may aid in delineating the 
clinical spectrum of Seckel Syndrome but there is certainly considerable overlap 
between MGS, MOPDII and Seckel. Indeed, it is possible that they are all the same 
MPD disorder but with varying degrees of severity. Patients with ORC1 mutations 
do appear to be more severely microcephalic than the other MGS patients. It is 
possible that the identification of any molecular differences in the phenotypes of 
patient cells, if indeed they exist, may be the only means of distinguishing between 
these disorders. This may be desirable from a clinical point of view in terms of 
management of the patients. MOPDII patients may need monitoring due to the 
increased risk of vascular problems, such as moya-moya disease that could result 
in death (Hall et al., 2004). It is also possible that the genetic deficiency may 
impact in different ways in different tissues, e.g. MGS patients display severe 
problems in patellae development (Faqeih et al., 2005). Identification of genetic 
defects coupled with an understanding of the role of each protein during 
development may aid in patient diagnosis and treatment.   
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7.1.5 MPD patients and cancer  
 
Given the role of ATR in the maintenance of genomic stability through the 
stabilisation of replication forks and checkpoint control, are Seckel or other MPD 
patients more prone to cancers? Although the number of patients is small it 
appears that the incidence of cancer is not significantly increased over the general 
population. Acute Myeloid Leukaemia (AML) has been observed in one Seckel 
syndrome patient to date (Hayani et al., 1994). No MOPDII related malignancies 
have been reported and none have been reported in MGS patients. In the context 
of reduced ATR function, the lack of an efficient G2/M checkpoint response may 
actually be beneficial to these patients. In rapidly replicating tumour cells, where 
there is extensive replication stress induced DNA damage, with efficient G2/M 
checkpoint activation, the cell may attempt to repair the damage and this could 
lead to mutagenesis. In the absence of an efficient G2/M checkpoint response, the 
cell enters mitosis with a level of DNA damage that makes the cell unviable. Cells 
would therefore either undergo apoptosis or die in mitosis and are therefore 
eliminated. Therefore the level of genomic instability is potentially kept to a 
minimum and the number of cells likely to cause cancer is reduced. Indeed, the 
ATR mouse engineered with the SS mutation does not form tumours within the six-
month timeframe examined (Murga et al., 2009). When these authors produced a 
double mutant mouse lacking both ATR and p53, they saw a synthetic lethal effect 
with an increased amount of apoptosis in embryos. It is possible therefore that 
extreme down regulation of the ATR DNA damage response confers a tumour 
suppressive effect. Indeed, a recent study showed that inhibition of ATR could 
inhibit the growth of murine cancers (Schoppy et al., 2012). A further ATR 
knockdown mouse does not die prematurely and also does not show an elevated 
tumour incidence (Ruzankina et al., 2008). The ATR+/- mouse from an early study 
to obtain a knockout mouse model, did however, show a small increase in tumour 
formation (Brown et al., 2000). It would be interesting to obtain embryonic 
fibroblasts from these heterozygous animals to examine G2/M checkpoint 
responses and possibly determine if this correlates with tumour incidence. In this 
context it would also be interesting to determine if heterozygous SS family 
members are prone to a higher incidence of cancers than the general population. 
Again, however, the small numbers of people available for examination could prove 
an obstacle to this kind of study.  
 
 
 
 
! "#!
7.1.6 MPD patients and premature aging 
 
Accelerated aging has been observed in mouse models of ATR deficiency, with 
phenotypes such as greying of hair, osteoporosis and kyphosis (Murga et al., 2009). 
In the ATRs/s mouse the hematopoietic stem cell (HSC) compartment of the animals 
was assessed and found to be lacking in multipotent progenitor cells indicating a 
loss of specific stem cell niches, as would be found in older animals (Murga et al., 
2009). It was proposed that this aging phenotype is a result of ‘intrauterine 
programming’ where insult to the embryo, in this case increased replicative stress, 
manifests as problems in adulthood. Premature aging has not been a striking 
feature manifesting in MPD patients although some features such as kyphosis are 
present in a few patients.  
 
7.1.7 Final summary 
 
In summary, the data I have presented in this thesis has contributed to the 
identification of the underlying genetic defects in various patients with MPD 
disorders. I have shown that novel mutations in ATRIP, PCNT and ORC1 impact on 
ATR-dependent DNA damage response signalling. I have also demonstrated an 
important mechanism involving the inhibition of the phosphorylation of AurA at the 
centrosome in ATR-dependent UV-induced checkpoint activation. 
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Studies into disorders of extreme growth failure (for example, 
Seckel syndrome and Majewski osteodysplastic primordial 
dwarfism type II) have implicated fundamental cellular 
processes of DNA damage response signaling and centrosome 
function in the regulation of human growth. Here we report  
that mutations in ORC1, encoding a subunit of the origin 
recognition complex, cause microcephalic primordial dwarfism 
resembling Meier-Gorlin syndrome. We establish that these 
mutations disrupt known ORC1 functions including pre-
replicative complex formation and origin activation. ORC1 
deficiency perturbs S-phase entry and S-phase progression. 
Additionally, we show that Orc1 depletion in zebrafish is 
sufficient to markedly reduce body size during rapid embryonic 
growth. Our data suggest a model in which ORC1 mutations 
impair replication licensing, slowing cell cycle progression and 
consequently impeding growth during development, particularly 
at times of rapid proliferation. These findings establish a novel 
mechanism for the pathogenesis of microcephalic dwarfism 
and show a surprising but important developmental impact of 
impaired origin licensing.
Severely impaired growth beginning from early fetal life is the defining 
feature of microcephalic primordial dwarfism, a group of disorders 
with autosomal recessive inheritance. The group encompasses 
several distinct disease entities, including Seckel syndrome1, micro-
cephalic osteodysplastic primordial dwarfism type II (MOPD II)2  
and Meier-Gorlin syndrome (MGS)3, which share common features 
of intrauterine growth retardation, severe postnatal short stature 
and marked microcephaly. Three genes have been implicated in 
Seckel syndrome and MOPD II4–7; to date, no gene has been identi-
fied for MGS. Mutations in ATR (the ataxia-telangiectasia and Rad3-
related gene), which encodes a DNA damage response kinase, have 
been found in related families with Seckel syndrome4. Mutations in 
PCNT have been identified in MOPD II and in individuals originally 
classified as having Seckel syndrome5,6,8. PCNT encodes pericen-
trin, a core centrosomal protein that facilitates nucleation of the 
mitotic spindle9. PCNT-deficient cells from affected individuals 
also show impaired ATR-dependent checkpoint arrest, connecting 
the centrosome with DNA damage-response signaling5,10. Recently, 
mutation of CENPJ, another centrosomal gene (originally identi-
fied as causing primary microcephaly), has been reported to cause 
Seckel syndrome7.
To identify further genes regulating human growth, we performed 
SNP array genome-wide homozygosity mapping on nine members 
of a consanguineous Saudi-Arabian family with two children who 
had microcephalic primordial dwarfism. We identified a single large 
homozygous region on chromosome 1p32 which was refined by 
microsatellite genotyping to a 15.6-cM region containing 105 anno-
tated genes (Supplementary Figs. 1 and 2). Screening of candidate 
genes encoding DNA damage response or centrosomal proteins 
(PIK3R3, RAD54L, KIF2C and STIL) did not identify pathogenic 
mutations. We then evaluated ORC1 as a candidate gene, in part 
because the encoded protein, ORC1, regulates centrosome dupli-
cation11. Sequencing the 16 coding exons of ORC1 in the affected 
siblings revealed a homozygous A>G transition (c.314A>G) in 
exon 4 generating a non-conservative amino acid substitution 
(p.Glu127Gly). Screening of 204 additional individuals with micro-
cephalic primordial dwarfism identified a further three families 
with biallelic missense mutations in ORC1. All mutations segregated 
appropriately in the respective families for an autosomal recessive 
disorder and were not present in 380 controls (Table 1). The major-
ity of the mutations, including a recurrent mutation resulting in 
p.Arg105Gln, occurred within conserved residues of the N-terminal 
BAH domain (Supplementary Fig. 1), a protein-protein interaction 
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domain implicated in ORC1 chromatin binding12. All individuals 
with ORC1 mutations had very marked growth retardation (−6.5 
standard deviations (s.d.) from the age-related normal population 
mean with proportionate microcephaly (−6.9 s.d.) and had received 
diagnoses of MOPD, Seckel syndrome or unspecified microcephalic 
dwarfism (Table 1 and Supplementary Fig. 3).
ORC1 is a component of the origin recognition complex (ORC), 
which encompasses six subunits (ORC1–ORC6). ORC binds to rep-
lication origins, licensing them for the initiation of replication13. The 
assembled ORC complex recruits CDC6 and CDT1 and promotes 
MCM2–MCM7 loading, generating the pre-replicative complex (pre-
RC)14. ORC assembly therefore defines where replication can begin.
To assess the cellular consequences of ORC1 mutations, we estab-
lished a lymphoblastoid cell line (LBL), ORC1-P1, from subject 1 
(p.Glu127Gly) and a skin fibroblast line, ORC1-P4, from subject 4 
(p.Arg105Gln). We also generated a telomerase-immortalized deriva-
tive (ORC1-P4 hTERT). Immunoblotting of ORC1-P1 cells using two 
ORC1 antibodies (Fig. 1a) revealed substantially reduced levels of 
ORC1 in comparison to control cells, both in soluble and insoluble 
fractions (the latter containing chromatin-bound proteins). Parental 
lines had partially reduced chromatin-bound ORC1 (Fig. 1b). 
Additionally, ORC1 was dramatically reduced in chromatin-enriched 
fractions generated by micrococcal nuclease digestion (Fig. 1c). 
Additional pre-RC complex components, ORC2 and MCM2, were 
also reduced in the chromatin-enriched fractions, showing impaired 
pre-RC complex assembly on chromatin. Although immunoblotting 
of ORC1-P4 fibroblasts showed normal ORC1 protein levels (Fig. 1d), 
reduced chromatin-bound ORC1 and ORC2 were evident in 
 chromatin-enriched insoluble extracts. ORC1-P1 has biallelic muta-
tions in the BAH domain, and reduced protein stability in this line is 
consistent with a previous mutagenesis study on the BAH domain12. 
Importantly, pre-RC assembly was diminished in both cell lines irre-
spective of protein stability.
We next assessed whether reduced pre-RC complex formation 
impairs licensing capacity using a previously described assay that 
monitors the replication of Epstein-Barr virus (EBV) episomes from 
a viral replication origin that requires cellular ORC for licensing15. 
Following transfection of the episome into hTERT immortalized 
fibroblasts and incubation to allow one population doubling, we 
extracted episomal DNA and examined it by DNA hybridization 
with or without DpnI digestion (which specifically degrades unrep-
licated episomes). Notably, EBV replication was severely reduced in 
Table 1 Clinical summary of the individuals with ORC1 mutations
Subject
Family 
Country of origin Sex
Alteration  
(mutation)
Gestationa/wgtb  
(s.d.)
Postnatal  
morphometric detailsc  
Age  
Height  
Weight  
OFC Intellect Facial features
Other notable clinical 
history Skeletal analysis
P1 Family 1  
Saudi Arabia  
(consanguineous)
M p.Glu127Gly 
(c.380A>G)
40/2.64 (−1.9) 4.5
85.5 (−4.5)
9.6 (−5.9)
42 (−7.1)
Normal Small chin, mildly  
small ears, full lips.
46XY. Mild, nonspecific 
icythyosis. Suboptimal 
growth hormone stimula-
tion test. Normal IGF1. 
No response GH therapy.
–
P2 Family 1 F p.Glu127Gly 
(c.380A>G)
39/2.18 (−2.5) 0.66
52 (−7.6)
3.1 (−9.3)
36 (−7.6)
Normal Small anterior 
 fontanelle, relatively 
small ears.
46XX. Gastro-oesophageal 
reflux. Normal brain MRI.
–
P3 Family 2  
Syria/USA  
(consanguineous)
F p.Phe89Ser 
(c.266T>C)
40/1.58 (−4.5) 4.5
73 (−7.6)
5.9 (−11)
38.5 (−11)
Normal Mild micrognathia  
small ears, mild  
synophrys, full lips.
Bronchomalacia.  
 Gastro-oesophageal  
reflux. Craniosynostosis 
surgery.
Hyper-extended 
dislocated knees 
at birth. Tibia  
posteriorly  
dislocated and  
surgically  
corrected, patella 
present.
P4 Family 3  
USA
F p.Arg105Gln,
p.Arg720Gln 
(c.314G>A, 
c.2159G>A)
36/1.46 (−3.2) 7.1
94 (−5.3)
10.9 (−6.6)
46.2 (−5.4)
Normal Normally shaped  
ears with small  
lobules, narrow 
 auricular canals,  
normal teeth,  
bifid uvula, full lips  
No micrognathia,  
nose slightly  
prominent.
46XX. Normal sister 
chromatid exchange  
analysis. Severe 
 conductive hearing  
loss. High-pitched  
voice. Normal muscle 
 biopsy, metabolic  
screen, endocrine  
screen, normal brain  
MRI.
Skeletal survey 
mildly gracile long 
bones, minimal 
metaphyseal 
widening, some 
undertubulation in 
the midshaft for 
some long bones. 
Delayed bone age. 
Patella present.
P5 Family 4  
UK
M p.Arg105Gln 
(c.314G>A)
28/1.00 (−0.6) 13
102.9 (−6.6)
18.4 (−6.1)
43.5 (−7.3)
Moderate 
learning 
difficulty
Normal or large ear  
size, short philtrum, 
normal teeth,  
full lips.
Lobectomy for lobar 
emphysema. Severe  
prematurity,  
consequently associated  
with intraventricular 
hemorrhage resulting  
in left hemiplegia.
Slender long 
bones, cupped 
 distal metaphyses 
of metacarpals, 
short fourth  
metacarpal.  
Patella present.
GH, growth hormone; MRI, magnetic resonance imaging.
aGestation in weeks. bWeight in kilograms. cAge in years, height in centimeters, weight in kilograms, OFC in centimeters.
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ORC1-P4 hTERT cells in contrast to the strong band of replicated 
episomal DNA in control cells (Fig. 2a–c and Supplementary Fig. 4). 
These results strongly suggest that ORC1-P4 fails to initiate replication 
from EBV oriP (origin-containing plasmid) origin.
We used a complementary approach to examine replication 
licensing in ORC1-P1 LBLs. Although new origin licensing is pre-
vented in the S and G2 phases, nuclei in binucleate cells can undergo 
re-replication when cytokinesis is abrogated using cytochalasin B16. 
We reasoned that a diminished capacity to license origins might 
impair such DNA re-replication in binucleate cells. Following cyto-
cholasin B treatment, we pulse labeled control and ORC1-P1 LBLs 
with BrdU and assessed its incorporation into binucleates (>4n DNA 
content) by fluorescence-activated cell sorting (FACS) (Fig. 2d). 
ORC1-P1 cells showed reduced BrdU incorporation in binucleates 
compared to control cells (Fig. 2d,e). These two approaches strongly 
suggest that the reduced pre-RC assembly observed by analysis of 
chromatin-bound ORC complex formation manifests as a reduced 
capacity to activate replication origins.
Only a fraction of licensed pre-RC complexes are utilized during 
replication. Thus, although ORC1 is essential, it is likely that markedly 
reduced ORC1 function may suffice for growth. However, because 
origin reutilization in the S phase is prevented13, we considered 
that reduced licensing capacity might impair the rate of S-phase 
 progression. Although the cultured ORC1 cells from the affected 
 subjects grew well, we considered that subtle changes in cell cycle 
 progression could have a developmental impact. We therefore 
 examined the time taken for control and ORC1-P1 LBLs to progress 
through S phase following pulse labeling with BrdU (Fig. 3a,b). We 
monitored the rate of loss of early S-phase cells (identified by their 
BrdU and DNA content) to determine the speed of S-phase progres-
sion (Fig. 3b). ORC-P1 cells progressed more slowly through S phase 
 compared to control LBLs (Fig. 3a,b).
To confirm and extend this finding, we used sucrose gradient 
sedimentation to monitor the size of replication intermediates 
following pulse labeling with [3H]-TdR. Following a 15-min 
pulse of [3H]-TdR, the DNA sedimentation profile was similar for 
control and ORC-P1 LBLs (Fig. 3c). However, following 60 min of 
growth in [3H]-TdR, markedly less labeled DNA from ORC1-P1 
LBLs had moved to a higher molecular weight size compared to 
control LBLs. This and the previous experiment have two possible 
explanations: a reduced rate of fork progression from multiple 
 origins or reduced origin usage (see Fig. 3d legend for an explana-
tion). The latter explanation is consistent with the described defect 
in origin licensing.
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As further confirmation, we used an immunofluorescence 
approach to examine S-phase progression in ORC1-P4 hTERT 
fibroblasts. We used BrdU pulse labeling and pan-nuclear ?H2AX 
 immunostaining to distinguish cells that are actively replicating 
from those that have progressed through S phase (see Fig. 3e 
 legend for details). This approach showed that ORC1-P4 hTERT 
fibroblasts also progress slowly through S phase (Fig. 3e). For all 
these approaches, transfection with exogenous DNA slowed S-phase 
progression, precluding examination of complementation by ORC1 
complementary DNA expression. In summary, these combined 
approaches provide strong evidence that ORC1 deficiency impairs 
the rate of S-phase progression, a previously unknown phenotype 
conferred by ORC1 deficiency.
Pre-RC complex assembly starts upon G1-phase entry, and a 
‘licensing checkpoint’ acts to preclude S-phase entry until a critical 
level of licensed origins assemble17,18. Therefore, we examined whether 
ORC1 deficiency prolongs the G1 phase. We synchronized primary 
fibroblasts in G0 by serum starvation, and we promoted G1 phase entry 
by serum addition. We added BrdU after serum addition to monitor 
S-phase entry by immunofluorescence. ORC1-P4 fibroblasts showed 
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substantially delayed S-phase entry compared to control fibroblasts 
(Fig. 4a). Small interfering RNA (siRNA) knockdown and comple-
mentation analysis using hTERT fibroblasts confirmed these findings 
(Fig. 4b,c). Finally, we also examined chromosome aberrations in 
ORC1-P1 LBLs because chromosome instability is a feature of many 
disorders with impaired DNA metabolism. We observed a normal 
frequency of chromosome aberrations (Fig. 4 legend). In summary, 
these data show that ORC1 deficiency in affected individuals delays 
S-phase entry, thereby prolonging the G1 phase, consistent with previ-
ous analysis of an ORC2-deficient cancer cell line19.
Previous developmental studies have not examined the conse-
quence of reduced ORC function on organism growth. To examine 
whether ORC1 deficiency could specifically reduce overall body size, 
we established a zebrafish morphant model. Injecting morpholino 
oligonucleotides targeting orc1 into one-cell-stage embryos substan-
tially reduced embryo size at 5 days after fertilization (Fig. 5a,b). 
Over 80% of injected embryos were structurally normal and viable 
with a general reduction in size of all tissues (Fig. 5). The remaining 
embryos displayed a ‘severe’ phenotype with abnormal body curvature 
and reduced viability (Fig. 5b,c), and phenotype correlated with the 
degree of orc1 transcript-level depletion (Fig. 5a). Similarities to a 
lethal amorphic mcm5 mutant20 led us to also deplete mcm5, and we 
found that these mcm5 morphants had an identical phenotype to our 
viable ‘dwarf ’ Orc1 zebrafish and exhibited similar levels of growth 
retardation (Fig. 5d,e). The finding of a similar phenotype between 
Mcm5- and Orc1-depleted zebrafish suggests that the phenotype 
might be a direct consequence of impaired origin licensing rather than 
an indirect consequence of any additional function of Orc1 distinct 
from its role in origin licensing.
Collectively, our cellular and developmental studies implicate 
impaired origin licensing as a cause of microcephalic dwarfism. We 
establish that reduced origin licensing in ORC1 cells is associated 
with alterations in cell-cycle kinetics with a prolonged G1 phase and 
delayed S-phase entry and S-phase progression. Although redundancy 
in origin usage allows efficient growth in cell culture, Orc1 reduction 
could be developmentally important. Cell-cycle timings vary markedly 
during development, with some stages being rapid. For example, in 
early neurogenesis, cell cycle length (in neural progenitors) is only 
8 h21. Furthermore, neuronal stem cells have a markedly truncated G1 
phase in which impaired pre-RC assembly could become rate limit-
ing. As the result of prolonged cell cycle times, even small changes in 
the number of cell divisions of progenitor and stem cells could have 
dramatic effects on eventual tissue and organ size22.
Given that defects in origin licensing causes primordial dwarfism 
(Supplementary Fig. 5), we screened ORC2–ORC6 in our general 
cohort of individuals with microcephalic dwarfism but did not iden-
tify any mutations. However, based on some potential overlapping fea-
tures of the individuals with MGS with ORC1 mutations (for example, 
subject 3; P3 Table 1), we screened a specific cohort of individuals 
with MGS and identified further mutations in ORC1 as well as in addi-
tional licensing proteins. This work is described in the accompanying 
paper23. A summary of the features of individuals with MGS with 
ORC1 mutations is shown here (Supplementary Table 1) to allow 
direction comparison. Based on these two papers, we conclude that 
ORC1 mutations cause a broad spectrum of phenotypes that includes 
MGS and cases of microcephalic dwarfism.
URLs. Alohomora, http://gmc.mdc-berlin.de/alohomora/; Pedcheck, 
http://watson.hgen.pitt.edu/register/docs/pedcheck.html; MERLIN, 
http://www.sph.umich.edu/csg/abecasis/Merlin; Allegro, http://www.
decode.com/software/.
METHODS
Methods and any associated references are available in the online 
 version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. The data from this study are deposited in the RefSeq 
database under the following accession codes: ORC1, NM_004153.3 
and orc1, NM_199933.1.
Note: Supplementary information is available on the Nature Genetics website.
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Figure 5 Depletion of Orc1 causes dwarfism in zebrafish. (a) Schematic 
of orc1 zebrafish protein and gene intron-exon structure. Red bars are the 
position of morpholino oligonucleotide (MO) target sites and the arrows 
are PCR primers. RT-PCR of orc1 MO from 3 days post fertilization (dpf) 
zebrafish embryos sorted according to phenotypic categories; WT, wild-type 
uninjected embryos. (b) Injection of splice-site targeted MOs to orc1 caused 
marked reduction in body size compared to standard control embryos or 
uninjected wild-type zebrafish. ‘Dwarf’ orc1 zebrafish were globally reduced 
in size and essentially otherwise normal aside from some subtle craniofacial 
features (hypoplasia of jaw cartilage, reduction in number or fusion of 
otoliths and smaller eye size). Severe embryos additionally had altered body 
curvature and decreased viability. (c) Quantification of phenotypes of MO-
injected zebrafish. We defined categories with respect to zebrafish size: 
short, less than −1 s.d.; dwarf less than −2 s.d.; severe, less than −3 s.d. 
with additional body curvature. We defined normal as −1 to 1 s.d. and long 
as >1 s.d. (d) Body surface area of zebrafish injected with orc1, mcm5 or 
control MOs expressed as s.d. relative to uninjected wild-type (AB) zebrafish 
embryos from the same matings. P < 0.001 for orc1-sp, orc1-atg or  
mcm5 MO versus control MO. Error bars, s.e.m. (n = 23 for control;  
n = 41 for orc1-sp; n = 66 for orc1-atg; and n = 65 for mcm5 MOs).  
orc1-sp, pooled splice-site targeted orc1 Mos; orc1-atg; translational 
blocking orc MO. (e) mcm5 MO zebrafish (5 dpf) also have reduced body 
size and are morphologically similar to orc1 MO zebrafish. Body surface 
area is significantly reduced (P < 0.001 mcm5 versus control MO). 
Quantification of mcm5 MO phenotype, see c,d.
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ONLINE METHODS
Research subjects. Genomic DNA was isolated from peripheral blood from 
the affected children and their family members. All individuals screened 
in the study fulfilled the inclusion criteria of head circumference less than 
−4 s.d. and height less than −4 s.d and included individuals with diagnoses of 
Seckel syndrome and MOPD as well as unspecified microcephalic dwarfism. 
Informed consent was obtained from all participating families, and the stud-
ies were approved by the Scottish Multicentre Research Ethics Committee 
(04:MRE00/19), the University of Sussex School of Life Sciences Research 
Governance Committee or the University of Texas Southwestern Medical 
Center at Dallas (IRB #032008-066). Permission to publish photographs 
was obtained.
Clinical features of individuals with microcephalic primordial dwarfism 
with mutations in ORC1. The average height of the affected subjects was 
−6.5 s.d. ? 1.7 s.d. and the average head circumference was −6.9 s.d. ? 1.0 s.d. 
All affected subjects were referred with diagnoses of microcephalic osteodys-
plastic primordial dwarfism (MOPD), Seckel syndrome or unspecified micro-
cephalic dwarfism. Subsequently, we also found ORC1 mutations in a cohort 
of individuals with a prior diagnosis of Meier-Gorlin syndrome (MGS), and 
retrospective assessment suggests some similarities between individuals with 
MGS and the individuals described here. First, ear size was reduced in several 
of our subjects (for example, individual P1; Supplementary Fig. 3), though 
to a lesser extent than that generally associated with MGS. Additionally, indi-
viduals P3 and P5 had a malformation also described in individuals with MGS 
in the accompanying paper (Supplementary Table 1; genu recurvatum and 
congenital lobar emphysema, respectively).
Mutation detection. Primers were designed using the ExonPrimer tool in the 
UCSC Genome Browser to amplify coding exons. Purified PCR amplification 
products were sequenced using dye-terminator chemistry and electrophoresed 
on an ABI 3730 capillary sequencer (Applied Biosystems). Mutation analysis 
was performed using Mutation Surveyor (Softgenetics). Anonymized control 
samples were screened by sequencing. Sequencing primers are detailed in 
Supplementary Table 2.
Genetic mapping. Genome-wide genotyping was performed by AROS 
Applied Biotechnology (Denmark) using Affymetrix Human Mapping SNP 
5.0 GeneChips. SNP genotypes were analyzed using Alohomora, Pedcheck and 
MERLIN, and multipoint linkage analysis was performed with Allegro (see 
URLs) under a model of autosomal recessive inheritance with full penetrance 
and using a disease allele frequency estimated at 1 in 1,000. DeCODE genetic 
map distances and Affymetrix SNP allele frequencies were used. The region 
of homozygosity on chromosome 1 was confirmed through high-resolution 
haplotype analysis using microsatellite markers.
Bioinformatics. Genetic locations are based on NCBI genome assembly build 36. 
Sequence alignments were performed by ClustalW.
Vector construction. The coding sequence of ORC1 from the open read-
ing frame shuttle clone IOH9757 (ImaGene) was cloned into an N-terminal 
T7 epitope–tagged mammalian expression vector using Gateway cloning 
(Invitrogen).
Cell culture. EBV-transformed control (GM2188), ORC1-P1 and parental 
LBLs (ORC1-M; ORC1-F) were grown in Roswell Park Memorial Institute 
(RPMI) medium supplemented with 15% fetal calf serum (FCS), penicillin 
and streptomycin. Primary human control fibroblasts (1BR.3), ORC1-P4 fibro-
blasts and hTERT derivatives (WT: 1BRhTERT; ORC1-P4hTERT) were grown 
in minimal essential medium (MEM) with 15% FCS, 1% non-essential amino 
acids (NEAA) and 1% antibiotics. For synchronization, fibroblasts were serum 
starved for 3–4 days in MEM containing 0.5% (primary) or 0.1% (hTERT) 
FCS to promote G0. Cells were released into the G1 phase by addition of FCS-
containing MEM. We added 10 ?M BrdU (Becton Dickinson) or 20 ?M CldU 
(MP Biomedicals) to identify S-phase cells.
Antibodies. ORC1 antibodies raised against the N (N17) or C terminus (H80), 
ORC2 (H300), MCM2 (N19), CDT11 (H300) and HP1 (FL191) were from 
Santa Cruz Biotechnology. KAP1 (Ab10484), HDAC1 (Ab19845) and Histone 
H3 (Y173) were from Abcam.
Chromatin extraction. Cells were lysed for 1 hour in buffer A (50 mM 
Tris-HCl, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 25 mM NaF, 25 mM 
?-glycerolphosphate, 0.1 mM NaOrthovanadate, 0.2% Triton X-100, 0.3%  
NP-40, plus protease inhibitor cocktail (Roche)) at 4 °C and pelleted. The 
insoluble pellet was re-suspended in buffer A containing 300 mM NaCl and 
sonicated for 15 min in a sonicating waterbath. For micrococcal nuclease 
(MNase), cells were extracted as above but the insoluble pellet was subjected 
to increasing MNase digestion. For C1, digestion was 10 U/ml MNase for 
10 min at 37 °C. For C2, the pellet from C1 was digested with 100 U/ml MNase 
for 45 min at 37 °C and then an equal volume of solubilization buffer was 
added (2% NP-40, 2% Triton X-100, 600mM NaCl) before sonication.
Fluorescence-activated cell sorting analysis. BrdU-labeled cells were fixed 
in 70% ethanol (−20 °C), treated with 2 M HCl in PBS for 20 min, washed 
in PBS/1% FCS, incubated in 0.1 M Na-tetraborate for 2 min, re-washed in 
PBS/1% FCS and incubated with fluorescein isothiocyanate (FITC)-conjugated 
monoclonal anti-BrdU (Becton Dickinson). Cells were counterstained with 
10 ?g/ml propidium iodide with 0.5 mg/ml RNase in PBS for 30 min. 
Cytocholasin B treatment was 0.75 ?g/ml for 24 h.
Nascent DNA sucrose gradient. Cells were pulse labeled with [3H]-thymidine 
(0.1 millicurie (mCi)) as indicated, harvested into PBS containing 0.17 M 
EDTA and then irradiated with 20 Gray (Gy) to minimize DNA entanglement. 
Cells were laid onto a layer of lysis buffer (2% SDS, 0.02 M EDTA) on a 2.5 ml 
5–20% alkaline sucrose gradient (5–20% sucrose, 0.1M NaOH, 0.1 M NaCl) 
and ultracentrifuged (Beckman XL-90) at ravg 139,500 (141,000 g) for 70 min. 
Gradient fractions (100 ?l) were collected onto a 3MM filter paper strip, fixed 
with 70% ethanol, washed in 5% TCA and then ethanol before quantification 
by liquid scintillation counting.
DNA blotting. We transfected 1 × 107 cells with the EBNA-containing plasmid 
p294(oriP) using Metafectene (Biontex). Plasmid DNA was isolated after one 
population doubling at the time indicated using the modified Hirt extrac-
tion procedure. Plasmid DNA was linearized with BamHI and half was also 
digested with DpnI. DNA was cleaned using MinElute columns (QIAGEN) 
and electrophoresed in 0.7% agarose in the absence of ethidium bromide. DNA 
was blotted onto a Hybond H+ membrane and probed with random primed 
?-dCTP32 labeled p294(oriP) (Rediprime II, GE Healthcare).
Small interfering RNA. Control ON-TARGETplus Control pool (Thermo 
Scientific Dharmacon) and ORC1Stealth (Invitrogen) siRNA were 
used as instructed by the manufacturers. The primers are detailed in 
Supplementary Table 2.
Zebrafish. orc1 and mcm5 were knocked down in zebrafish using sequence-
specific morpholinos (Gene Tools). For all morpholinos used, a total of 
1.5 nl of 0.95 nM/?l morpholino was microinjected into one- cell-stage 
embryos obtained from natural spawning of wild-type (AB) zebrafish lines. 
Primers are detailed in Supplementary Table 2. Live zebrafish were imaged 
on a Leica MZFL III stereo microscope, and body surface area was calculated 
using IPLab software (Biovision).
Statistics. Statistical testing was performed using the Student’s t-test.
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Identification of the First ATRIP–Deficient Patient and
Novel Mutations in ATR Define a Clinical Spectrum for
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Abstract
A homozygous mutational change in the Ataxia-Telangiectasia and RAD3 related (ATR) gene was previously reported in two
related families displaying Seckel Syndrome (SS). Here, we provide the first identification of a Seckel Syndrome patient with
mutations in ATRIP, the gene encoding ATR–Interacting Protein (ATRIP), the partner protein of ATR required for ATR stability
and recruitment to the site of DNA damage. The patient has compound heterozygous mutations in ATRIP resulting in
reduced ATRIP and ATR expression. A nonsense mutational change in one ATRIP allele results in a C-terminal truncated
protein, which impairs ATR–ATRIP interaction; the other allele is abnormally spliced. We additionally describe two further
unrelated patients native to the UK with the same novel, heterozygous mutations in ATR, which cause dramatically reduced
ATR expression. All patient-derived cells showed defective DNA damage responses that can be attributed to impaired ATR–
ATRIP function. Seckel Syndrome is characterised by microcephaly and growth delay, features also displayed by several
related disorders including Majewski (microcephalic) osteodysplastic primordial dwarfism (MOPD) type II and Meier-Gorlin
Syndrome (MGS). The identification of an ATRIP–deficient patient provides a novel genetic defect for Seckel Syndrome.
Coupled with the identification of further ATR–deficient patients, our findings allow a spectrum of clinical features that can
be ascribed to the ATR–ATRIP deficient sub-class of Seckel Syndrome. ATR–ATRIP patients are characterised by extremely
severe microcephaly and growth delay, microtia (small ears), micrognathia (small and receding chin), and dental crowding.
While aberrant bone development was mild in the original ATR–SS patient, some of the patients described here display
skeletal abnormalities including, in one patient, small patellae, a feature characteristically observed in Meier-Gorlin
Syndrome. Collectively, our analysis exposes an overlapping clinical manifestation between the disorders but allows an
expanded spectrum of clinical features for ATR–ATRIP Seckel Syndrome to be defined.
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Introduction
Seckel Syndrome (SS) (OMIM 216000) is an autosomal
recessive disorder characterised by marked microcephaly, intra-
uterine and post-natal growth retardation, developmental delay
and characteristic facial features, encompassing micrognathia
(small and receding chin), receding forehead and pronounced
nose [1]. Majewski (microcephalic) osteodysplastic primordial
dwarfism (MOPD) type II and Meier-Gorlin Syndrome (MGS)
also display microcephaly and primordial dwarfism [2,3]. How-
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ever, each of these disorders display an additional spectrum of
features conferring clinical distinction. Despite this, on an
individual basis, assigning patients to a specific classification is
difficult. Additionally, primary microcephaly represents a disorder
displaying pronounced microcephaly without marked impact on
growth [4]. Five loci conferring SS have been described with four
genes identified [5,6]. The first causal genetic defect identified for
SS was the Ataxia-Telangiectasia and RAD3 related (ATR) gene [7]. A
homozygous mutation in ATR was identified in two related SS
families and cell-based studies provided strong evidence for an
impact on ATR function in patient cell lines. This sub-class of SS
was designated ATR–SS. More recently, mutations in CTIP were
identified in a SS patient as well as in a family described as
displaying Jawad Syndrome [8]. Additionally, mutations in
CENPJ and CEP152, two centrosomal proteins, have been
described in SS patients, although mutations in these genes more
frequently confer primary microcephaly [9,10]. Mutations in
PCNT, which encodes a centrosomal protein, and ORC1L, a
component of the original licensing complex, were reported in
patients originally classified as SS although in both cases
retrospective analysis revealed that such mutations more frequent-
ly cause MOPD type II or MGS, respectively, highlighting the
diagnostic challenge faced in the clinic [11–15]. These studies
demonstrate that evaluation of multiple patients is required to
provide insight into the spectrum of clinical features conferred by
specific gene defects, which ultimately aids an understanding of the
role of the defective protein during development. To date all
ATR–SS patients belong to one of two related families, which
harbour the identical homozygous mutation in ATR, thereby
limiting the characterisation of the clinical phenotype conferred by
ATR deficiency. Furthermore, no patients deficient in ATR
interacting protein, ATRIP, which is required for ATR stability,
have hitherto been described.
ATR, like the related Ataxia-Telangiectasia mutated (ATM)
protein, is a phosphoinositol-3 kinase (PI3)-like kinase that
functions at the centre of a signal transduction network activated
by DNA damage, and most importantly, by replication fork
stalling [16]. ATR and ATM share phosphorylation targets but
whilst ATM is activated by DNA double strand breaks (DSBs) that
arise, for example, following exposure to ionising radiation (IR),
ATR is activated by single stranded (ss) regions of DNA that arise
following replication fork stalling or exposure to agents that induce
bulky DNA adducts [17,18]. Importantly, since replication fork
stalling occurs during most cycles of replication, ATR is essential.
ATM, in contrast, is non-essential presumably because endoge-
nous DSBs arise infrequently. ATR forms a stable complex with
ATR–interacting protein (ATRIP), which is required for ATR
stability [19]. Further, ATRIP is required for ATR localisation to
ssDNA regions and hence for ATR activation. Consequently, in a
range of organisms loss of ATRIP or its homologue, phenocopies
ATR deficiency [17,20–22]. Although ATM and ATR share
overlapping substrates, ATR specifically phosphorylates Chk1
whilst ATM phosphorylates the related kinase, Chk2. The major
functions of ATR are to activate cell cycle checkpoint arrest,
stabilise stalled replication forks and promote replication fork
restart, which is achieved through its ability to phosphorylate a
range of substrates including p53 and H2AX [18,23,24].
Interestingly, in the context of SS, CtIP promotes DNA end
resection, which leads to ss DNA formation, the lesion activating
ATR. Hence, CtIP functions in a mechanism leading to ATR
activation. It is noteworthy that cells derived from PCNT-mutated
MOPD type II patients are also defective in ATR–dependent G2/
M checkpoint arrest although upstream steps in the ATR–
signalling pathway are activated normally [11]. These findings
suggest that PCNT is required for an important end-point of ATR
function. Additionally, the origin licensing complex, components
of which are mutated in MGS, is required for the initiation of
replication and ORC1L-deficient MGS cell lines display slow S
phase progression [13]. Similarly, ATR promotes S phase
progression by facilitating recovery from replication fork stalling.
Together, these findings demonstrate mechanistic overlap between
ATR, PCNT and ORC1L, which may underlie some clinical
overlap in the disorders conferred by mutations in the genes
encoding these proteins.
Here, we provide the first description of a SS patient with
mutations in ATRIP. Interestingly, the mutational change in one
ATRIP allele causes impaired ATR–ATRIP interaction and our
extensive cellular analysis confirms a deficiency in ATR signalling
and damage responses. Additionally, we describe two further,
unrelated patients with mutations in ATR. The identification and
clinical description of an ATRIP patient and two further ATR
patients provides a more definitive characterisation of the clinical
phenotype conferred by ATR deficiency.
Results
Cells derived from patient CV1720 display a
compromised DNA damage response
Patient CV1720 displayed severe microcephaly, growth delay
and dysmorphic facial features and was classified as a SS patient
(see Table 1 and Figure S1A for details of the clinical features).
Cell line CV1720 is a lymphoblastoid cell line (LBL) derived from
the patient; fibroblasts were not available. Cells from the
previously described ATR–SS (DK0064) patient display impaired
DNA damage responses and phosphorylation of ATR substrates
[7]. To determine whether CV1720 cells are defective in ATR–
dependent G2/M checkpoint arrest, the mitotic index (MI) was
monitored at 2 h following UV exposure, a form of DNA damage
known to activate ATR–dependent checkpoint arrest. Whilst WT
LBLs show a significantly reduced MI following UV exposure
compared to undamaged cells, CV1720 cells showed only a
modest decrease similar to that observed in DK0064 (ATR–SS)
cells (Figure 1A). Cells from the parents of patient CV1720
Author Summary
Seckel Syndrome (SS) is a rare human disorder charac-
terised by small head circumference and delayed growth.
Patients can show additional features including abnormal
bone development, receding chins, sloping foreheads, and
small ears. In 2003, we identified ataxia telangiectasia and
Rad3 related (ATR) as a causal genetic defect in two related
families displaying SS. However, additional patients with
mutations in ATR have not hitherto been identified. Here,
we describe two further patients with novel mutations in
ATR. Additionally, we identify a patient with mutations in
ATRIP, which encodes an interacting partner of ATR,
representing a novel genetic defect causing SS. ATR
functions to promote the ability of cells to recover from
difficulties encountered during replication. We show that
patient-derived cells have reduced ATR and ATRIP protein
levels and defective ATR/ATRIP function. Our identification
of further ATR–ATRIP defective patients and a consider-
ation of their clinical features aids the characterisation and
identification of this form of SS and provides insight into
the role played by the ATR–ATRIP complex during
development.
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(CV1780 and CV1783) displayed normal G2/M checkpoint
arrest.
We have previously observed that cells from other SS patients
display defects in ATR–dependent G2/M checkpoint arrest but
activate upstream steps in the ATR signalling cascade normally
[25]. This is exemplified by cell lines from MOPD type II patients
with mutations in PCNT, which are defective in ATR–dependent
G2/M checkpoint arrest but proficient in ATR phosphorylation
events [11]. Therefore, next, we examined whether CV1720 LBLs
efficiently activate upstream steps in ATR signalling. Since these
assays predominantly reflect the response of replicating phase cells,
we first verified that CV1720 and control LBLs harbour a similar
percentage of S phase cells (Figure S2). Pan-nuclear phosphory-
lation of H2AX (cH2AX) after replication fork stalling represents
an ATR–specific damage response [24]. Strikingly, whilst expo-
sure to 5 mM HU for 2 h resulted in an elevated number of cells
staining positively for cH2AX in WT cells, this was not observed
in either CV1720 or DK0064 (ATR–SS) cells (Figure 1B). We
note that although previous studies have shown that ATM can be
activated and phosphorylate cH2AX at DSBs arising following
HU treatment in the absence of ATR due to enhanced fork
collapse, this was not observed at 2 h post 5 mM HU exposure in
these patient cells most likely due to residual ATR activity and/or
the early times examined [26,27]. Chk1 represents an important
ATR substrate required for G2/M checkpoint arrest. To examine
Chk1 activation, we carried out Western Blotting using p-Chk1
antibodies. Following the same UV exposure conditions (2 h post
5 Jm22) employed to examine G2/M checkpoint arrest, we
Table 1. Clinical features of ATR/ATRIP–deficient patients.
ATRIP–SS ATR–SS 27-4BI 19-8BI
Ethnicity Gujarati-Indian (consanguineous) Pakistani (consanguineous) English English
Birth.
OFC (cm) 27.1 24 (-8SD) 27 24.2
Wgt (Kg) 2.06 1.1 (-3SD) 1.15 0.77
Hgt (cm) NR NR 36 NR
Age. 14 mts 3 yrs 3 mts 9 yrs 20 mts 4.5 yrs
OFC (cm) -9SD -10SD -12SD -10SD -10SD
Wgt (Kg) -5SD -6SD -3.3SD -8SD -7SD
Hgt (cm) -5SD -6.5SD NR -8SD -8SD
Face Micrognathia, receding forehead,
prominent nose.
Micrognathia, receding
forehead, prominent nose.
Micrognathia, prominent
nose, hypoplastic alae
nasi, low set columella,
deep set short palpebral
fissures.
Micrognathia, blepharophimosis,
short palpebral fissures. Prominent
nose; high nasal bridge. High
anterior hairline.
Teeth Dental crowding. Dental crowding and
malocclution.
4 teeth at 20 months. Dental crowding.
Ears Small lobes. Posteriorly rotated with
absent lobes.
Small, round, low set
with poorly formed
antihelix tragus &
antitragus. Absent lobes.
Small ears with absent lobes
Hands Bilateral 5th finger clinodactyly. Multiple ivory epiphysis. Small, tapering fingers. Bilateral 5th finger clinodactyly. 5th
metacarpels appear short. Blue
colouration to both thenar eminence.
Skeletal Survey Delayed bone age (wrist & hips),
symmetric dwarfism.
Microcrania with fuse sutures.
Mild thoracic kyphosis. Ribs
angulated posteriorly. Narrow
iliac blades, cox valga and minor
subluxation of the hips. No
disslocation of the radial heads
Symmetric dwarfism.
Small patellae. No joint
hypermobility or
kyphoscoliosis.
Symmetric dwarfism. Copper beaten
skull. No ossification of the patellae
(age 4 yrs). Marked hip & shoulder
flexibility. No kyphosis.
Endo-crinology Normal IGF1, TFT, LH, FSH & cortisol. NA NA NA
MRI 14 mts:generalised cerebral atrophy,
normal ventricular systems. Delayed
myelination in the anterior limb of
the internal capsule. Pituitary is
present though of unusual shape
with absent fossa.
NA NA 2 yrs: abnormal gyration in posterior
aspect of the cingulated gyrus
extending into the parietal occipital
region. Hypoplastic corpus collasum.
Other NR Developmental delay.
Walked at 7 yrs.
No abnormal skin
pigmentation.
Small feet with
metatarsus adductus
No abnormal skin pigmentation.
Developmental delay. Sat at 15 mts,
walked at 3 yrs 10 mts. High pitched
voice, asthma, multiple chest infections,
feeding difficulties-reflux (gastrostomy
fed). Multiple liver cysts consistent with
Caroli’s disease found at 17 mts.
NR; not recorded. NA; not assessed.
doi:10.1371/journal.pgen.1002945.t001
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Figure 1. CV1720 cells show impaired ATR–dependent DNA damage responses. A) WT, DK0064 (ATR–SS), CV1720 (patient), CV1780
(patient’s mother) and CV1783 (patient’s father) cells were exposed to 5 Jm22 UV and the mitotic index (MI) assessed 2 h post exposure. A greater
than two fold decrease in mitotic index is observed in WT and both paternal cell lines but not in DK0064 (ATR–SS) or CV1720 (patient) cells. B) Cells
were exposed to 5 mM HU for 2 h and the percentage of p-H2AX (c-H2AX) positive cells assessed by immunofluorescence. Note that HU causes pan
nuclear p-H2AX formation rather than defined foci as observed after exposure to ionising radiation. Thus, the percentage of c-H2AX positive cells was
scored. C) Cells were exposed to UV (5 Jm22) and subjected to Western Blotting (WB) using p-Chk1 (p-Ser317) antibodies at 2 h. Chk1 expression was
shown to be similar in WT and patient cells (lower panel). D) Cells were exposed to 3 mM HU for 2 h and whole cell extracts analysed by WB using
FANCD2 antibodies. The ubiquitylation of FANCD2, detectable by a product with reduced mobility, is diminished in DK0064 (ATR–SS) and CV1720
cells compared to WT cells. E) Cells were exposed to 5 mM HU and examined for the percentage of cells showing.5 53BP1 foci at 2 h post exposure.
53BP1 foci formation is reduced in DK0064 (ATR–SS) and CV1720 cells compared to WT cells. F–I) The indicated cells were processed by WB using
ATRIP and ATR–Deficient Seckel Syndrome Patients
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observed a pronounced p-Chk1 band in WT LBLs but not in
CV1720 cells although Chk1 levels were similar in the two lines
(Figure 1C). These results provide strong evidence that CV1720
show impaired ATR–dependent substrate phosphorylation.
A further ATR–dependent response is mono-ubiquitylation of
FANCD2 following exposure to HU [28]. Mono-ubiquitinated
FANCD2 can be detected by the presence of a slowly migrating
isoform of FANCD2 generated post exposure to 3 mM HU.
Whilst such a product was detected in WT cell extracts, it was
absent in CV1720 and DK0064 (ATR–SS) cell extracts
(Figure 1D). Finally, ATR also regulates the formation of 53BP1
foci following replication fork stalling via a Chk1-dependent
process. We observed a failure to form 53BP1 foci following
exposure to 5 mM HU in CV1720 and DK0064 (ATR–SS) LBLs
in contrast to WT LBLs (Figure 1E), consistent with the
diminished levels of p-Chk1 observed in CV1720 cells.
Collectively, these studies provide strong evidence that CV1720
cells are defective in an upstream step of the ATR–dependent
signalling response defining them as distinct to the majority of
previously characterised SS cell lines, which, though defective in
UV-induced G2/M checkpoint arrest, are proficient in upstream
steps of the ATR signalling response [25].
Reduced ATR and ATRIP protein expression in CV1720
cells
Given the overlapping cellular phenotype between CV1720 and
DK0064 (ATR–SS) cells, we examined CV1720 cells for
expression of ATR and ATRIP protein by Western Blotting.
Strikingly, we observed markedly reduced levels of both ATR and
ATRIP in CV1720 cells (Figure 1F). Since ATRIP stabilises ATR,
this does not distinguish whether the primary defect lies in ATR or
ATRIP and indeed a similar reduced level of ATR and ATRIP
was observed in DK0064 (ATR–SS) cells (Figure 1G). Signifi-
cantly, we observed reduced ATRIP and ATR in both parental
LBLs (CV1780 and CV1783), which was approximately 50% of
the level in WT LBLs (Figure 1G–1I).
Sequencing analysis reveals mutational changes in ATRIP
in CV1720 cells
To examine whether the causal genetic defect in CV1720 lies in
ATR or ATRIP, we carried out sequencing of the two genes. First,
we undertook PCR-based gDNA sequencing of the 47 exons and
neighbouring exon-intron boundaries of the human ATR gene
from CV1720 cells and failed to observe any mutational changes
likely to be of functional significance. Next, we undertook gDNA
sequencing of ATRIP exons and observed a heterozygous
mutational change, c.2278C.T, in exon12 which generated a
stop codon predicting a truncated protein at position arginine 760
(p.Arg760*) (Figure S3). However, no mutational changes in any
other exons were identified although we detected several novel
intronic changes that could potentially impact on splicing (Table
S1). Significantly, the c.2278C.T mutational change was
observed as a heterozygous change in the patient’s mother but
not in the father (Figure S3).
We also performed RT-PCR sequencing of ATRIP cDNA from
CV1720 and both parents. These analyses revealed a low level of a
smeared PCR product following amplification of the 59ATRIP
cDNA region using patient but not control cDNA (data not
shown). Following multiple analyses, we found specifically that
RT-PCR amplification using primers located in exons 1 and 4,
reproducibly yielded a smeared product from CV1720 cDNA with
discrete bands at 458 bp (the expected product size) and 325 bp
whereas only the 458 bp product was observed using cDNA from
WT cells (Figure 2A). Direct sequencing of the gel purified smaller
(325 bp) and full-length (458 bp) RT-PCR products showed that
the small fragment specifically lacked exon 2. Sequencing analysis
of the RT-PCR product of CV1720 cDNA using the same primers
revealed the predicted double sequence with the product lacking
exon 2 being less than 50% of the product containing exon 2
(Figure 2B). It is notable that there were also some PCR products
larger than the full length product although a discrete band was
not evident. In sequencing the RT-PCR product, we observed
some that harboured intron 2 sequences although these repre-
sented a minor product relative to that lacking exon 2.
Collectively, these findings strongly suggested that there could be
mis-splicing in CV1720 cells with loss of exon 2 being the major
product.
To assess this further, qRT-PCR was undertaken using sets of
primers that allow selective amplification of the WT and mutant
products (c.2278C.T mutant as well as the mis-spliced product).
The aim was to determine if the mis-spliced product originated
from the paternal allele and if it impacted upon the transcript
level. Primer pairs, P1 and P3C, located in exons 12 and 13,
respectively, allow selective amplification of the WT (paternal)
c.2278C allele whilst primers P2 and P3C selectively amplify the
mutated (maternal) c. 2278C.T allele (Figure 2C). As expected,
the mutant (c.2278C.T)-allele-specific PCR product (right
columns, red bars) was only detected in the patient and mother
whereas the WT-specific PCR product (left columns, blue bars)
was detected in all samples, demonstrating that the primers
distinguished the two alleles (Figure 2C). The results also showed
that the c.2278C.T and the WT (c.2278C) alleles were expressed
at nearly equal levels (normalised against HPRT1) in the mother
(compare blue and red bars labelled ‘mother’ in Figure 2C),
suggesting that the c.2278C.T ATRIP mRNA is not subject to
nonsense mediated RNA decay (NMD) (Figure 2C).
To evaluate the expression level of the mis-spliced ATRIP
mRNA, we designed primers located at the exon 2/exon 3
boundary (primer P4) and within exon 3 (primer 6C) to allow
selective amplification of the correctly spliced mRNA (Figure 2D);
primers located at the exon 1/exon 3 boundary (primer P5) and
within exon 3 (primer 6C) selectively amplify the mis-spliced
mRNA. Whilst the correctly spliced product was amplified to
similar (although slightly different) extents from father, mother and
patient mRNA (compare the column heights, left panel in
Figure 2D), the mis-spliced product was more abundant in the
patient and father, suggesting that mis-splicing is a consequence of
a mutational change linked to the paternal allele (compare the
column heights, right panel in Figure 2D). Since we observed
nearly equal expression levels of the wild type (c.2278C) and
mutant (c.2278C.T) alleles in the mother (Figure 2C, compare
the right and left panels), we considered that the PCR products
derived from the mother using primers P4/P6C or P5/P6C would
ATRIP or ATR antibodies. MCM2 was used as a loading control. F shows the analysis of a range of protein levels for accurate comparison. CV1720
(patient) cells show markedly reduced ATR and ATRIP protein levels. G shows that both parental lines have approximately half the level of ATR and
ATRIP compared to two WT cell lines. DK0064 (ATR–SS) and CV1720 cells, in contrast, have more dramatically reduced ATR and ATRIP protein levels.
50 ug protein was loaded. WT in all panels was GM2188. Patient, mother and father were as shown in panel A. H and I show the quantification of
ATRIP and ATR protein levels from at least three independent WB experiments.
doi:10.1371/journal.pgen.1002945.g001
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be equally derived from the c.2278C and c.2278C.T alleles,
which have, therefore, been depicted as equal sized contributions
(shown in red or blue in mother columns in Figure 2D). Similarly,
the mutant c.2278C.T allele is likely to be expressed at an equal
level in the patient as in the mother (shown in red in patient
columns in Figure 2D). Based on these assumptions, we estimated
that the normally spliced WT mRNA is reduced to around 1/4 of
the WT level in the patient and to 3/4 in the father (shown in blue
in the left hand panel in Figure 2D). Assuming that the
c.2278C.T allele is fully inactivated (see below), the patient
Figure 2. Identification of mutational changes in ATRIP in CV1720. A) Upper panel shows primer pairs used to distinguish cDNA products
encompassing or lacking exon 2. Lower panel shows RT-PCR products obtained using the primers shown in the upper panel. RT-PCR from patient
CV1720 generated a smeared product with a defined band of 458 bp, as observed in WT cells, and a weaker band of 325 bp. The latter band was not
detected using cDNA from WT cells (MRC5). A similar single 458 bp band was obtained using the same primers with cDNA derived from a distinct
wild type cell line (GM2188; data not shown). (B) Sequencing of the RT-PCR products derived from WT (MRC5) and patient (CV1720) cells. A double
sequence pattern at the exon 2–3 boundary is observed using patient CV1720 cDNA. C) Selective quantitative amplification of the WT or 2278C.T
ATRIP alleles. Primers located in ATRIP exon 12 and 13 were designed to selectively amplify the WT (c.2278C) (P1 and P3C) versus the mutated
(c.2278C.T) (P2 and P3C) alleles. The WT PCR product is shown in blue and the c.2278C.T PCR product in red. The exon 12 mutated allele is only
observed in the patient and mother cDNA whilst the WT allele is observed in the patient, mother and father cDNA although the level is reduced in the
patient and mother. D) qRT-PCR analysis of ATRIP splicing variants from patient CV1720 and parental cells. qRT-PCR analysis of the level of the
normally spliced (encompassing exons 1-2-3) and the aberrantly spliced (Dexon2) ATRIP cDNA in the patient and parent cells. PCR primers were
designed at the exon2-exon3 or exon1-exon3 boundaries to selectively amplify the splicing variants. Transcripts from HPRT1 were used as a
quantification control. The correctly spliced transcript from the paternal allele of the patient (wild type c.2278C, blue fraction in the cumulative bar
labelled, ‘patient’, at the left panel) was estimated to be,25% of the normal level. (E) The mis-spliced paternal allele is subject to nonsense mediated
mRNA decay (NMD). Cycleave-qPCR confirmed that the ATRIP c.2278C.T mutant allele was expressed exclusively in the patient and the mother. The
ATRIP exon12-13 fragment was amplified with PCR primers P7/P8 as shown in the figure. A set of fluorescent probes were used to distinguish the WT
versus c.2278C.T allele (probe1 and probe2, respectively). In the patient, the paternal mRNA transcript level (emerald lines) is low because of NMD
(top left). Puromycin treatment eliminated the NMD and the paternal transcript level returned to the normal level. In all panels WT represented MRC5,
patient was CV1720 and parents were as shown in Figure 1A.
doi:10.1371/journal.pgen.1002945.g002
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therefore has around 25% of ATRIP activity compared to a
normal individual.
The findings above suggested that the mis-spliced mRNA,
which generates an out of frame cDNA, is subject to NMD. To
examine this and substantiate our findings, qRT-PCR was also
carried out using fluorescent cycleave probes with or without
exposure to puromycin, an antibiotic which prevents NMD
(Figure 2E) [29]. Primers (P7 and P8) and fluorescent probes
(probe 1 and 2) were designed to allow amplification of a product
encompassing exon 12–13 that distinguished the maternal (probe
2) from the paternal (probe 1) allele. We confirmed detection of
the c.2278C.T allele exclusively in the patient and mother as
well as the WT allele in all samples (Figure 2E). In the mother,
the wild type (c.2278C) and mutant (c.2278C.T) signals were
detected at equal levels regardless of whether puromycin was
added, indicating that the alleles are equally expressed and are
not subjected to NMD. In patient CV1720, the WT product was
reduced relative to the mutant product in the absence of
puromycin but was at similar levels in the presence of puromycin
(Figure 2E). These findings are consistent with the notion that
the mRNA expressed from the parental allele is aberrantly
spliced and partially subject to NMD. Perhaps surprisingly, we
did not detect any obvious difference of the WT product
following puromycin treatment in the father; however, in this
case, we anticipate a 25% decreased product, which is unlikely to
be detected without an internal control. However, despite this,
there was evidence for abnormal splicing in the paternal cDNA
from analysis of the PCR products spanning exons 1–3
(Figure 2B, 2D).
Finally, to gain insight into the basis underlying mis-splicing, we
sequenced introns 1 and 2 from the patient, mother, and father
and identified a previously unreported mutational change in intron
2, 13 bp from the intron-exon 2 boundary in the patient and
paternal gDNA (Table S1). However, given the modest impact on
splicing we did not attempt to examine whether this represented
the causal mutational change affecting splicing.
Arg760* ATRIP does not promote ATR–dependent G2/M
arrest and reduces ATR–ATRIP interaction
It is likely that ATRIP c.2278C.T causes an impacting
mutational change since the low levels of ATRIP protein (10–
20% WT levels) in CV1720 cells suggest that p.R760* ATRIP is
unstable (given that the mRNA level of this allele is normal). To
substantiate that p.R760* expression impairs the ATR–dependent
response to DNA damage, we examined whether its expression
could complement the G2/M checkpoint defect of CV1720 cells.
We also examined whether p.R760* might exert a dominant
negative impact (since this represented a possible explanation for
the low ATRIP protein level in CV1720 cells). The c.2278C.T
mutational change was introduced into ATRIP cDNA by site
directed mutagenesis. cDNA encoding WT ATRIP and/or R760*
ATRIP was transiently transfected into LBLs and G2/M
checkpoint arrest examined at 2 h post exposure to 5 Jm22 UV.
Consistent with previous findings, WT but not CV1720 cells
showed a G2/M checkpoint arrest (Figure 3A). Whilst transfection
with WT ATRIP cDNA completely rescued the G2/M checkpoint
defect of CV1720 cells, no correction was observed in CV1720
cells following expression of c.2278C.T ATRIP cDNA (encoding
R760* ATRIP). Surprisingly, expression of WT ATRIP cDNA also
corrected the G2/M checkpoint defect in DK0064 (ATR–SS)
cells, which we propose could result from elevated ATRIP
expression causing stabilisation of residual ATR protein, since
ATR–SS cells have low ATR and ATRIP expression. Significant-
ly, c.2278C.T ATRIP cDNA was unable to rescue ATR–SS cells.
Finally expression of c.2278C.T ATRIP cDNA in WT cells did
not affect G2/M checkpoint arrest demonstrating that p.R760*
ATRIP does not exert a dominant negative impact. Collectively,
we conclude that p.R760* ATRIP impacts upon ATRIP function.
Next we examined how loss of the ATRIP C-terminus might
impact upon ATRIP function. Two studies have previously
observed that the C-terminal region of ATRIP is required for
interaction with ATR [21,30]. Falck et al [30] reported that ATR–
ATRIP interaction required the C-terminal 32 amino-acids of
ATRIP (769–791) whilst Ball et al [21] found that interaction was
abolished in a protein that lacked exon 11, which encompasses
amino-acids 658–684. Arg760 lies close to these regions. To
examine whether p.R760* ATRIP can interact with ATR, HA-
tagged WT or c.2278C.T (ATRIP R760*) cDNA was co-
expressed with untagged WT ATR cDNA in HEK293 cells.
Following IP with HA-agarose, the level of co-immunoprecipitated
ATR was assessed by Western Blotting. Although there was a low
level of non-specific ATR binding to the HA beads, the level of
ATR present after HA-R760* ATRIP expression (derived from
c.2278C.T ATRIP cDNA) was substantially lower than after HA-
WT ATRIP expression (Figure 3B left panel). Both WT and
R760* ATRIP were efficiently expressed, however (Figure 3B
right panel). Thus, we conclude that R760* impairs the binding of
ATRIP to ATR.
Identification of further patients with mutations in ATR
In the course of our functional characterisation of cell lines from
SS patients, we examined LBLs derived from two SS patients, 27-
4BI and 19-8BI (see Figure 4A, Figure S4, and Table 1 for clinical
details). Western Blotting revealed that both cell lines displayed
substantially reduced ATR protein whilst showing normal
expression of other DNA damage response components, including
CtIP, TOPBP1 and RAD17 (Figure 4B). 27-4BI also had reduced
ATRIP levels. Additionally, the 27-4BI cell line expressed normal
levels of PCNT, excluding MOPD type II as a potential genetic
diagnosis, since most of these patients exhibit severely reduced
PCNT expression. These findings raised the possibility that the
patients could harbour mutations affecting ATR or ATRIP
expression. Sequencing of ATR cDNA revealed the same
c.3477G.T mutational change in both patients (Figure S5A).
This change causes an amino acid substitution, p.Met1159Ile,
which lies within a conserved UME (NUC010) domain of ATR.
UME domains, and particularly the methionine residue within the
domain, are highly conserved in ATR species, including yeast
although their function is unknown (Figure 4C and 4D).
The second ATR mutation identified was c.6897+464C.
G;p.Val2300Gly fs75*, which, surprisingly, was also present in
both patients. RT-PCR sequencing showed that a 142 bp
sequence, which originated from a repeat region present in intron
40, was inserted at the boundary between exon 40 and 41 in both
patients (Figure S5C). Genomic sequencing revealed the presence
of a single C.G mutation in intron 40, which generates a
preferred splice signal causing insertion of the intron sequence to
the start of exon 41 (Figure S5D for further details). This insertion
causes a frameshift and the generation of a stop codon at c.6978 in
exon 41. Sequencing of ATRIP cDNA in patient 27-4BI failed to
reveal any mutational changes. Thus, our findings provide strong
evidence that mutational changes in ATR underlie the reduced
ATR/ATRIP expression observed in both patients.
To verify that these mutational changes impact upon ATR
function, we examined whether 27-4BI cells could activate UV-
induced ATR–dependent G2/M checkpoint arrest. Significantly,
we observed an inability to activate UV-induced G2/M check-
point arrest in 27-4BI cells similar to that observed in DK0064
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(ATR–SS) cells (Figure 5A) [7]. Checkpoint arrest after exposure
to ionising radiation was activated normally. Additionally, we
examined the phosphorylation of a range of ATR substrates
following exposure to 0.5 mM HU and observed impaired
phosphorylation in both 27-4BI and 19-8BI cells (Figure 5B).
Collectively, these functional data substantiate a deficiency in the
ATR–dependent DNA damage response in LBLs from these two
cases. Thus, we conclude that both patients represent further
ATR–SS patients.
Discussion
Although the first causal defect for SS was identified as ATR in
2003, further patients with mutations in ATR have not been
reported [7]. SS patients are characterised by microcephaly and
growth delay, features also observed in other microcephalic,
primordial dwarfism syndromes including MOPD type II and
MGS. Given that all ATR–SS patients to date share consanguinity,
there are limitations in defining the spectrum of clinical features
conferred by ATR deficiency to support a clinical distinction
between ATR–SS and related disorders such as MOPD type II and
MGS as well as other sub-classes of SS [1–3,31].
Here, we describe the novel identification of a patient mutated
in ATRIP, the binding partner of ATR. Thus, we identify ATRIP
as a new causal gene for SS. The mutational change in one ATRIP
allele lies within a region previously suggested to be required for
interaction with ATR, which is consolidated by our work [21,30].
We demonstrate that the second allele is abnormally spliced causing
a reduction in ATRIP mRNA from that allele. qRT-PCR analysis
suggested that there could be 25% residual WT ATRIP expressed in
the patient cells. Consistent with this, we routinely observed ,10–
20% of WT ATRIP protein in CV1720 cells by Western Blotting,
although the level was variable between preparations. Although not
examined in detail, there appeared to be a correlation between
proliferation status and ATRIP levels, with the levels decreasing as
proliferation slowed. Thus, differences in the proliferative state of
cells at the time of analysis may underlie the apparent difference
betweenWestern Blotting and qRT-PCR analysis. Notwithstanding
some limitations in quantification, the patient clinical features were
marked despite,10–20% residual ATRIP expression. Similarly, in
patient DK0064, residual ATR protein can be readily detected [7].
Thus, we conclude that reduced but detectable levels of ATR/
ATRIP protein can confer a clinical phenotype.
Additionally, we identify two further SS patients with ATR
mutations in two unrelated families native to the UK. Interest-
ingly, despite being unrelated, 27-4BI and 19-8BI carry the same
compound heterozygous mutations, possibly representing founder
mutations in the UK population.
Figure 3. WT ATRIP cDNA but not cDNA encoding p.Arg760* ATRIP complements the G2/M checkpoint defect in CV1720 cells, and
p.Arg760*ATRIP impairs ATR–ATRIP protein interaction. A) Analysis of the G2/M checkpoint defect in CV1720 cells following expression of
ATRIP cDNA. G2/M checkpoint arrest was examined 2 h post exposure to 5 Jm22 UV. As shown in Figure 1A, WT cells showed proficient checkpoint
arrest whilst DK0064 (ATR–SS) and CV1720 (patient) cells are unable to undergo arrest. Expression of WT ATRIP cDNA restored the ability of CV1720
(patient) and DK0064 (ATR–SS) to undergo checkpoint arrest but this was not observed following transfection of cDNA encoding R760* ATRIP.
Significantly, expression of ATRIP R760* did not impair checkpoint arrest in WT cells verifying that it does not exert a dominant negative impact.
Results represent the mean and SD of three experiments. WT cells were GM2188. ATR–SS represents DK0064 and patient, CV1720. B) R760* ATRIP
impairs ATR–ATRIP interaction. Crude lysates were prepared from HEK293T cells and either mock transfected (lane1), transfected with HA-tagged WT
ATRIP cDNA (lane2), or R760* ATRIP cDNA (lane3) (generating p.Arg760* ATRIP protein) together with ATR cDNA. The extracts were
immunoprecipitated with agarose-conjugated rabbit anti-HA-tag antibody (MBL). Interaction with ATR was examined by immunoblotting with
ATR antibodies (left panel). Immunoblotting using the HA-tag (ATRIP; right panel) verified expression of the appropriately sized ATRIP in the samples.
33% of the crude lysate was loaded; IP, immunoprecipitate.
doi:10.1371/journal.pgen.1002945.g003
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All four ATR/ATRIP patients displayed severe microcephaly
and growth delay (Table 1). All patients also displayed microgna-
thia, receding forehead, dental crowding and microtia with small
or absent lobes (Figure 4A). Interestingly, an MRI scan of the
ATRIP–SS patient revealed an abnormally small pituitary with
absent fossa, which could contribute to the delayed growth
observed (Figure S1). In distinction to the original ATR–SS
patient (DK0064), patients 27-4BI and 19-8BI showed more
marked skeletal abnormalities including digital features and
aberrant patellae suggesting that ATR deficiency can have a
detrimental impact on bone development (Table 1, Figure S4)
[32]. Interestingly, aberrant patellae is a clinical feature commonly
exhibited by MGS patients suggestive of a biological overlap
between the ATR checkpoint pathway and the replication
machinery during skeletal development and maintenance. In
keeping with this, characterisation of a mouse model harbouring
the same mutational change identified in the original ATR–SS
patient (DK0064) revealed marked bone abnormalities including
kyphosis and osteoporosis [32]. Our findings suggest that ATR–
ATRIP SS shows more overlap with MGS than previously
recognised (Table 2). However, whereas ATR–ATRIP SS patients
tend to have very marked microcephaly, growth delay, dental
crowding, small ears and less severe skeletal abnormalities, the
spectrum for MGS tends to be less marked microcephaly and
growth delay but a striking impact on skeletal development.
Nonetheless, there does not appear to be an absolute clinical
divide between these two disorders. Significantly, these overlap-
ping clinical features could reflect the fact that both ATR/ATRIP
Figure 4. Patients 27-4BI and 19-8BI have reduced ATR and ATRIP expression and mutations in ATR. A) Photographs of patient included
with informed consent of parent. B) Cell extracts (50 mg) from LBLs derived from WT (IM257), patient 27-4BI or patient 19-8BI were immunoblotted
using the indicated antibodies. Reduced expression of ATR was observed in both patients. 27-4BI also had reduced ATRIP expression. C) Structure of
ATR showing the site of the mutations identified and the UME domain. D) The UME domain is conserved between species and the methionine
residue within this domain is conserved in yeast.
doi:10.1371/journal.pgen.1002945.g004
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and the origin licensing complex play an essential role in
promoting efficient replication and recovery from fork stalling,
which may be vital during developmental stages involving rapid
replication [13].
In summary, we provide the first report of a SS patient with
mutations in ATRIP, defining a further novel genetic defect for this
disorder, and describe two additional patients native to the UK,
with mutations in ATR. The description of multiple ATR–ATRIP
patients allows us to define a spectrum of clinical features conferred
by ATR–ATRIP mutations. The clinical characteristics include
severe microcephaly and growth delay, small or absent ear lobes,
micrognathia and dental crowding. In addition, the novel ATR–
mutated cases described here expand the clinical impact of impaired
ATR–function to include more marked skeletal involvement.
Methods
Ethics Statement
Ethical approval for the research was granted by the School of
Life Sciences Research Governance Committee, University of
Sussex. Informed consent was obtained and clinical investigations
were conducted according to the principles expressed in the
Declaration of Helsinki. Patient material was gathered under
conditions of the Human Tissue Authority (HTA licence number
12119).
Patients and cell lines
CV1720 is a SS patient of Gujarati-Indian origin. Patients 27-
4BI and 19-8BI are English. The clinical features are described in
Figure 5. LBLs from patient 27-4BI and 19-8BI showed impaired ATR–dependent damage responses. A) 27-4BI cells were examined for
their ability to activate G2/M checkpoint arrest at 4 h following exposure to 7 Jm22 UV. In contrast to WT cells (GM2188), no significant arrest was
observed in 27-4BI cells. The checkpoint response to ionizing radiation, which is ATM rather than ATR dependent, was normal. B) LBLs derived from
patients 27-4BI and 19-8BI were examined for their ability to phosphorylate the indicated ATR substrates at 1 h following exposure to 0.5 mM HU. WT
represents IM257. 27-4BI and control LBLs have a similar cell cycle profile demonstrating that the lack of ATR substrate phosphorylation cannot be
attributed to the lack of S phase cells (Figure S2).
doi:10.1371/journal.pgen.1002945.g005
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Table 1. Lymphoblastoid cell lines (LBLs) were derived from blood
following EBV transformation. WT LBLs were GM2188 or
LB197 as indicated. All LBLs were grown in RPMI medium
supplemented with 10% foetal calf serum, penicillin, and
streptomycin. Transfection with ATRIP cDNA was with Genejuice
Transfection Reagent (Novagen, Merck Millipore, UK) following
the manufacturers protocol.
qRT–PCR. Transcript levels of the ATRIP–c.2278C (normal)
and ATRIP–c.2278C.T (p.Arg760*) alleles in LBLs from patient
CV1720, and the parents were determined by the cycleave
quantitative real time PCR (Cycleave-qPCR, TaKaRa Co. Ltd,
Kyoto Japan) as well as standard site specific q-PCR (carried out in
triplicate). Transcripts from the HPRT1 allele were used as a
quantification control. In the Cycleave qPCR, RNaseH sensitive
fluorescent probes that specifically recognize the c.2278C and
c.2278C.T alleles were used for the assay. qPCR results were
analyzed by the DDCTmethod. qPCR primers and probes used for
the assay are listed below. (172F, 59-CTTCACTGCCGAC-
GACCTGG-39; 191R, 59-TTTGCTCGTTCACTGGTCTG-39;
P1, 59-GGGGTCAGCATGCTCATCC-39; P2, 59-GGGGGTC-
AGCATGCTCATCT-39; P3C, 59-ACCTCGGGGTCTTCCA-
CATC-39; P4, 59- -39; P5, 59- -39; P6C, 59- -39; P7, 59-GCC-
TATCGCAGAAGGACAAG-39; P8, 59-GGGTCTTCCACAT-
CGGTTTC-39; probe1 for c.2278C, 59Eclipse-CCCTC(rG)GAT-
39FAM; probe2 for c.2278C, 59Eclipse- GCCCTC(rA)GA-39ROX)
Co-immunoprecipitation. To investigate the interaction of
the ATRIP proteins with ATR, HEK293T cells were transfected
with the HA-tagged ATRIP cDNA expressing plasmids (wild type
and 2278C.T ATRIP) together with ATR cDNA, followed by
24 h incubation. Whole cell lysates were prepared using CelLytic
Nuclear Extraction Kit (Sigma, St. Louis). Co-immunoprecipita-
tion was performed using rabbit anti-HA antibody-conjugated
agarose beads (MBL, Nagoya, Japan). Western blotting was
carried out using ATR or anti-HA (detecting HA-tagged ATRIP)
antibodies. Anti-ATR was N19 (Santa Cruz, Santa Cruz) at 1:200
dilution. Anti-HA-tag antibody, 132-3 (MBL, Nagoya, Japan), was
used at 1:1000 dilution.
Immunofluorescence for analysis of cH2AX and 53BP1
staining
Cells were cytospun onto slides, fixed with 3% formaldehyde for
10 min and permeabilized in 0.5% Triton-X100. After antibody
treatment and staining with 4,6-diamidino-2-phenylindole (DAPI),
coverslips were mounted in Vectashield mounting medium (Vector
Laboratories, Burlingame). Samples were incubated with primary
antibodies for c-H2AX (Millipore, Billerica) or 53BP1 (Bethyl,
Montgomery). Secondary antibodies were from Sigma (St. Louis).
Western blotting
Cells were lysed for one hour in IPLB (50 mM Tris-HCl,
150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 25 mM NaF,
25 mM b-glycerolphosphate, 0.1 mM NaOrthovanadate, 0.2%
Triton X-100, 0.3% NP-40, plus protease inhibitor cocktail
(Roche, Basel) at 4uC, centrifuged at 13,000 rpm for 10 minutes.
The soluble fraction was subjected to SDS-PAGE and transferred
to a nitrocellulose membrane for protein detection.
Antibodies raised against ATR, CHK1 (FL476) and MCM2
(N19) were from Santa Cruz (Santa Cruz). Anti-FANCD2, ATRIP
and phospho-Chk1 (Ser317) antibodies were from Novus (Lit-
tleton), Bethyl (Montgomery), and Cell Signaling (Beverly,
Woburn), respectively.
G2/M checkpoint arrest
Cells were exposed to 5 or 7 Jm22 UV, or 3Gy ionising
radiation and incubated for 2 or 4 hours (as indicated) in complete
medium containing 0.2 ug/ml Colcemid (Invitrogen, Carlsbad),
followed by processing for immunofluorescence as detailed above.
Mitotic cells were detected by a-Histone H3-pSer10 antibodies
(Millipore, Billerica) and cells were counterstained with DAPI.
Table 2. MGS and Seckel syndrome patient phenotypes.
ORC1 - MGS Pre-RC MGS ATR/ATRIP SS
Number of patients 10 25 4
OFC (cm)* 25.4 to 211 SD +1.7 to 25.0 SD 210 to 212 SD
Height (cm)* 24.5 to 29.6 SD 20.4 to 26.4 SD 25 to 28 SD
Weight (kg)* 0.8 to 211 SD 20.3 to 29.9 SD 23.3 to 28 SD
Intellectual disability Ranges from none to mild/moderate None Developmental delay (2/4)
Facial Features Small and abnormal ears (9/10),
micrognathia (5/10), down slanted
palpebral fissures (1/10)
Small and abnormal ears(25/25),
micrognathia (20/25), down slanted
palpebral fissures (8/25)
Small and/or abnormal ears (4/4),
micrognathia (4/4), receding forehead (4/4),
prominent nose (4/4), short palpebral fissures
(2/4)
Skeletal abnormalities Delayed bone age (3/10), Slender long
bones (2/10) , absent patellae (6/10),
genu recurvatum (4/10)
Delayed bone age (11/25), slender
long bones, absent patellae (24/25)
Delayed bone age (1/4), 5th finger
clinodactyly (2/4), symmetric dwarfism (3/4),
small/abnormal patellae (2/4), kyphosis (1/4),
hip abnormality (2/4), narrow pelvis (iliac
blades) (1/4)
MRI Normal in 2 patients examined NA Generalised cerebral atrophy, delayed
myelination, abnormal gyration (2 patients
examined)
Other High pitched voice (1/10), full lips (7/10),
cryptochordism (2/4 examined), mammary
hypoplasia (2/2 examined), feeding and
respiratory problems during infancy (8/10)
Full lips (14/25), cryptochordism (7/14
examined), mammary hypoplasia (8/8
examined), feeding (20/25) and respiratory
(9/25) problems during infancy
Dental crowding (4/4), feeding and
respiratory problems during infancy (1/4)
*standard deviations from the age-related normal population mean, NA= not assessed.
MGS data from [13,14] [33,34].
doi:10.1371/journal.pgen.1002945.t002
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Supporting Information
Figure S1 Photograph of limbs and MRI scan of patient
CV1720. Left hand photograph showing hands and feet. Right
hand photograph shows an MRI scan where a small pituitary is
evident.
(TIF)
Figure S2 Cell cycle analysis of WT, DK0064 (ATR–SS), 27-
4BI, and CV1720 patient LBLs. A) Asynchronous growing
cultures of WT, DK0064 (ATR–SS), 27-4BI and CV1720 patient
cells were pelleted, fixed in 70% ice-cold ethanol and stained with
propidium iodide prior to FACs analysis. Populations were gated
and the proportion of cells in G1, S and G2/M phases of the cell
cycle measured. B) WT, DK0064 (ATR–SS), 27-4BI and CV1720
patient cells were treated with nocodazole for 16 h and then fixed
and analysed as in a). C) Asynchronous growing cultures of WT,
DK0064 (ATR–SS), 27-4BI and CV1720 patient cells were pulse-
labelled with 50 mM BrdU for 1 h. Cells were then fixed in 70%
ice-cold ethanol and processed for BrdU FACs analysis as
described in Bicknell et al, 2011 [13]. The proportion of cells in
S phase were gated and measured. Each graph represents the
mean of three independent experiments. The error bars represent
the standard deviation.
(TIF)
Figure S3 Identification of a truncating mutation in ATRIP in
patient, CV1720. Genomic DNA sequencing of ATRIP exons
showed that patient CV1720 and the unaffected mother, CV1780,
are heterozygous for a c.2278C.T mutational change in exon12
of ATRIP. The father has a WT sequence at this site. 2278C.T
generates a primary stop codon predicting a truncated protein at
position arginine 760 (p.R760*). WT sequence shown in blue, the
mutation is shown in Red.
(TIF)
Figure S4 Photographs of patients 27-4BI and 19-8BI. A) Shows
abnormal digits of patient 27-4BI. B) Copper beaten appearance
of skull of patient 19-8BI. C) Frontal and Lateral view of left knee
of patient 19-8BI showing an absence of ossification of the patella.
(TIF)
Figure S5 Mutational changes observed in ATR in patients 27-
4BI and 19-8BI. A) c.3477G.T mutational change in patients 27-
4BI and 19-8BI. RT-PCR sequencing revealed a heterozygous
3477G.T mutational change in both patients causing an amino
acid substitution, p.Met1159Ile, which lies within a conserved
UME (NUC010) domain of ATR. B) A double sequence was
observed at the boundary between exons 40 and 41 in both
patients. Sequencing showed that the double sequence was caused
by insertion of a 142 bp region from intron 40. C) A C to G
mutational change was observed in intron 41 of both patients
converting the sequence CAGCT to CAGGT, a splice site. The
insertion causes a frameshift and a stop codon at p.Val2300-
Glyfs*75. D) Diagram showing the likely origin of the insertion
observed at the exon 40/41 boundary. Sequencing of intron 40
revealed a C.G mutation as indicated creating a cryptic splice site
causing splicing of exon 40 to the indicated intronic sequence
(which represents an Alu repeat sequence). Thus one ATR allele of
the patients harbours a 142 nucleotide insertion between exons 40
and 41. Exons 40 and 41 are highlighted in green and the inserted
intronic sequence is shown in red. The intronic C.G change is
highlighted in red. The insertion causes a frameshift and a stop
codon at c.6978 in exon 41.
(TIF)
Table S1 The table shows the position of single nucleotide
polymorphisms identified in intron 1 and 2 in the patient and
parental genomic DNA. * The contig position is defined as the
position of the single nucleotide variant (SNV) on the contig
(NT_022517.17) when counting from the first base (base
position = 1). **rs# is the NCBI’s reference SNP ID. *** minor
allele (indicated as a base) and its frequency (MAF) (second most
frequent allele) in a default global population reported in dbSNP
database (1000 Genome phase 1, May 2011). N.A. not
available.
(DOCX)
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